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Life on the planet is incredibly diverse and it is often easy to compare and 
contrast the many features that distinguish any two pairs of species from each other. 
Despite this diversity, all organisms on Earth share a common origin. This shared 
ancestry establishes conservation at the core of biology. The concept of conservation (or 
what’s equivalent) across species organizes biology and stems from the natural selection 
of favorable traits in organisms. Evolutionary conservation extends even to the genetic 
and molecular level with genes, proteins, and the networks they constitute also sharing 
common ancestry. This property enables biologists to study conserved genes (orthologs) 
in simpler model organisms and relate them to their corresponding human equivalents. 
Despite this, it is largely unclear the extents to which orthologs between species are 
functionally compatible. The dissertation aims to directly address this question via cross-
species gene swaps. By systematically humanizing yeast genes, this dissertation provides 
insights into how orthologous genes between species functionally diverge and evolve 
over vast timescales. In chapter one, I present conservation as a powerful organizing 
principle in biology and the roles orthologous biological systems play in connecting 
 ix 
genotype and phenotype. In chapters two and three, I describe efforts to apply humanized 
yeast as a platform to study functional divergence in orthologs constituting expanded 
gene families and examine the trends that underlie them. In chapter four, I describe the 
synthesis of observations from multiple research threads including humanized yeast, 
model organisms, evolutionary conservation of biological systems, and global signatures 
of pesticide resistance to uncover a novel class of antifungals all capable of functioning 
as vascular disrupting agents. Finally, in chapter five, I discuss the future of cross-species 
gene swaps, humanized yeast, and their utility to human health and disease. 
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Chapter 1: Introduction 
 
“Nothing in Biology Makes Sense Except in the Light of Evolution.” 
-Theodosius Dobzhansky, 1973 
1.1. EVOLUTIONARY CONSERVATION: AN ORGANIZING PRINCIPLE IN BIOLOGY 
Life on earth is incredibly diverse with the number of species estimated to range 
between 2 million to 1 trillion (Locey and Lennon 2016). Many species are similar, but 
no two species are the same and it is often easy to observe and point out all the features 
that distinguish them from one another (e.g., lifespan, appearance, habitat, diet). Despite 
this vast diversity, the ancestry of life on earth is shared and deep-rooted in evolution. To 
make sense of all this diversity one might want to study all the characteristic biological 
features that distinguish a particular species from its neighbors. Conversely, one might 
ask the opposite of what is equivalent (conserved) given this vast diversity? This is where 
the concept of conservation becomes central to biology (and to this thesis). Broadly, a 
few examples include the process of copying and propagating genetic material from one 
generation to the next (DNA replication), the ability to convert food to energy 
(metabolism), and the ability to build macromolecular machines and processes (protein 
complexes and signaling pathways) involved in various cellular roles. All of these 
aforementioned examples are central to life and have to be carried out by all organisms in 





This concept of conservation is deeply rooted in all of biology. It organizes 
biology and arises from the retention of favorable traits in organisms via natural 
selection. This shared ancestry extends even to the genetic and molecular level with even 
genes, proteins, pathways, complexes, and their respective interaction networks also 
sharing a common origin. The concept of conservation is what allows researchers to 
study cellular and molecular functions of systems in a particular organism and translate it 
to others. Therefore, studying conserved systems in simpler organisms serve as valuable 
proxies in supplying key insights into their corresponding human equivalents. This 
principle often forms the foundation to most contemporary biomedical research including 
the genetics of human disease, pharmaceutical therapeutics, and drug discovery. The 
principles of evolutionary conservation and orthology especially in the light of human 
health and disease inspire this thesis. 
 
1.2. ORTHOLOGOUS SYSTEMS CONNECT GENOTYPE TO PHENOTYPE 
One of the ultimate goals in biology is to connect genotype to phenotype. 
Directly, this connection is probed by observing the consequences (or phenotype) of 
disrupting the genotype either by introducing mutations or repressing the expression of a 
gene. Before the genomics era and much before sequences of genes and genomes were 
available, this was the go-to strategy to infer gene function by association to its 
phenotype. Since then, the advent of high-throughput DNA sequencing has led to the 
birth of comparative genomics allowing us to directly identify orthologous genes in 





the effects of their disruption back to humans. These efforts have been largely advanced 
by the sequencing of the human genome along with forward and reverse genetics. 
Forward genetics studies allowed scientists to identify the genetic basis behind 
deleterious phenotypes thereby identifying the corresponding orthologous human genes 
potentially implicated in disease. On the other hand, reverse genetics enabled scientists to 
selectively make mutations and/or disruptions in orthologs of known human disease 
genes in better understood organisms to understand the related phenotypes. Both these 
approaches gave rise to new model organisms including bacteria (Escherichia coli), yeast 
(Saccharomyces cerevisiae), worms (Caenorhabditis elegans), fruit flies (Drosophila 
melanogaster), frogs (Xenopus laevis) and mice (Mus musculus) to study human disease. 
Studies in these organisms often served as powerful platforms to discover genes 
implicated in many human diseases. Over the years, these studies have aggregated into a 
vast ocean of genotype-phenotype associations in model organisms (Fig. 1.6.1).  
This rich well of data serves as a strong basis to discover and identify seemingly 
non-obvious relationships between phenotypes in model organisms and human diseases. 
Motivated by this extensive phenotyping of genetic manipulations in model organisms, 
McGary et al. developed a powerful strategy leveraging these gene-phenotype 
associations to identify orthologous phenotypes or phenologs. This strategy defines 
orthologous phenotypes between organisms by systematically overlapping sets of 
orthologous genes associated with each organism-specific phenotype (McGary et al. 
2010). In other words, two phenotypes (between species) are said to be phenologs if they 
share a set of orthologous genes at a statistically significant rate higher than by random 





conserved gene modules often work in organism-specific contexts and identifies quite 
inconspicuous relationships between humans and distant species. A few notable 
relationships discovered included a yeast model for angiogenesis, a worm model for 
breast cancer, and a plant model for Waardenburg syndrome. Obviously, yeast lack blood 
vessels, worms don’t suffer from breast cancer and plants don’t experience Waardenburg 
syndrome, but these phenotypic relationships are linked by the same sets of orthologous 
genes these organisms. Phenologs allow for the identification of new candidate genes that 
are likely implicated in disease opening up new routes to understand disease states. 
Expanding the definition of phenologs to include phenotypic assays beyond mutant 
phenotypes can be quite powerful in identifying compounds that therapeutic potential. 
This was well demonstrated subsequently by Cha et al. leveraging the yeast model of 
angiogenesis to discover that the widely used antifungal Thiabendazole (TBZ) behaved 
as a vascular disrupting agent allowing for repurposing of the compound as an anti-
cancer therapeutic (Cha et al. 2012). These methods are only beginning to scratch the 
surface of the phenotypic relationships that can be established through deeply conserved 
systems, phenologs, and model organisms. With richer phenotyping, comparative and 
systems-wide approaches, the number of phenologs will only steadily rise.  
 
1.3. CROSS-SPECIES GENE SWAPS AND HUMANIZED YEAST 
This link between model organisms and human health is only reinforced by 
phenologs making these studies extremely relevant not to mention all the curiosity-driven 





genome editing, fluorescent protein tags, and proximity protein labeling) central to 
contemporary biomedical research. As we continue to learn more about phenotypic 
associations between species and the conserved genetic systems that underlie them, the 
central question is whether orthologous genes between species function similarly. 
Generally, molecular roles of orthologous genes are thought to be conserved between 
species. But the disruption of the same orthologous genes across species can lead to 
radically different phenotypic outcomes. For example, mutating the RB1 gene in humans 
results in cancer of the retina while disrupting its nematode ortholog causes ectopic 
vulvae. While both these genes may be executing the same molecular roles, the contexts 
and environments in which they do so are inherently different between the two species 
leading to characteristic organism-level phenotypes. The key is that these dissimilar 
phenotypes are connected by the same set of orthologous genes and it is this principle 
that has linked studies in model organisms back to the roles of human genes in health and 
disease. Despite this remarkable power, it is still largely unknown how and to what extent 
orthologous genes evolve, diverge, and retain function over vast timescales.  
Cross-species gene swaps offer direct opportunities to test the ability of functional 
equivalency among orthologous genes. Such complementation assays have been around 
since the mid-1980s wherein microbial orthologs of human genes were “humanized”. 
These early studies used these complementation assays to identify human genes capable 
of rescuing mutant phenotypes in yeast. Notably, Kataoka et al. complemented fully 
human or chimeric yeast-human versions of RAS genes in rasΔ strains demonstrating the 





Nurse screened a library of human cDNAs to identify human orthologs capable of 
rescuing CDC2’s function in fission yeast (Lee and Nurse 1987).  
Even though humans and yeast last diverged from their last common ancestor 
nearly a billion years ago, many genes still share common ancestry. The Saccharomyces 
cerevisiae genome contains ~6,000 protein coding genes while the human genome 
encodes ~20,000. Comparing orthologs across species, humans and yeast share >2,000 
orthologous groups comprising of ~2,000 yeast and ~4,000 human genes (Sonnhammer 
and Östlund 2015). Baker’s yeast (Saccharomyces cerevisiae) has been instrumental in 
advancing our knowledge of basic biology and how they translate to humans. There are 
several reasons behind this including its short replicative cycles, ease of handling, access 
to a suite of tools for genetic and biochemical manipulation, genetic tractability and 
scalability. In 30 years since the early humanization experiments, over 700 yeast genes 
have been swapped for their human orthologs (Heinicke et al. 2007; Cherry et al. 2012; 
Kachroo et al. 2015; Hamza et al. 2015, 2020; Sun et al. 2016; Yang et al. 2017; Laurent 
et al. 2020; Garge et al. 2020). These complementation studies have been motivated by 
varied goals including uncovering the roles of human orthologs in simpler yeast contexts 
(Dunham and Fowler 2013), screening of the functional capacity and pathogenicity of 
human genetic variants (Hamza et al. 2015; Sun et al. 2016, 2018; Yang et al. 2017) and 
more broadly leveraging systematic gene swaps to uncover functional divergence across 
vast timescales across orthologous genes and the families that constitute them (Kachroo 
et al. 2015, 2017; Laurent et al. 2020; Garge et al. 2020). 
Even though there were several reports of human genes replacing their yeast 





systems and sets of orthologous genes. This inspired the early humanization work in the 
Marcotte lab. By systematically swapping essential yeast genes for human orthologs, 
functional complementation could be assayed via simple growth rescue assays. On 
assaying >400 genes, Kachroo et al. found that nearly half of tested essential genes were 
indeed functionally replaceable revealing remarkable conservation of roles across billion-
year timescales (Fig. 1.6.3). Additionally, replaceability was driven by modularity 
meaning that genes involved in common pathways or processes tended to be similarly 
replaceable or not (Kachroo et al. 2015). This is but an entry point to study human 
processes in yeast. Possessing a census of humanizable yeast genes now allows us to 
functionally characterize these genes and understand the interactions between them in 
yeast. The modular nature of replaceability now facilitates the construction of entire 
human systems and processes in a simpler eukaryotic context. Finally, the scalability and 
tractability offered by yeast allow for massively parallel functional characterization of 
allelic variation that can be tolerated by human genes. These topics form the basis for 
subsequent humanization efforts in this thesis.  
 
1.4. INTRODUCTION TO DISSERTATION 
The central theme tying this dissertation together is understanding the 
conservation of core biological systems, particularly how shared genes (orthologs) 
between species functionally duplicate, diverge, and evolve over vast timescales. 
Building off previous work (Kachroo et al. 2015, 2017; Laurent et al. 2016), this 





constituting expanded gene families retain ancestral function through the course of 
evolution (Chapter 2). Chapter 3 focuses on how ancestral roles are distributed in gene 
families constituting a core eukaryotic module (i.e., cytoskeleton). Finally, Chapter 4 
synthesizes the insights gained from orthologous systems, cross-species gene swaps, and 
model organisms to uncover a novel class of widely used antifungal compounds all 
capable of disrupting blood vessels and inhibiting angiogenesis. Besides these main 
projects, I was involved in several collaborative projects which are described in the 
appendices. These include applying CRISPR-Cas9 mediated genome editing tools in 
yeast (Appendix A) and omics-based approaches to understanding the dynamics of 
biological systems across temporal processes (Appendices B and C). 
 
1.5. PUBLISHED PAPERS 
This dissertation consists of an aggregation of my graduate work published during 
my time at The University of Texas at Austin all of which are listed below 
chronologically. The papers featured in the main chapters of this dissertation are marked 
with an asterisk while the others are included in the appendices. 
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Figure 1.6.1. Rapid growth of genotype-phenotype associations in organisms. 
Mapping of model organism genes to human diseases is growing rapidly as compared to 








Figure 1.6.2. The concept of phenologs. 
 Two phenotypes are said to be phenologs when they share a statistically significant set of 
overlapping orthologous genes. In this figure, the genes in the green box are associated 
with phenotype 1 in organism 1 while those in blue are associated with phenotype 2 in 
organism 2. The genes in grey represent candidate genes that can be tested for their 
respective cross-species phenotypic association. Gene A’s ortholog Gene A’ as a 
candidate for phenotype 2 in organism 2 and the ortholog of Gene E’ in organism 1 for 








Figure 1.6.3. Substantial fraction of essential yeast genes can be replaced by their 
human counterparts.  
On assaying >400 essential yeast genes, Kachroo et al. found that 200 (~47%) or nearly 
half of tested genes could be replaced by their human orthologs. Grey circle indicates 
gene that tended to be toxic when overexpressed some of which became replaceable 





Chapter 2: Humanization of yeast genes with multiple human orthologs1 
 
A central question in evolutionary biology is how genes evolve and diverge from 
ancestral roles through the course of evolution. Previously, Aashiq Kachroo and Jon 
Laurent in the lab systematically addressed this question by performing functional cross-
species gene swaps in Saccharomyces cerevisiae (Baker’s yeast). These assays mainly 
tested the ability of human and in some cases even bacterial genes to replace their yeast 
counterparts. However, these tests were largely restricted to genes with no duplication in 
any lineage (Kachroo et al. 2015, 2017). They showed that ~47% of human and >60% of 
bacterial orthologs could actually substitute for their yeast equivalents. 
Orthologous genes can however duplicate and expand in species-specific fashions 
to give rise to multiple gene orthology relationships between species and within gene 
families. This central question of how ancestral roles are distributed among orthologs (or 
co-orthologs) within gene families was not tested systematically and experimentally. This 
chapter describes the systematic humanization of essential yeast genes, one gene at a 
time, with their human orthologs that have undergone lineage-specific gene 
amplification. These assays allowed us to directly test which of the paralogous human 
genes have retained ancestral functionality and can replace the orthologous yeast gene. 
Similar to previous work, we take advantage of simple yeast growth assays to determine 
the functional divergence of genes in human multigene families. This chapter contains 
 
1This chapter was published as Laurent, J.M., Garge, R.K., Teufel, A.I., Wilke, C.O., Kachroo, A.H., and 
Marcotte, E.M. (2020). Humanization of yeast genes with multiple human orthologs reveals functional 
divergence between paralogs. PLOS Biology 18, e3000627. This work was led by Jon M. Laurent and 
Aashiq H. Kachroo. My contributions were performing a subset of humanization experiments and helping 





the results from >400 additional yeast humanization experiments bringing the overall 
tally of human genes known to functionally replace essential yeast genes to 280. Most 
interestingly, we observe a striking pattern of replaceability across different ortholog 
groups, with an obvious trend towards differential replaceability inside gene families, 
rarely observing replaceability by all members of a family. 
Subsequently, we quantitatively measured many properties of the genes to 
discover rules governing the observed patterns of replaceability. This work represents one 
of the most extensive and rigorous direct functional studies of duplicated genes yet 
performed and extends the humanization assays to nearly all conserved, essential genes in 
yeast. Thus, contributing a significant number of new reagent strains that can be used by 




Despite over a billion years of evolutionary divergence, several thousand human 
genes possess clearly identifiable orthologs in yeast, and many have undergone lineage-
specific duplications in one or both lineages. These duplicated genes may have been free 
to diverge in function since their expansion, and it is unclear how or at what rate ancestral 
functions are retained or partitioned among co-orthologs between species and within gene 
families. Thus, in order to investigate how ancestral functions are retained or lost post 
duplication, we systematically replaced hundreds of essential yeast genes with their 





including those with single duplications (1 yeast gene to 2 human genes, 1:2) or higher-
order expansions (1:>2) in the human lineage. We observe a variable pattern of 
replaceability across different ortholog classes, with an obvious trend toward differential 
replaceability inside gene families, and rarely observe replaceability by all members of a 
family. We quantify the ability of various properties of the orthologs to predict 
replaceability, showing that in the case of 1:2 orthologs, replaceability is predicted 
largely by the divergence and tissue-specific expression of the human co-orthologs, i.e., 
the human proteins that are less diverged from their yeast counterpart and more 
ubiquitously expressed across human tissues more often replace their single yeast 
ortholog. These trends were consistent with in silico simulations demonstrating that when 
only one ortholog can replace, it tends to be the least diverged of the pair. Replaceability 
of yeast genes having more than 2 human co-orthologs was marked by retention of 
orthologous interactions in functional or protein networks as well as by more ancestral 
subcellular localization. Overall, we performed >400 human gene replaceability assays, 
revealing 50 new human–yeast complementation pairs, thus opening up avenues to 
further functionally characterize these human genes in a simplified organismal context. 
 
2.2. INTRODUCTION 
Humans and budding yeast differ dramatically with respect to cell and tissue 
organization, metabolism, motility, and environment; nonetheless, yeast has remained an 
important eukaryotic model for informing and answering questions related to our own 





et al. 2001) (Fig. 2.6.1A), all deriving from genes of a common opisthokont ancestor 
living approximately a billion years ago (Kumar et al. 2017). Many studies have related 
function and disruption of yeast genes to their human counterparts, relying on a strong 
tendency for ancestral function to be retained between homologous genes (i.e., for 
sequence similarity to imply functional similarity). A more rigorous test of ancestral 
function being retained involves exchanging genes between related species to test for 
their ability to replace loss of the homologous genes. Indeed, interspecies swaps have 
been used for decades to identify homologs with equivalent function even before 
sequence comparison was as routine as it is today (Lee and Nurse 1987; Elledge and 
Spottswood 1991). More recently, large-scale systematic studies have identified many 
human genes that can substitute for their yeast equivalents and sustain yeast growth 
(Kachroo et al. 2015; Hamza et al. 2015; Sun et al. 2016; Yang et al. 2017). These 
systematic studies of functional replacement of yeast genes by homologs from humans 
(Kachroo et al. 2015; Hamza et al. 2015; Sun et al. 2016; Yang et al. 2017) and bacteria 
(Kachroo et al. 2017) demonstrate the power of interspecies gene swaps to directly test 
functional divergence and identify properties that determine functional conservation 
across vast evolutionary distances. 
Most (but not all) prior yeast humanization studies have considered genes that 
have not acquired observable duplications in either the human or yeast lineage, referred 
to as 1:1 orthologs; that is, one yeast gene has one human ortholog. Two homologous 
genes related by speciation are termed “orthologs” and are distinguished from those 
related by gene duplication, termed “paralogs” (Conant and Wolfe 2008; Innan and 





that have duplicated and diverged along the human lineage. Importantly, an expanded 
family of human genes may often correspond to a single gene on the yeast lineage (or 
vice versa). (For simplicity, we will generally refer to such cases as co-orthologs, 
although lineage-specific gene deletions can complicate such assignments.) 
More broadly, gene duplication is regarded as a major contributor to the 
production of new genetic material (Ohno 1970). Because of the immediate functional 
redundancy and dosage increase created following duplication, a common fate of 
duplicated genes is loss of one functional copy, returning to the ancestral state (Lynch 
and Conery 2000). However, duplicate genes can also either retain their ancestral roles or 
diverge and adopt new functions (Conant and Wolfe 2008; Innan and Kondrashov 2010). 
Lineage-specific duplications also have a major practical impact on how homologous 
genes between species are identified and defined. How ancestral functions are 
partitioned, lost, or retained during these duplication events is a major topic of study for 
evolutionary biology (Mushegian and Koonin 1996; Koonin 2005; Studer and Robinson-
Rechavi 2009; Nehrt et al. 2011; Gabaldón and Koonin 2013; Dunn et al. 2018). Thus, 
expanding systematic tests of functional replacement across these expanded gene families 
could help address questions of how functions are retained or lost following duplication, 
as well as provide researchers with many more opportunities to study human gene 
function in the simplified context of budding yeast. 
In this work, we sought to directly assay functional divergence within expanded 
gene families by using yeast humanization. We identified all essential yeast genes in 
yeast–human ortholog groups (orthogroups) that have undergone expansions in the 





their human co-orthologs, assaying functional replaceability by complementation of a 
lethal growth defect. We find that duplicated human genes tend to differentially replace 
their yeast ortholog, rarely observing broad replaceability across members of expanded 
human gene families. Further, we quantified the ability of several protein-, gene-, or 
ortholog-based properties to explain the differential ability of human co-orthologs to 
replace and further support our observations with in silico simulations of protein 
evolution post duplication. 
Collectively, our results suggest that within paralogous human gene families, at 
least one gene generally tended to retain ancestral function well enough to replace a 
billion-year–diverged ortholog in a yeast cell. These resulting strains and observational 
data serve as important resources for addressing questions in evolutionary biology, as 
well as for genetic and biotechnology applications. For example, they will enable new 
yeast-based drug screens against human genes, guide pathway and genome engineering 
efforts, and enable tests of human disease allele functionality, among other applications, 
all in the much simpler eukaryotic context of the yeast cell (Laurent et al. 2016). Our data 
underscore the remarkable extent to which genes are functionally equivalent between 







2.3. MATERIALS AND METHODS 
2.3.1. Identifying orthologs 
Orthologs were calculated with a local installation of InParanoid (Remm et al. 
2001), using UniProt proteomes for the two species (downloaded November 2014). 
InParanoid identifies orthogroups between two species by first performing an all-versus-
all BLAST search between the two species to identify bidirectional best hits (BBH). Each 
proteome is then subjected to an all-versus-all BLAST against itself to identify within-
species homologs. The BBH pairs are used as seed matches, and any within-species 
genes from the self-BLAST that are at least as close to the gene of interest as its BBH in 
the other species are added to the ortholog group and termed an “in-paralog” or co-
ortholog. We used the “table” output of InParanoid to identify orthogroup classes as 
follows: those groups with one listed yeast gene and two human genes were dubbed one-
to-two (1:2) orthologs, whereas those with one yeast gene and more than two human 
genes were identified as one-to-more-than-two (1:>2) orthologs. Together, these two sets 
make up the 1:M ortholog class. 
2.3.2. ORFeome cloning 
Human genes were obtained from the human ORFeome collection (Lamesch et al. 
2007). The ORFeome comprises a collection of Escherichia coli strains, each harboring a 
plasmid encoding a single human gene in a Gateway “entry” vector. Sequences cloned in 
the entry vectors are flanked by attL sites. To create expression vectors, each human 
entry vector was isolated from E. coli, added to a Gateway LR reaction with a Gateway 





(Liang et al. 2013). As ORFeome clones lack stop codons, we modified the Advanced 
Yeast Gateway kit (Alberti et al. 2007) pAG416-GPD-ccdB destination vector, which 
does not encode a stop codon immediately outside of the cloning region, resulting in a tail 
of approximately 60 amino acids being added to any protein expressed from it. We thus 
mutagenized the vector downstream of the cloning region to introduce a stop codon, 
shortening the tail to six amino acids (this plasmid is termed pAG416-GPD-
ccdB+6Stop)(Kachroo et al. 2015). Entry and expression clones were verified by 
sequencing into the gene sequence from the upstream and downstream regions of the 
plasmid. 
2.3.3.MGC cloning 
For human genes not available in the ORFeome, we obtained clones from the 
Mammalian Gene Collection (Temple et al. 2009), a collection of sequence-verified 
human cDNA sequences. To obtain entry vectors for these genes, we designed primers 
for each gene that would amplify the coding sequence while adding attB sites to either 
end of the human gene and performed PCR using the MGC plasmid as a template. PCR 
products were combined with plasmid pDONR221 in a Gateway BP reaction (Liang et al. 
2013) and transformed to E. coli to obtain entry clones. The entry clones were then 
combined in a Gateway LR reaction with p416-GPD-ccdB+6Stop and transformed to E. 
coli to obtain expression clones. Each entry and expression clone was verified by 





2.3.4. Functional replaceability assays 
Yeast strains were grown in a 96-well format in YPD medium supplemented with 
G418 (200 µg/ml). The strains were transformed with matched expression clones or 
empty control vectors and selected on minimal medium lacking uracil. Complementation 
assays were performed as follows: 
1. TS assays.  
Each of the strains in the TS strain collection (Li et al. 2011) encode a yeast 
protein with a mutation that allows growth at permissive temperatures of 22–26 °C but 
not at the restrictive temperature of 35–37 °C. We therefore identified human genes 
capable of rescuing growth of the mutant at restrictive temperature on selective plates. 
Each strain was transformed and assayed separately with either the human gene-
expressing vector or the empty vector control by growing transformed strains in the 
following manner: −Ura dextrose medium at the permissive temperature (26 °C), which 
serves as a control for transformation efficiency and/or toxicity because both the yeast 
and the human gene are expressed; and −Ura dextrose medium at the restrictive 
temperature (37 °C), testing for human gene functional replacement under conditions in 
which the corresponding yeast gene is nonfunctional. 
2. hetKO assays.  
Strains in the hetKO collection (obtained from ATCC) are heterozygous diploid 
strains, each harboring one allele of a yeast gene knocked out by replacement with the 
KanMX kanamycin-resistance cassette, allowing for selection on G418 (Pan et al. 2004). 
We transformed human expression clones or an empty control vector into appropriate 





replated on GNA-rich presporulation medium containing G418 and 50 mg/L histidine. 
Individual colonies were then inoculated in liquid sporulation medium containing 0.1% 
potassium acetate, 0.005% zinc acetate, and incubated with vigorous shaking at 26 °C for 
3–5 days, after which sporulation efficiency was estimated by microscopy, and the 
mixture was then resuspended in water and equally plated on two assay conditions: (1) 
−G418 Magic Marker dextrose medium (−His −Arg −Leu +Can −Ura) incubated at 30 
°C. The haploid spores that carry the wild-type allele grow in this medium, providing us 
with the control for sporulation efficiency. This condition also assays for toxicity of the 
human gene if the haploid spores fail to grow. (2) +G418 Magic Marker dextrose 
medium (−His −Arg −Leu +Can −Ura) containing 200 μg/ml G418. In the absence of the 
human gene (as for control transformants), the resulting haploid knockout strain is 
expected not to grow, providing an assay for replaceability in strains expressing the 
human gene. Cases with approximately equal numbers of colonies growing in the 
absence or presence of G418 were considered functional replacements. For cases with 
ambiguous growth (marked by moderate numbers of isolated colonies growing on the 
+G418 medium relative to −G418 medium), we screened varying quantities of the 
sporulation mixtures. 
Positive assays were verified independently. Individual colonies were isolated 
from selective plates and were assayed for growth defects on YPD or Magic Marker 
medium + G418 (Fig. 2.6.1B, S4 and S5). After growth on YPD + G418, each strain was 
spotted on 5-FOA agar to test plasmid dependency. 





For human gene replaceability assays performed in the yeast hetKO collection 
that were ambiguous in our large-scale screen, we performed tetrad dissections to more 
clearly test for complementation (Fig. 2.6.S2). In total, 33 human genes were assayed and 
analyzed. We transformed each human expression clone or empty vector control into the 
appropriate yeast strains and selected on SC-Ura + G418 (200 µg/ml) to select for the 
human gene expression vector (CEN, Ura+) and yeast gene knockout (KanMX marker) 
simultaneously. Transformants were then plated on GNA-rich presporulation medium 
containing G418 (200 μg/ml). Individually isolated colonies were inoculated into liquid 
sporulation medium containing 0.1% potassium acetate, 0.005% zinc acetate, and were 
incubated with vigorous shaking at 25 °C for 3–5 days. Following this, sporulation 
efficiency was estimated by microscopy, and successful sporulations were subjected to 
tetrad analysis. In all, 15–20 μL of each sporulation was digested with an equal volume of 
Zymolyase (5 mg/ml stock) for 30–45 minutes to remove the ascus coats. The digestions 
were diluted 1:1 with sterile water, after which 20–30 μL of the Zymolyase-treated spores 
was carefully applied to a tilted YPD plate using a pipette, allowing the droplet of cell 
suspension to gently run down the agar surface. The plates were dried and visualized on 
the tetrad dissection microscope. For each human gene, a minimum of five tetrads were 
dissected. Dissections were selected and replica plated both on 5-FOA (for plasmid 
counterselection) and YPD + G418 (for yeast null allele selection). A successful 
complementation consists of 2:2 segregation with survival on YPD + G418 and failure to 
grow on 5-FOA (Fig. 2.6.S2, Table 2.7.1). We subsequently performed quantitative 
growth assays (in triplicate) on tetrads passing the 5-FOA/G418 segregation test. Each 





SC-Ura. Subsequently, dissections were replica plated to SC-Ura to orthogonally confirm 
plasmid dependencies in the G418-resistant clones. Each medium-specific growth profile 
(shown in one of the conditions as in Fig. S4 and S5) was analyzed and quantified to 
detect any growth defects in yeast. In all, 14 out of 33 human genes assayed in this 
manner showed functional replaceability of the yeast gene function (Table 2.7.1). 
2.3.5. Isolating haploid humanized yeast strains and quantitative growth curve 
assays 
Select yeast hetKO strains carrying human gene expression vectors (CEN, Ura+) 
showing functional replaceability were sporulated and plated on independent petri plates 
to obtain single colonies. Each colony was tested for plasmid loss in the presence of 5-
FOA. Colonies that did not grow in the presence of 5-FOA were subjected to further 
analysis to quantitatively measure their growth rates. Yeast strains were either 
precultured in liquid YPD + G418 (200µg/ml) or −Ura dextrose selective medium + 
G418 (200 µg/ml) for 2 hours or overnight, respectively. Each culture was diluted in 
YPD or −Ura dextrose medium to an OD of approximately 0.1 in 100 or 150 μL total 
volume in a 96-well plate. Plates were incubated in a Synergy H1 shaking incubating 
spectrophotometer (BioTek), measuring the OD every 15 minutes over 48 hours. Growth 
curves were performed in triplicate for each strain by splitting the preculture into three 
independent cultures for each 48- to 60-hour time course (Fig. 2.6.S4A, S5A and S5C). 
In the case of TS humanized yeast strains, the growth assays were performed first 
at permissive temperatures (25–26 °C) for a 48- to 60-hour time course. These growth 
assays were largely identical to the empty vector transformed yeast strains. The strains 





growth assay for a 48- to 60-hour time course (Fig. 2.6.S4B and S5B). Growth curves 
were performed in triplicate for each strain by inoculating cells from the same preculture 
into three independent cultures. 
For computational analyses of the trends underlying replaceability, we computed 
a diverse set of features (Table 2.7.3), based in part on those from Kachroo and 
colleagues (Kachroo et al. 2015), as follows: 
2.3.6. Sequence properties 
Sequence features for human genes obtained from the human ORFeome 
(Lamesch et al. 2007) were calculated using the ORFeome-provided fasta file for the 
sequences, which was downloaded from 
http://horfdb.dfci.harvard.edu/hv7/docs/human_orfeome71.tar.gz. For clones not obtained 
from the human ORFeome collection, we calculated sequence features using the longest 
annotated transcript or its translation from Ensembl version 74, available at 
http://Dec2013.archive.ensembl.org/index.html. To analyze protein features, we 
translated the above nucleotide sequence for each gene using the standard genetic code. 










Length was calculated as the count of amino acids in the protein. 
LengthDifference was calculated as the length of the human ortholog protein subtracted 









Orthologous pairs were first identified by InParanoid (Remm et al. 2001). Global 
alignments for all preidentified ortholog pairs were then calculated using NWalign 
(http://zhanglab.ccmb.med.umich.edu/NW-align/) with BLOSUM62 and gap open 
penalty of −11 and extension −1. Identity and similarity were calculated as the fraction of 
identical amino acids and amino acids with positive BLOSUM score in the alignment, 
respectively. “Longest” refers to amino acid identity or similarity calculated as a fraction 
of the longer of the two orthologs. “Aligned” refers to calculating identity or similarity 
calculated as a fraction of the length of the aligned region of the sequences. OrthoScore 
and OrthoRank refer to the scores assigned by InParanoid. For each orthogroup, 
InParanoid calculates a confidence score between 0 and 1 for each in-paralog that 





in-paralogs of a group based on their orthoscore, with 1 being the LDO ortholog, and 








Calculated from the amino acid sequences using CodonW 
(http://sourceforge.net/projects/codonw/). Properties for the human genes were calculated 
using the yeast codon optimality table as a measure of closeness or divergence from yeast 
optimality. 
2.3.7. Network properties 
Network features were calculated using custom Python scripts, typically utilizing 
the package “networkx” (available from 
http://networkx.github.io/documentation/latest/download.html). When applicable (e.g., 
HumanNet, YeastNet), provided weights of interactions were taken into account when 
calculating these features. Otherwise, a default weight of 1.0 was used. Network features 
were defined as follows: Degree represents the count of interaction partners for a node in 





a network a given node is, calculated as the number of shortest paths between all node 
pairs in a network that pass through a given node. Clustering represents the node 
clustering coefficient, calculated as the fraction of edges that could possibly be present in 
a node’s neighborhood that are actually present. FractionComplementing is the fraction 
of interaction partners observed to complement (including results obtained in our 1:1 
humanization assays (Kachroo et al. 2015)). FractionOrthologPartners is the fraction of a 
gene’s interaction partners that have orthologs in the other species and interact with the 
gene of interests’ ortholog in the corresponding network (i.e., if gene Sc-A interacts with 
Sc-X, Sc-Y, and Sc-Z, and Hs-A interacts with Hs-X and Hs-Y but not Hs-Z [which is a 
legitimate gene], the FractionOrthologPartners for Sc-A is 2/3 or 0.66). It represents a 





Calculated from interactions present in BIOGRID 3.1.93 (Stark et al. 2006) , 




Human and yeast functional gene network features were calculated based on 













Protein abundances were used as reported by Kulak and colleagues (Kulak et al. 
2014). TranscriptAbundance, Ribosome Protected Fragments (RPF), Abundance, and 
TranslationEfficiency were calculated from Guo and colleagues (human) (Guo et al. 
2010) and Ingolia and colleagues (yeast) (Ingolia et al. 2009). Translation efficiency was 
calculated as the ratio of RPF reads to mRNA reads. SubCellHamming is a measure of 
the difference in subcellular localization between a yeast–human ortholog pair, calculated 
using data from the COMPARTMENTS database ((Binder et al. 2014), downloaded in 
February 2017). We utilized the “benchmark” sets to create, for each protein in its 
respective species, a binary vector of subcellular localization across 11 compartments 
(cytoskeleton, cytosol, endoplasmic reticulum, extracellular space, Golgi apparatus, 
lysosome, mitochondrion, nucleus, peroxisome, plasma membrane) that were common to 
both human and yeast in the database. Then, for each ortholog pair, we calculated the 






2.3.8. Calculating predictive strength of features 
The predictive power of each feature was calculated as the AUC when treating 
that feature as an individual classifier. Each feature was sorted in both ascending and 
descending directions, retaining the direction providing an AUC > 0.5. To assess 
significance, a permutation procedure was performed as follows: for each feature, the 
replaceable/nonreplaceable status of each ortholog pair was shuffled (retaining the 
original ratio of replaceable-to-nonreplaceable assignments), and the AUC was 
calculated. The shuffling procedure was carried out 1,000 times for each feature, and the 
mean AUC values and their standard deviations were reported. 
1.Features of expanded orthogroups. In order to avoid overweighting expanded gene 
families and compensate for uneven sampling, we considered median properties of genes 
in each orthogroup as follows. 
For each orthogroup, we collapsed all yeast–human ortholog pairs with the same status 
(replaceable or not) into a single case, with the value of each feature calculated as the 
median value of the collapsed ortholog pairs for that feature from the original table. Thus, 
each 1:M orthogroup is collapsed to be represented by either two pairs (complement and 
noncomplement) or one pair (either complement or noncomplement). 
2.3.9. Simulations 
We constructed a simulation of protein evolution in which one member of an 
interacting pair was duplicated. The simulation was initialized with the yeast SMT3–
UBC9 complex, a small heterodimeric protein complex, as the resident genotype (PDB: 
2EKE) (Duda et al. 2007). This complex initially had two subunits, which we refer to as 





setup (Teufel et al. 2019) is based on an accelerated origin-fixation model (Kachroo et al. 
2015; Teufel and Wilke 2017). Here, we further analyzed five of the previously published 
sets of 100 simulation trajectories (Teufel et al. 2019) (summarized in the Fig. 2.6.6A 
Selection Schemes panel). Briefly, under the first selection scheme, we enforced 
selection for A to bind B and for A to bind B′ (bind both). In the second scheme, 
selection acts on the ability of A to bind B or A to bind B′, and the maximum stability of 
those interactions was considered (bind max). In the third scheme, the ability of A to bind 
B was selected for, but the ability of A to bind B′ was not (bind B). In the fourth scheme, 
the ability of A to bind B was also selected for, but the ability of A to bind B′ was 
selected against (bind B and not B′). We also implemented a control selection scheme in 
which selection does not act on the ability of A to bind either B or B′ (no bind). We 
performed 100 replicates of each of these selection schemes. 
The percent of simulations in which an evolved duplicate has the ability to bind 
the ancestral partner (Fig. 2.6.6A and 6B) corresponds to Figs S7A-B in Teufel and 
colleagues’ publication (Teufel et al. 2019). We further analyzed these data by examining 
instances in which only one of the duplicates is able to bind the ancestral partner at the 
end of the simulation run. We recorded each duplicate’s divergence, defined as the 
fraction of amino acid positions that were nonidentical between the initial and final 
sequences of a simulation run (Fig. 2.6.6C). For each selection scheme, the distribution 
of the divergence of duplicates that can bind the ancestral partner was compared with the 
distribution of divergence of duplicates that cannot bind the ancestral partner with a 





Simulation data and scripts are available at https://github.com/a-
teufel/Laurent_etal_2020. 
 
2.4. RESULTS AND DISCUSSION 
2.4.1. Identifying and selecting orthologs in expanded orthogroups and ortholog 
replaceability assays 
Previous work from our group demonstrated that roughly half (47%) of one-to-
one (1:1) yeast-to-human orthologs were capable of replacing essential yeast genes across 
a panel of three complementation assays (Fig. 2.6.1A)(Kachroo et al. 2015). We had 
specifically restricted these earlier tests to ortholog groups for which no lineage-specific 
gene duplications were easily identified to mitigate any effects of functional redundancy 
between paralogs. In the present study, we now focus on these cases of ortholog groups 
that have undergone lineage-specific gene family amplifications (Fig. 2.6.1A). We again 
restricted our test set to include only those groups in which the yeast gene was annotated 
as essential for growth under standard laboratory conditions (Fig. 2.6.1A, Table 2.7.1) 
(Winzeler et al. 1999; Tong et al. 2001) and tested each human co-ortholog for its ability 
to individually complement loss of its yeast ortholog. We tested all human gene:yeast 
strain combinations for which reagents were available, even when not all members of an 
orthogroup could be tested. 
In total, we identified 2,073 orthogroups, comprising 4,556 ortholog pairs (2,424 
yeast proteins and 3,690 human proteins), using InParanoid (Remm et al. 2001). 





there are 1,001 ortholog pairs (Fig. 2.6.1A) distributed in 706 orthogroups. In our 
previous study, we obtained results for 424 human genes belonging to 1:1 orthogroups 
(Fig. 2.6.1A) (Kachroo et al. 2015). The remaining orthogroups comprise 468 additional 
pairs with essential yeast orthologs (Fig. 2.6.1A) and are the focus of this study. These 
expanded protein families were further split according to whether they had expansions 
only on the human lineage (one-to-many [1:M]) or expansions on either the yeast or both 
lineages (many-to-one or many-to-many, collectively referred to here as M:M), resulting 
in 378 1:M pairs (involving 140 orthologous yeast genes) and 90 M:M pairs (representing 
36 yeast genes and 83 human genes) (Fig. 2.6.1A). The 1:M orthogroups varied widely in 
size, with the majority having only two human members, and the largest orthogroup (the 
melanoma antigen gene [MAGE] family) comprising 28 human co-orthologs (Fig. 
2.6.S1). 
We obtained human gene clones for our assays from either the human ORFeome 
collection or human sequence-verified Mammalian Gene Collection (Lamesch et al. 
2007; Temple et al. 2009). Human genes were subcloned via Gateway cloning (Alberti et 
al. 2007) into yeast expression vectors under the control of the yeast GPD promoter, 
driving constitutive, robust expression. We performed complementation assays in one or 
both of two distinct yeast strain backgrounds: The first, referred to as the heterozygous 
diploid knockout deletion (hetKO) collection, represents a collection of diploid yeast 
strains, each of which contains a hetKO of a single gene, with a selectable marker 
cassette allowing isolation of the haploid knockout post sporulation (Pan et al. 2004). The 
second mutant background is a library of temperature-sensitive (TS) haploid yeast strains, 





be inactivated by growth at restrictive temperatures (typically 36 or 37 °C). These two 
strain backgrounds allow precise conditional loss of an essential yeast gene or protein for 
assaying complementation by its human ortholog(s) (Fig. 2.6.1B, Materials and 
Methods) (We had previously demonstrated that 41 of 42 assayed strains could be 
rescued by plasmid-based expression of the corresponding yeast gene (Kachroo et al. 
2015, 2017), confirming the utility of this approach.) We verified our assay results by 
isolating haploid humanized yeast gene knockout strains (either using Magic Marker 
medium or by tetrad dissection) while simultaneously verifying dependency on the 
human gene-encoding plasmid (Fig 2.6.S3, , Materials and methods). We further 
performed quantitative growth assays for each of the humanized yeast strains to more 
accurately characterize the robustness of complementation. The majority of 
complementing human genes exhibits similar growth profiles to the parental yeast strain 
(Fig. 2.6.1B, S4 and S5). 
In total, we obtained informative results for 308 of the 378 1:M ortholog pairs. 
(“Informative” here refers to those assays in which all controls behaved appropriately. 
See Materials and methods for details.) This translates to successful results from at least 
one human ortholog for approximately 93% (130 of 140) of testable 1:M yeast genes. Of 
the 90 M:M pairs, 29 were successfully assayed. (Fig. 2.6.1A, Table 2.7.1). Because of 
the scarcity of replaceable M:M ortholog pairs and the complicated nature of their 
orthology relationships, we simply report the results of their assays but do not include 
them in any subsequent analysis. 






Of the 130 successfully tested 1:M yeast genes, 52 (40%) had at least one human 
ortholog that replaced, whereas 78 were not replaceable by any tested human ortholog 
(Fig. 2.6.2, S4 and S5, Table 2.7.1). Notably, this rate of replaceability from the yeast 
gene perspective is similar to that previously observed for 1:1 orthologs (40% compared 
with 47%) (Kachroo et al. 2015). 
From the perspective of human genes in these expanded gene families, 74 of the 
308 successfully tested 1:M human genes could functionally replace their yeast ortholog, 
whereas 234 could not (Fig. 2.6.2A, S4 and S5). Of the orthogroups with at least one 
complementing human gene, the majority (34/52 groups, or 65%) showed differential 
replaceability, whereas all human co-orthologs in a group replaced only in a few cases 
(12/52 or approximately 23%) (Fig. 2.6.2C, S4 and S5, Table 2.7.1). In marked contrast, 
the great majority of human genes belonging to the M:M class were not able to replace 
their yeast orthologs, with only three human genes replacing in these cases, distributed 
across three different ortholog groups (Figs 2.6.2C, S4C, Table 2.7.1). 
When available, we compared our 1:M and M:M replaceability results with 
published reports, observing a strong agreement, with our assays recapitulating literature 
results (here, defined solely by the YeastMine database (Balakrishnan et al. 2012)) with 
88% accuracy (Table 2.7.2). Accounting for our previous assays as well as other 
published tests, we report an additional 50 novel yeast–human complementation pairs. 
With previously published cases from the 1:1 set, this brings our total count of known 





2.4.3. Computational analysis of trends governing replaceability 
Because the ability of human co-orthologs to functionally replace their singleton 
yeast orthologs was generally differential within expanded gene families, we sought to 
identify characteristic features governing selective replaceability of specific human genes 
in expanded orthogroups. To that end, we assembled and/or calculated a number of 
quantitative properties for all genes and ortholog pairs. These properties include direct 
properties of the genes in an orthogroup (e.g., protein length, codon usage bias), as well 
as comparative properties between co-orthologs (e.g., protein sequence similarity, length 
difference). We could then assess each property for its ability to explain replaceability as 
the area under a receiver–operator characteristic (ROC) curve, treating each feature as an 
individual classifier, in a similar manner to the previous 1:1 ortholog study (Kachroo et 
al. 2015). To simplify pairwise comparisons, we considered median values of co-
orthologs within each orthogroup that had the same replaceability status (i.e., in which 
both could replace or not) (Fig. 2.6.S6). Our analysis is robust to missing data, ignoring 
features for gene pairs that had no informative assay. Of the 378 testable 1:M pairs, the 
majority (208 pairs in 104 orthogroups) belonged to a group that had only two human co-
orthologs (referred to as the 1:2 class) (Fig. 2.6.S1). The remaining orthogroups with 
more than two human co-ortholog members were dubbed the 1:>2 class. Owing to this 
disparity, we chose to consider these two groups separately in subsequent analyses. 
2.4.4. Differential replaceability in 1:2 orthogroups is predicted by co-ortholog 
divergence and mRNA expression specificity 
In the 104 1:2 ortholog groups, we obtained informative results for 171/208 





tested human genes functionally replaced the yeast gene, whereas 127 could not (36 
human genes were either not tested or did not result in an informative assay). Seventy-
seven of these groups were completely tested (i.e., both human co-orthologs were 
assayed and yielded informative results), 17 groups had only a single tested human gene, 
and 10 had no informative assay results (Table 2.7.1). From the yeast genes’ 
perspectives, 34/95 (36%) of those assayed were replaceable by at least one human 
ortholog. 
Applying our computational analysis pipeline to the 1:2 orthogroups revealed 
several explanatory features. Most prominent in its explanatory ability, and in opposition 
to results from assays of 1:1 orthologs (Kachroo et al. 2015), was the relative divergence 
of the human co-orthologs from each other and from the yeast ortholog (Fig. 2.6.3A). In 
particular, the highest predictive power (measured as area under the ROC curve [AUC]) 
was seen for the InParanoid ortholog rank (Hs_OrthoRank), which ranks the human co-
orthologs from more diverged (MDO) to least diverged (LDO) from the yeast 
counterpart, and ortholog score (Hs_OrthoScore, a score ranging from 0 to 1, with scores 
closer to 1 meaning nearer to the yeast ortholog) (Fig. 2.6.3A). Of the 77 completely 
tested 1:2 orthogroups, there were 23 groups in which the two human genes displayed 
differential ability to replace (i.e., one human gene replaced, whereas the other did not). 
These groups are particularly interesting because they provide an opportunity to 
investigate properties that distinguish co-orthologs that can replace the yeast gene or not 
within the same orthogroup. To assess this difference, we performed the ROC analysis 
for each feature specifically on the set of differentially replaceable 1:2 orthogroups (Fig. 





standing as the most predictive feature in these orthogroups, demonstrating that the LDO 
of two human co-orthologs was considerably more likely to replace (Fig. 2.6.3B). Indeed, 
in this differentially replaceable set, 86% of the replaceable human genes are also the 
LDO in their respective orthogroups (a trend similar to that observed by Hamza and 
colleagues (Hamza et al. 2015)). Further, when we compared the divergence of the 
differentially replaceable set (“one replaces”) with the “both replace” and “none replace” 
sets, the average InParanoid ortholog scores of the MDO were similarly low for “one 
replaces” and “none replace” (0.52 and 0.47, respectively), whereas the MDO in the 
“both replace” class is notably more similar to the LDO (0.73) (Fig. 2.6.4A). The mean 
sequence identities between human and yeast orthologs for the “both replace” and “one 
replaces” classes are not significantly different, whereas the “none replace” class has a 
modestly lower mean identity to the yeast ortholog (Fig. 2.6.4B). Thus, although human 
co-orthologs in the three complementation classes have diverged from their yeast 
ortholog to a similar extent, those in the “both replace” class have maintained similarity 
to each other and are thus more likely to both replace (Fig. 2.6.4C-4E). 
An additional significantly predictive feature appearing in the differentially 
replaceable 1:2 class pertains to the tissue-specific expression of the human orthologs. 
Specifically, co-orthologs with more widespread (less–tissue-specific) expression were 
more likely to replace (Fig. 2.6.3B). This feature is particularly predictive of the 
differentially replaceable set but was not a strong feature for the full 1:2 orthogroup 





2.4.5. MDO yet replaceable 1:2 orthologs are highly expressed and more similar to 
their yeast counterparts 
Despite the fact that in the majority of the 1:2 cases the LDO human co-ortholog 
replaced the corresponding yeast gene, there were several cases wherein the MDO co-
ortholog was replaceable. Of 80 informative assays for human MDOs, 12 replaced the 
yeast ortholog. To determine what drives these replacements, we applied our ROC 
analysis scheme to the set, not restricting it to completely assayed groups or those in 
which the LDO also replaced. For these genes, the ability to complement is dominated by 
protein sequence similarity to the yeast ortholog as well as protein abundance features 
(Fig. 2.6.3C). These results are in line with the previous observation that human co-
orthologs that both replace are more similar than those in which only one or none 
replaces, but they also suggest that these highly diverged co-orthologs retain high 
expression levels. Thus, some highly diverged human co-orthologs still seem to maintain 
ancestral functionality, irrespective of the other co-ortholog’s function. 
2.4.6. Human co-ortholog replaceability in 1:>2 orthogroups is marked by 
conserved interactions and subcellular localization 
In the case of 1:>2 orthogroups, 137/170 human genes were successfully assayed, 
30 of which replaced the yeast ortholog, whereas 107 did not (22% replaceable). There 
were 23 1:>2 groups completely assayed for all human co-orthologs, represented by 78 
pairwise tests (Fig. 2.7S5A and S4B, Table 2.7.1). From the yeast perspective, 18 of 36 
yeast genes with one or more successful assays were replaceable by at least one human 
co-ortholog. Six of those were replaceable by only one co-ortholog, and only two yeast 





Because orthogroups with more than two human members had differing rates of 
replaceability within them and not all human genes could be assayed, we again collapsed 
the orthogroups using median values of replaceable versus nonreplaceable genes in each 
1:>2 orthogroup prior to analysis (Fig. 2.6.S6). Unlike for 1:2 orthogroups, but 
reminiscent of prior 1:1 findings, although sequence similarity appears near the most 
explanatory features, the ability of 1:>2 orthologs to replace was most strongly marked 
by functional context (Fig. 2.6.5A). In particular, the dominant predictive features 
included the fraction of conserved protein–protein interactions along with their centrality 
in their respective functional interaction networks and the number of interactions in those 
networks, albeit to a lesser extent. Specifically, human co-orthologs that have maintained 
a higher fraction of orthologous interaction partners relative to the yeast ortholog were 
more likely to replace. Further, human co-orthologs with relatively higher centrality in a 
functional network were more likely to be replaceable. Thus, in the case of highly 
expanded gene families, paralogs that maintain ancestral protein contacts and centrality in 
their interaction networks tend to be more replaceable (Fig. 2.6.5A), consistent with 
previous suggestions that “functional orthologs” retain a higher proportion of shared 
network contact (Bandyopadhyay et al. 2006) and observations that centrally placed 
proteins in interaction networks tend to carry out crucial cellular functions (Zotenko et al. 
2008) that have been retained over vast evolutionary timescales. 
We further sought to identify features that distinguished replaceable co-orthologs 
from nonreplaceable ones within the same orthogroup for the 1:>2 set. We again 
considered median features of both replaceable versus nonreplaceable co-orthologs 





to the differential 1:2 set. No features showed an AUC more than 2 standard deviations 
above the mean of permutation tests, likely due to the small size of this specific 
orthogroup set. Nonetheless, the strongest trend observed was for replaceable co-
orthologs to be localized in more similar subcellular compartments (Binder et al. 2014) in 
human cells as the yeast ortholog(s) (Fig. 2.6.5B). Our observations are consistent with a 
model that at least one co-ortholog in an expanded human gene family will tend to retain 
essential ancestral functionality by maintaining ancestral interactions and network 
centrality, as well as similar cellular localization (Fig. 2.6.5C). 
2.4.7. Simulations suggest MDO duplicates are less likely to bind their ancestral 
interaction partners 
To assess whether these trends would be evident in a controlled evolution 
experiment, we performed in silico simulations of functional divergence in a duplicated 
gene family. We analyzed a small heterodimeric protein complex consisting of A and B 
subunits (the SMT3–UBC9 protein complex (Duda et al. 2007; Kachroo et al. 2015)) in 
which the subunit B was duplicated in silico to yield A, B, and B′. Using binding of A to 
B and/or B′ as a proxy for functionality, we carried out evolutionary simulations of 
molecular structural divergence (considering all atom models using the Rosetta molecular 
modeling suite (Rohl et al. 2004; Leaver-Fay et al. 2011)). As described previously 
(Teufel et al. 2019), we examined functional replaceability across five different selection 
scenarios. All of the simulations assumed that selection acts on the stability of each 
subunit but differed in how they imposed selective pressure on binding. We ran 100 
replicates for each of the five selection schemes and quantified replaceability of each of 





sequence divergence (Fig. 2.6.6A and 6B). Notably, selection for A to bind both B and 
B′ results in a continued ability for either B or B′ to bind the ancestral variant A, whereas 
application of diversifying selection to prevent binding to B′ results in a rapid decay in 
the ability of B′ to bind A (Fig. 2.6.6B). 
We then looked across our simulated lineages at those cases in which one of the 
duplicates functionally replaces (i.e., binds to the ancestor) and the other does not. We 
found a systematic pattern across all five selection schemes that the nonbinding duplicate 
tends to be the MDO one (Fig. 2.6.6C; all pairwise comparisons within selection schemes 
are significant, p < 0.001 paired t test). These results mirror our experimental 
humanization findings for the relative divergence of 1:2 human co-orthologs that the 




By extending the scope of our systematic yeast humanization assays to include 
those yeast genes that have more than one human ortholog, we successfully added 337 
human genes to our tested set (Fig. 2.6.2). We have therefore greatly expanded the set of 
human genes that can now be functionally studied in the simplified unicellular eukaryotic 
context of budding yeast by adding 50 novel human genes to those that can successfully 
replace their yeast ortholog. Overall, we found that yeast genes with duplicated human 
orthologs can be replaced by at least one co-ortholog at a slightly lower rate (40%) than 





was replaceable only by one or two co-orthologs, rather than being broadly replaceable 
by many human genes in the same family. This pattern of replaceability between and 
within orthogroups suggests divergence among gene family members away from 
ancestral functions, at least to the degree that yeast complementation assays can probe 
this effect (Koonin 2005; Gabaldón and Koonin 2013). 
After testing many properties of the gene families for their ability to explain 
replaceability, our analysis revealed divergent patterns across groups that have two (1:2) 
or more than two (1:>2) human co-ortholog members. In the case of the 1:2 class, the top 
predictors were dominated by features that capture divergence from the yeast ortholog; in 
particular, we observed that the less-diverged variant strongly tended to be the 
replaceable one. This observation was supported by computational simulations of protein 
divergence after duplication, in which the LDO of the duplicates retained ancestral 
binding ability in most cases. In addition to sequence divergence, we also observed a 
strong trend of replaceable 1:2 human co-orthologs to have broader, less–tissue-specific 
expression. Somewhat rarely, the MDO human co-ortholog could replace, and these 
tended to be more similar to their yeast counterpart and expressed at a higher level, 
perhaps due to retaining important ancestral functions. In the case of the 1:>2 set, 
replaceability was marked largely by network-based properties of the genes. Replaceable 
co-orthologs in this set seem to have retained more ancestral interaction partners as well 
as higher centrality, even across a billion years of divergent evolution, likely indicative of 
their functional importance. Although not significant by our criteria, we also observed 





their corresponding yeast gene, highlighting a trend to maintain their ancestral 
localization. 
Overall, our extended set of humanization assays and their analysis reveals trends 
in functional divergence among co-orthologs. We observed a strong tendency for 
orthogroups to exhibit only one or a few swappable human genes rather than many. We 
also extended our observation that network centrality and interaction properties aid in 
determining how ancestral gene function across orthologs is retained over deep 
evolutionary timescales. Our study was limited to those yeast genes that are known to be 
essential for growth, providing us with a straightforward phenotypic readout for our 
systematic screening strategy. Future studies incorporating custom phenotyping will be 
needed to determine whether similar rates and trends of replaceability are obeyed by 
nonessential genes. 
Such assays help to advance our understanding of duplicate gene evolution in the 
billion years since yeast and humans diverged (Douzery et al. 2004) and add powerful 








Figure 2.6.1. Systematic functional replacement of essential yeast genes with 
multiple human co-orthologs. 
 (A) We identified 994 human genes that are orthologs of 709 essential yeast genes. Of 





duplications in either yeast or human lineage (i.e., with 1:1 orthology) (Kachroo et al. 
2015). In this study, we tested the remaining set of essential yeast genes that have 
acquired lineage-specific duplications, classifying them as 1:M (1 yeast to 2 or more 
human co-orthologs) or M:M (≥2 yeast to ≥2 human co-orthologs) or M:1 (≥2 yeast to 1 
human ortholog). There are 140 essential yeast genes with more than one human 
ortholog, representing 378 ortholog pairs to be tested. In the case of the 1:M category, we 
obtained 308 informative assays out of 378 testable pairs, whereas in the case of the M:M 
or M:1 set, we had 29 informative assays out of 90 testable pairs. Replaceability assays 
were performed in both the hetKO collection and the temperature-sensitive haploid yeast 
collection. (B) Representative assays performed in yeast hetKO strains for 1:2 (top) and 
1:>2 (bottom) are shown. HetKO yeast strains expressing human genes were sporulated, 
and the sporulation mix was spotted on Magic Marker medium (see Materials and 
methods) with (yeast gene absent) or without (yeast gene present) G418. Assays were 
performed with empty vector control (human gene absent) or yeast expression vectors 
carrying a human cDNA (human gene expression). In the 1:2 class, three different 
outcomes of human gene replaceability in yeast were obtained. Top panel: both human 
co-orthologs (Hs-PYCR1 and Hs-PYCR2) can replace their yeast equivalent (Sc-PRO3). 
Middle panel: one of the two human co-orthologs (Hs-PSMA7 but not Hs-PSMA8) can 
replace its yeast equivalent (Sc-PRE6). Bottom panel: neither of the two human co-
orthologs (Hs-CSFT2 or Hs-CSFT2T) can replace its yeast equivalent (Sc-RNA15). In the 
1:>2 class, an example of all human co-orthologs (Hs-KDELR1, two variants of Hs-
KDELR2, and Hs-KDELR3) replacing their yeast gene counterpart equally well is shown. 





each. Haploid yeast gene deletion strains carrying plasmids expressing functionally 
replacing human genes (colored solid lines) generally exhibit comparable growth rates to 
the wild-type parental yeast strain BY4741 (black dotted lines). Plotted growth curves 
display the mean of triplicate growth experiments. 1:M, one-to-many; hetKO, 






Figure 2.6.2. Distribution of replaceability across orthology classes.  
Only rarely did all human co-orthologs in one orthogroup replace. Rather, a family of 
human proteins typically had one or a few replaceable members or none at all. (A) 
Previously, systematic replacement of essential yeast genes with 1:1 orthologs (1 yeast to 
1 human) demonstrated nearly 50% replaceability of essential yeast genes (Kachroo et al. 
2015). Here, we tested the replaceability of essential yeast genes with their human 
counterparts that have acquired lineage-specific duplications in either yeast or human 
lineage. Of the 308 informative assays obtained in the 1:M class (1 yeast to 2 or more 
human co-orthologs), 74 human genes replaced their yeast equivalents, whereas 234 did 
not. Of the 29 informative assays obtained in the M:1 and M:M class (≥2 yeast to 1 or 
more human co-orthologs), three human genes replaced their yeast equivalents, whereas 
26 did not. (B) Combining our previous replaceability assays (Kachroo et al. 2015) with 
the assays done in this study, we have identified 248 essential yeast genes that are 





perspective of human proteins, 277 replace their yeast versions, whereas 477 do not. 
Summary of all the humanized yeast assays performed thus far. (C) Nearly half of the 
essential yeast genes belonging to the 1:1 orthology class were replaceable by their 
human equivalents (yellow). The distribution of essential yeast genes replaced by at least 
one human ortholog in the 1:M (both 1:2 and 1:>2 combined) closely matched the 1:1 
results. These yeast genes were rarely replaced by all human co-orthologs in an 
orthogroup (yellow), with the majority of replaceability falling in the differentially 
replaceable set (green). M:M yeast orthologs were rarely replaceable by any human 
ortholog, with only three (of 29 tested) human genes replacing three separate yeast 
orthologs. Nonreplaceable genes are indicated in blue. * indicates data from previous 






Figure 2.6.3. Replaceability of 1:2 orthologs is explained largely by relative 
divergence of human co-orthologs.  
(A) AUCs for the top 30 predictive features for median-collapsed 1:2 orthogroups are 
shown. The top two predictive features (HsOrthoScore and HsOrthoRank) for this class 
indicate that replaceability is driven largely by the nearness of the replacing human co-
ortholog to the yeast gene relative to a nonreplacing co-ortholog (i.e., most 1:2 
orthogroups have only one replacing human co-ortholog, and it is almost always the 
least-diverged one). (B) The observed trend is even more strongly demonstrated when 
analysis is restricted to the specific set of 1:2 orthogroups that displays differential 





nearing 0.9. The extent of tissue-specific expression also becomes significantly predictive 
in this set, indicating that human co-orthologs that are more broadly expressed are more 
likely to replace than their more tissue-specifically expressed co-ortholog. The top 12 
features are plotted. (C) More-diverged human co-orthologs in a 1:2 pair do replace in 
several cases (mostly those in which both co-orthologs replace). When restricting 
analysis to this set, it is apparent that the most predictive property is sequence similarity 
to the yeast ortholog, along with proteins that are translated efficiently and are typically 
in high abundance. Black overlapping bars indicate mean, and error bars indicate 
standard deviation for 1,000 shuffled AUC calculations for each feature. AUCs were 
calculated for n = 208 1:2 ortholog pairs, collapsed to 117 and 46 median metaorthologs 
([A] and [B], respectively) depending on feature availability. AUCs for MDO assays in 
(C) were calculated for up to 104 MDO pairs (Materials and methods, Table 2.7.3). The 
top 12 features are plotted. For full source data, see supporting information AUC, area 






Figure 2.6.4. Replaceability is explained by relative divergence of 1:2 human co-
orthologs from each other and their yeast ortholog.  
(A) The average ortholog score of the more-diverged (lighter color) 1:2 co-ortholog is 
more similar to the less-diverged co-ortholog for co-ortholog pairs that both replace than 
pairs in which only one or neither of the co-orthologs replace. (B) The average percent 
amino acid identity for 1:2 co-orthologs is not significantly different between the “all 
replace” (yellow) class and the “one replaces” (green) class, whereas the “none replace” 
(blue) class is slightly, but significantly, lower than either. Error bars indicate standard 
deviation. Raw data for (A) and (B) are available with the supporting information. (C–E) 
Phylogenetic models depicting gene trees for generic 1:2 orthogroups in the various 
replaceability classes. In (C), the human co-orthologs belong to the “both replace” class 





yeast ortholog as the “one replaces” class (D), in which the co-ortholog more closely 
related to the yeast gene is the one that replaces. In (E), the “none-replace” co-orthologs 






Figure 2.6.5. Replaceable 1:>2 human co-orthologs retain orthologous interaction 
partners and are more central in interaction networks.  
(A) AUCs of the top 30 predictive features for median-collapsed informative 1:>2 co-
ortholog pairs. The top two most significant features demonstrate the importance of 
network context in retaining ancestral functions. Specifically, human co-orthologs in 
highly expanded gene families that have retained a higher fraction of orthologous protein 
interaction partners with their yeast ortholog (FractionOrthologPartners) are more likely 
to replace, as well as those that maintain higher centrality in functional interaction 
networks (betweenness). (B) Similar to the 1:2 case, we further restricted our analysis to 
a subset of median-collapsed 1:>2 orthogroups that had both replaceable and 





proteins appears to be predictive, in that more broadly localized co-orthologs are more 
likely to replace than their more organellar-specific co-orthologs. Although this AUC is 
not significant (indicated by being just less than 2 standard deviations off the mean), it is 
an obvious trend and does overtake fraction of orthologous partners as the highest 
performing AUC for this set. (C) Phylogenetic model of a generic 1:M orthogroup 
showing that the replaceable human co-ortholog has retained more orthologous 
interactions in a network and is localized in a similar manner to the yeast ortholog. For 
AUC bar plots, black overlapping bars indicate mean, and error bars indicate standard 
deviation for 1,000 shuffled AUC calculations for each feature. AUCs were calculated for 
n = 170 1:>2 ortholog pairs, collapsed to 49 and 26 median metaorthologs ([A] and [B], 
respectively) depending on feature availability (Materials and methods, Table 2.7.3). The 
top 12 features are plotted in (B). For full source data, see supporting information 








Figure 2.6.6. Simulated protein evolution suggests that diverged duplicates are less 
likely to bind their ancestral interaction partner.  
(A) Inset: Five different types of selection scenarios were considered for a heterodimeric 





molecular modeling platform. (1) AB and AB′ (bind both). (2) AB or AB′, and only the 
most stable binding interface is considered (bind max). (3) AB, but AB′ was not enforced 
(bind B). (4) AB, and AB′ is selected against (bind B and not B′). (5) Neither AB nor AB′ 
is selected for (no bind). Percent of simulations in which an evolved B subunit has the 
ability to bind the ancestor to A. Divergence is measured by the amount B has diverged 
from the ancestor of B. (B) Percent of simulations in which an evolved B′ subunit has the 
ability to bind the ancestor to A. Divergence is measured by the amount B′ has diverged 
from the ancestor of B. (C) Percent divergence of duplicates when only B or B′ is able to 
bind the ancestor A. Lighter hues denote a duplicate that is able to bind the ancestor of A, 
and darker hues denote the nonbinding duplicate. Data and scripts for these are available 
at the following link:https://github.com/a-teufel/Laurent_etal_2020. Figure A.8.dapted 






Figure 2.6.S1. Count of orthogroups with the corresponding number of human gene 
members.  
The vast majority of one to multiple orthologs are of the 1:2 variety (1 yeast gene to 2 
human co-orthologs), whereas the rest were classified as 1:>2 (1 yeast gene to >2 human 







Figure 2.6.S2. Detailed overview of the ortholog groups in this study.  
(A) Venn diagram indicating the overlap of essential yeast genes with their human 
orthologs in various ortholog classes. Ortholog definitions are based on InParanoid 
(Remm et al. 2001), whereas essentiality of yeast genes is based on the systematic yeast 
knockout study by Winzeler and colleagues (Winzeler et al. 1999). (B) A thorough 








Figure 2.6.S3 Detailed illustration of yeast gene replaceability, tetrad dissection, and 
plasmid loss assays performed in a yeast hetKO collection.  
(A) Yeast strains were grown in 96-well plates in selective medium (YPD + 200 μg/ml 
G418). The matched orthologous human gene expression clones in 96-well plates were 
transformed into the appropriate yeast strains, followed by selection on the appropriate 
dropout medium (SD-URA). The resulting transformants were spotted onto selective 





hetKO collection, replacement was further verified by carrying out tetrad dissection 
followed by testing for plasmid dependency (selection on 5-FOA). Representative tetrad 
dissection assays are shown (right). Hs-YIPF5 functionally replaces its yeast counterpart. 
Dissected tetrads showed 2:2 segregation, with tetrads 1 and 3 containing the wild-type 
yeast allele (surviving on 5-FOA), whereas tetrads 2 and 4 contain the KanMX allele 
(yeast null allele) complemented by the human gene (surviving on YPD + G418). We 
used 5-FOA was for counterselecting the human gene encoding plasmid, whereas YPD + 
G418 was used to select for the yeast null allele (KanMX selection), respectively. 
However, in cases on noncomplementers (e.g., Hs-CDC14A), only two yeast spores 
(carrying the wild-type yeast allele) survive on YPD and fail to grow on YPD + G418 but 
grow on 5-FOA, indicating plasmid loss. (C) Each confirmed humanized haploid yeast 








Figure 2.6.S4. Quantitative growth assays of all humanized yeast strains belonging 
to the 1:2 class.  
(A) Growth curves of humanized haploid yeast strains obtained after sporulation and 





were performed in the presence of G418 (yeast gene–absent and human gene–present 
condition). Haploid yeast gene deletion strains carrying plasmids expressing functionally 
replacing human genes (colored red or purple solid lines) generally exhibit comparable 
growth rates to the wild-type parental yeast strain BY4741 (black dotted lines), except in 
the case of Hs-ALAS2, which shows reduced ability to replace the orthologous yeast gene 
compared with Hs-ALAS1. Mean and standard deviation plotted from triplicate assays. 
(B) Growth curves of humanized haploid temperature-sensitive yeast strains performed at 
a restrictive temperature of 37 °C (yeast gene–inactive and human gene–present 
condition). Temperature-sensitive haploid yeast strains carrying plasmids expressing 
functionally replacing human genes (colored red, purple, or blue solid lines) generally 
exhibit comparable growth rates to the wild-type parental yeast strain BY4741 (black 
dotted lines). The yeast strains harboring empty vector without a corresponding human 
gene, showing no or poor growth at restrictive temperatures of 37 °C (gray solid lines), 
serve as controls. In total, 208 individual assays were performed (as two independent 
biological replicates). In all, 45 human genes showed functional replaceability in either 
assay, whereas 127 did not, and 36 human gene complementation assays were 
noninformative (cases in which the control experiments did not behave appropriately). 
Raw data for growth curves are available with the supporting information. hetKO, 






Figure 2.6.S5. Quantitative growth assays of all humanized yeast strains belonging 
to 1:>2, M:M, and M:1 orthogroups.  
In total, 170 individual assays were performed (as two independent biological replicates): 





and 33 human gene replaceability assays were noninformative (cases in which the control 
experiments did not behave appropriately). (C) Growth curves of humanized haploid 
yeast strains (M:1 and M:M class) obtained after sporulation and/or tetrad dissection and 
followed by 5-FOA screening of hetKO strains. The assays were performed in the 
presence of G418 (yeast gene–absent and human gene–present condition). In total, 40 
individual assays were performed (as two independent biological replicates). Three 
human genes showed functional replaceability, whereas 26 did not, and 11 human gene 
replaceability assays were noninformative (cases in which the control experiments did 
not behave appropriately). Mean and standard deviation plotted with N = 3. (A) Growth 
curves of humanized haploid yeast strains (1:>2 class) obtained after sporulation and/or 
tetrad dissection followed by 5-FOA screening of hetKO strains. The assays were 
performed in the presence of G418 (yeast gene–absent and human gene–present 
condition). Haploid yeast gene deletion strains carrying plasmids expressing functionally 
replacing human genes (colored red, purple, and blue solid lines) generally exhibit 
comparable growth rates to the wild-type parental yeast strain BY4741 (black dotted 
lines), except in the case of Hs-PABPC1 and Hs-PABPC3, which shows reduced ability 
to replace the orthologous yeast gene. Mean and standard deviation plotted from triplicate 
assays. (B) Growth curves of humanized haploid temperature-sensitive yeast strains (1:M 
class) performed at a restrictive temperature of 37 °C (yeast gene–inactive and human 
gene–present condition). Temperature-sensitive haploid yeast strains carrying plasmids 
expressing functionally replaced human genes (colored red, purple, or blue solid lines) 
generally exhibit growth rates comparable to their parental wild-type yeast strain BY4741 





which showed reduced ability to functionally replace their orthologous yeast gene. Yeast 
strains harboring an empty vector without a corresponding human gene, showing no or 
poor growth at a restrictive temperature of 37 °C (gray solid lines), serve as controls. 
(Raw data for growth curves are available in the supporting information) 1:M, one-to-







Figure. 2.6.S6. Demonstration of the “median-collapse” feature table procedure.  
(A) An example subset of full ortholog data for two orthogroups in the 1:M ortholog 
class. (B) The same data as in (A) following median collapse. Orthogroup 218 has been 
collapsed to a single metaortholog pair with the status “noncomplement” because all 
human co-orthologs failed to complement. Group 249 has been collapsed to two 
metaortholog pairs because there were co-orthologs that complemented and did not. 
Metaortholog feature values are the medians of the full ortholog values with the same 







Owing to their extensive size and large format, all tables and supporting 
information are provided with the supplementary materials. Additionally, they can also 
be in this website. 
 
Table 2.7.1. Complementation results for all assays.  
We list the results of each assay background (TS or MM) as well as tetrad 
complementation reassay status and the final overall status used for subsequent analyses. 
Also listed is the literature status of genes found in YeastMine as previously reported 
literature assays. Those without a literature status are considered novel to this study. TS, 
temperature-sensitive. 
Table 2.7.2. Literature assay status from YeastMine.  
We list the results of 1:M ortholog assays previously reported in the literature as found 
via the YeastMine database. We also indicate whether these match our reported assays 
and the accuracy calculation reported in the text. 1:M, one-to-many. 
Table 2.7.3. Protein and ortholog properties.  
Includes all properties assembled and calculated for all proteins or ortholog pairs used for 






Chapter 3: Systematic humanization of the yeast cytoskeleton discerns 
functionally replaceable from divergent human genes2 
 
One of the central themes of my graduate work here has been understanding the 
principles that underlie cross-species gene complementarity and how genes diverge over 
evolution. Until recently, the majority of the humanization assays in yeast surveyed the 
ability of human gene families to complement a lethal defect induced by the loss of their 
corresponding yeast ortholog. However, assaying conditionally essential roles and/or 
context-dependent non-essential roles were only being studied to a limited extent in the 
lab. This prompted us to study this question of complementarity beyond growth assays to 
more fine-grained phenotypes.  
This chapter explicitly focuses on the core structural elements of the yeast 
cytoskeleton including the actin, myosin, tubulin, and septin gene families, testing the 
abilities of human genes to complement defects in a rich assortment of critical cellular 
roles caused by loss of their yeast counterparts. We observe a striking pattern of 
replaceability across different ortholog groups, with differential replaceability being a 
noticeable trend, seldom observing replaceability by all human members within the 
family. In addition to the rescue of growth defects, we also probe functional 
complementation in more detail. We observe varying extents of the functional rescue of 
the deletion of yeast genes by their human orthologs corresponding to cytoskeletal 
 
2This chapter was published as Garge, R.K., Laurent, J.M., Kachroo, A.H., and Marcotte, E.M. (2020). 
“Systematic Humanization of the Yeast Cytoskeleton Discerns Functionally Replaceable from Divergent 
Human Genes.” And was featured on the cover of Genetics 215, 1153–1169. My contributions were 
carrying out the complementation experiments, analysis and writing of the manuscript while being 





family-specific roles, specifically cell morphology, meiosis, and mating. By comparing 
distinct morphological phenotypes observed in humanized strains with their respective 
yeast interaction network(s), we identify replaceable human orthologs capable of 
executing essential yeast roles but seemingly breaking key non-essential interactions 
crucial for maintaining cell morphology. 
 
3.1. ABSTRACT 
Many gene families have been expanded by gene duplications along the human 
lineage, relative to ancestral opisthokonts, but the extent to which the duplicated genes 
function similarly is understudied. Here, we focused on structural cytoskeletal genes 
involved in critical cellular processes including chromosome segregation, 
macromolecular transport, and cell shape maintenance. To determine functional 
redundancy and divergence of duplicated human genes, we systematically humanized the 
yeast actin, myosin, tubulin, and septin genes, testing ~81% of human cytoskeletal genes 
across 7 gene families for their ability to complement a growth defect induced by 
inactivation or deletion of the corresponding yeast ortholog. In 5 of 7 families—all but α-
tubulin and light myosin, we found at least one human gene capable of complementing 
loss of the yeast gene. Despite rescuing growth defects, we observed differential abilities 
of human genes to rescue cell morphology, meiosis, and mating defects. By comparing 
phenotypes of humanized strains with deletion phenotypes of their interaction partners, 
we identify instances of human genes in the actin and septin families capable of carrying 





of their yeast orthologs, thus leading to abnormal cell morphologies. Overall, we show 
that duplicated human cytoskeletal genes appear to have diverged such that only a few 
human genes within each family are capable of replacing the essential roles of their yeast 
orthologs. The resulting yeast strains with humanized cytoskeletal components now 




Gene duplication is regarded as one of the key drivers of evolution, contributing 
to the generation and accumulation of new genetic material within species (Koonin 2005; 
Soukup). Duplication creates an initial multiplication of dosage and functional 
redundancy, but the trends dictating how duplicated genes retain function or diverge are 
still unclear. The processes governing the distribution of molecular roles within gene 
families also have important consequences for annotating genes, which generally takes 
advantage of sequence similarity and conservation over vast timescales of divergence to 
infer functions of homologous genes across species. Many individual studies have 
directly tested the conservation of function among orthologs from different species by 
swapping them from one species into another (Heinicke et al. 2007; Cherry et al. 2012). 
However, only recently have efforts been made to test such functional equivalence more 
systematically, with several recent large-scale studies harnessing “the awesome power of 
yeast genetics” to systematically replace yeast genes by their human, plant, or even 





Hamza et al. 2015; Laurent et al. 2016; Sun et al. 2016; Yang et al. 2017). Although 
humans and yeast last shared a common ancestor nearly a billion years ago, these studies 
have demonstrated that substantial fractions (12-47%) of tested essential yeast genes 
could be replaced by their human equivalents (Kachroo et al. 2015, 2017; Hamza et al. 
2015; Sun et al. 2016; Yang et al. 2017; Laurent et al. 2019). The ability of many human 
genes to functionally replace their yeast orthologs demonstrates the high degree of 
functional conservation in eukaryotic systems over billion year evolutionary timescales 
(Kachroo et al. 2015; Laurent et al. 2016).  
Previous humanization efforts in yeast have primarily focused on ortholog pairs 
with no obvious duplications within yeast and human lineages (1:1 orthologs), only 
partially testing the orthologs in expanded gene families (Kachroo et al. 2015; Hamza et 
al. 2015; Sun et al. 2016; Yang et al. 2017; Laurent et al. 2019) and seldom beyond 
assaying impact on growth rate. In this study, to better understand functional 
conservation across expanded gene families in core eukaryotic processes, we focused on 
the major structural components of the eukaryotic cytoskeleton, including actins, 
myosins, septins, and tubulin genes. Genes constituting the eukaryotic cytoskeleton play 
key roles in critical cellular processes, mainly organizing the contents of the cell by 
dynamically controlling cell shape, positioning organelles, and transporting 
macromolecules including chromosomes across the cell through the generation of 
coordinated mechanical forces (Wickstead and Gull 2007, 2011; Wickstead et al. 2010). 
Importantly, cytoskeletal gene families have undergone large expansions along the 





Advances in comparative genomics have shed light on the likely cytoskeletal 
components present in the last eukaryotic common ancestor (LECA)(Wickstead et al. 
2010; Wickstead and Gull 2011). Additionally, phylogenetic profiling studies of the 
cytoskeleton have been highly informative in inferring gene loss and retention events 
across eukaryotic clades (Wickstead et al. 2010; Wickstead and Gull) (Fig. 3.6.1). Such 
studies suggest that the origins of the eukaryotic cytoskeleton predate eukaryogenesis and 
ancestrally trace back to primitive tubulin- and actin-like homologs in bacteria13. These 
components critical in cell division subsequently evolved to incorporate families of 
accessory motors and regulatory proteins expanding towards performing vital cellular 
roles, including phagocytosis, motility and vesicular transport, still evident across vast 
eukaryotic clades of life (McKean et al. 2001; Wickstead et al. 2010; Janke 2014; Jékely 
2014; Hall and Russell). 
Though the cellular roles of human cytoskeletal gene families have been broadly 
elucidated, aided by studies in simpler eukaryotes (Schatz et al. 1986a; Winsor and 
Schiebel 1997; Bode et al. 2003; Nogales et al. 2010; Li et al. 2011), the specific 
functions of their constituent family members in humans have to date still only been 
partially characterized (Tischfield et al. 2010; Feng et al. 2016; Stottmann et al. 2016; 
Wawro et al. 2017; Huang et al. 2018b; Yuan et al. 2018; Chen et al. 2019). Functional 
assays in human cell lines pose the challenge of functional redundancy, with buffering by 
other paralogs complicating the determination of paralog-specific roles within 
cytoskeletal gene families. The high degree of sequence conservation among paralogs 
within each cytoskeletal family make functional analysis of individual cytoskeletal genes 





cross-species gene swaps have the potential to provide direct assays of individual 
paralogs within these expanded gene families, thereby revealing the extent to which 
present day orthologous genes retain ancestral function. 
To understand the extent to which human cytoskeletal genes in expanded 
orthogroups retain cross-species functional equivalence, we systematically humanized 
major elements of the yeast cytoskeleton. We tested ~81% (50/62) of all human genes 
from actin, myosin, septin, and tubulin families, using a combination of classical yeast 
genetics and CRISPR-Cas9 mediated genome editing to assay the replaceability of 
essential cytoskeletal orthologs, as initially determined via simple growth rescue 
complementation assays. Overall, we show that (13/50) members from 5 of 7 tested gene 
families (actin, heavy myosin, septin, β- and ɣ-tubulin) can indeed execute essential roles 
of their yeast counterparts. Within each replaceable family we show that several present-
day human orthologs still possess functional roles of their respective opisthokont 
ancestors compatible in a yeast cellular context. Additionally, we characterized cellular 
phenotypes beyond growth and observed differential abilities among complementing 
human cytoskeletal genes to carry out non-essential cytoskeletal roles, including those in 
cell morphology, sporulation, mating, meiosis, and cytokinesis. Besides revealing human 
cytoskeletal orthologs capable of performing their core eukaryotic roles, yeast strains 
with human cytoskeleton components additionally serve as cellular reagents to study the 
specific roles of expanded cytoskeletal gene family members in a simplified unicellular 






3.3. MATERIALS AND METHODS 
3.3.1. Curating human orthologs to yeast genes 
Yeast genes to be tested for replaceability were curated from Saccharomyces 
Genome Database (Cherry et al. 1998, 2012), and human orthologs were curated from the 
InParanoid (Sonnhammer and Östlund 2015) and EggNOG (Huerta-Cepas et al. 2016) 
databases both of which employ graph-based algorithms that recognize orthogroups 
between species by exhaustively performing an all-vs-all bidirectional BLAST search of 
all protein sequences and Hidden Markov Models to estimate ortholog groups 
respectively. We curated a total of 62 human cytoskeletal proteins with yeast orthologs in 
the 7 major cytoskeletal gene families.  
3.3.2. Cloning human cytoskeletal ORFs 
Human genes were extracted from the ORFeome (Lamesch et al. 2007), a 
collection of E. coli strains, each containing a single human ORF cDNA cloned into a 
Gateway ‘entry’ vector (Alberti et al. 2007). Human genes cloned in this manner are 
flanked by attL recombination sites. To generate yeast expression vectors, the human 
entry vectors were isolated and subjected to Gateway LR reactions with a yeast Gateway 
‘destination’ vectors followed by transformation into competent E. coli to obtain yeast 
expression clones. We used destination vectors from the Advanced Yeast Gateway kit 
(Alberti et al. 2007), specifically pAG416-GPD-ccdB, pAG416-GPD-ccdB-eGFP, 
pAG426-GPD-ccdB-eGFP, pAG426-GPD-ccdB (CEN, Ura) destination vectors. Since 
the original version of pAG416-GPD-ccdB does not encode a stop codon immediately 





~60 amino acid tail being translated to any protein expressed from it. To eliminate 
potential issues from the tail, we mutagenized the vector downstream of the cloning 
region to introduce a stop codon, thereby shortening the tail to six amino acids (pAG416-
GPD-ccdB+6Stop) (Kachroo et al. 2015). Prior to performing complementation assays, 
all expression clones were verified by Sanger sequencing to ensure there were no 
sequence errors or mutations in the human cytoskeletal genes prior to complementation 
assays in yeast. 
3.3.3. Assaying human cross-species complementation in yeast  
1. Tetrad dissection and analysis 
In all, 40 human genes were assayed using tetrad dissection (Fig. 3.6.S2A): The 
yeast heterozygous diploid deletion strain (Magic Marker) collection (Giaever et al. 
2002) (obtained from ATCC) with one allele replaced with a Kanamycin-resistance 
(KanMX) cassette was used. Human genes in Gateway entry clones (pDON223) were 
curated from the Human ORFeome collection(Lamesch et al. 2007) and cloned into yeast 
destination vectors. We transformed each human clone or an empty vector (pAG416-
GPD-ccdB+6Stop lacking the human ORF) control into the appropriate heterozygous 
diploid deletion strain yeast strain and grew them on SC–Ura + G418 (200µg/ml) to 
select for the human clone (Ura) and KanMX (G418) simultaneously. Transformants 
were then plated on GNA-rich pre-sporulation media containing G418 (200μg/ml). 
Individual colonies were inoculated into a liquid sporulation medium containing 0.1% 
potassium acetate, 0.005% zinc acetate, and were incubated at vigorous shaking at 25˚C 
for 3-5 days. Following this, sporulation efficiency was estimated by microscopy, and 





protocols (Dunham et al. 2015). We initially plate the spores from tetrads on YPD media. 
This allows us to check for the spore viability. The colonies are then replica-plated onto 
either YPD+G418 media or -Ura (+ or - G418) media or 5-FOA plates. We 
predominantly observe 2 spores with Ura selection that tend to be G418 resistant as well. 
This behavior could be due to various patterns of segregation of CEN vectors or that the 
YPD selection allows the Ura to be lost from the wild-type spores. Successful dissections 
were replica plated both on 5-FOA (for plasmid counter-selection) and YPD + G418 (for 
yeast null allele selection). Successful complementations consisted of 2:2 segregation 
with survival on YPD+G418 and failure to grow on 5-FOA (Fig. 3.6.S2B). We 
subsequently performed quantitative growth assays (in triplicate) on the tetrads passing 
the 5-FOA and G418 segregation test (Fig. 3.6.S2B, S2C). Each profile (Fig. 3.6.S2C) 
was analyzed and quantified to detect any growth defects in yeast. 10 out of 40 human 
genes assayed in this manner functionally rescued yeast from the lethal phenotype. For 
population-based plasmid complementation assays, we selected the spores on SC-Arg-
His-Leu+Can-Ura +/- G418. A complementation consists of spores being able to 
proliferate on both in the presence (+G418, selecting for spores with the null allele) and 
absence (-G418, selecting for wild-type spores). Assays where this threshold was not met 
was deemed non-complementing.  
2. Yeast temperature-sensitive (ts) assays 
Where available, temperature-sensitive (ts) strains from Li et al. (Li et al. 2011) were 
used to assay human gene complementation. These strains grow ideally at lower 





human gene expression vectors and empty vector control plasmids (pAG416-GPD-
ccdB+6Stop) into the corresponding ts strains (Fig. 3.6.S3A). Transformants were plated 
on SC-Ura media at both permissive and restrictive temperatures allowing us to control 
for transformation efficiency and expression toxicity while simultaneously testing for 
functional replacement by the human gene (Fig. 3.6.S3B). Successful complementations 
consisted of transformants with the human gene surviving at both conditions (growth at 
permissive or restrictive temperatures) while those with the empty vector failing to 
survive at restrictive temperatures. Successfully humanized strains were then subjected to 
quantitative liquid growth assays to monitor robustness of complementation (Fig. 
3.6.S3C). 
 3. Genomic replacement via CRISPR-Cas9 
29 human genes were assayed using a CRISPR-Cas9 mediated yeast genome 
editing protocol as previously described (Kachroo et al. 2017; Akhmetov et al. 2018a). 
For every yeast gene to be replaced endogenously, a minimum of 2 synthetic guide RNAs 
(sgRNA) with high on-target and high off-target scores were designed using the Geneious 
v10.2.6 CRISPR-Cas9 tools suite. Selected sgRNAs were ordered as oligos from IDT and 
cloned into yeast CRISPR-Cas9 knockout plasmids from the yeast toolkit (YTK) (Lee et 
al. 2015) to express a synthetic guide RNA, Cas9 nuclease and a selectable marker (Ura). 
Wild-type yeast strains (s288c/BY4741) were transformed with a knockout plasmid and a 
repair template in the form of a PCR amplicon composed of the human open reading 
frame flanked with sequence homology to the targeted yeast locus (Fig. 3.6.S4A). 





While CRISPR-mediated double-stranded breaks are intrinsically lethal, targeted editing 
of an essential gene locus acts as an added layer of selection in replacing the human gene 
of interest, allowing cells to survive only if the human ortholog being assayed 
functionally replaces the yeast gene at the appropriate locus (Kachroo et al. 2017; 
Akhmetov et al. 2018a). Surviving colonies (Fig. 3.6.S4B) obtained in the presence of 
repair templates were screened for successful humanization by colony PCR using primers 
outside the region of homology. Confirmed clones were Sanger sequenced and 
subsequently subjected to quantitative liquid growth assays to evaluate overall fitness. In 
the case of tubulins, all CRISPR-Cas9 assays were carried out in a BY4741 tub3Δ strain 
to avoid homologous repair of the TUB1 locus by the TUB3 gene. To generate diploid 
strains homozygous for human β-tubulin alleles, we replaced the yeast TUB2 allele in our 
heterozygous diploids by re-transforming the CRISPR-Cas9 and sgRNA expression 
vector specifically targeting yeast β-tubulin allele (TUB2) and selected for viable strains 
without supplying an external repair template, forcing homology -directed repair of the 
TUB2 lesion by the human ortholog(s) on the other homologous chromosome. 
3.3.4. Growth Assays  
Liquid growth assays were performed in triplicate using a Biotek Synergy HT 
incubating spectrophotometer in 96-well format. All humanized strains were pre-cultured 
to saturation in YPD and diluted into 150µL of medium to finally have 0.05-0.1 x 10⁷ 
cells/ml. Each growth assay lasted for 48 hrs, with absorbance measured at 600nm every 
15 min. For human genes assayed using heterozygous diploid deletion collections, 
growth assays were performed in YPD, SC-Ura, and YPD+G418 medium to confirm 





assays, humanized strains were grown in YPD. Human genes assayed via temperature-
sensitive alleles were grown at both temperatures (permissive and restrictive). Growth 
curve data was processed in Rstudio and plotted using the ggplot2 package or GraphPad 
Prism. 
3.3.5 Microscopy and image analysis 
For imaging, for plasmid-based complementation assays, all the yeast strains were 
grown in selection conditions to maintain the plasmid (Ura+). For the genomically 
integrated humanized yeast strains, the cells were grown in YPD medium.  
For DAPI staining, cells were grown in liquid medium to saturation and fixed in a 
final concentration of 3.7% (v/v) formaldehyde for 10 minutes at room temperature. Cells 
were then washed with water and 1M sorbitol after which they were resuspended in 
sorbitol (1x of the original volume) and fixed in 50% ethanol (final concentration). The 
cells were washed and resuspended in 1M sorbitol. DAPI was then added to the solution 
to a final concentration of 1µg/ml and incubated for 5-10 min at room temperature. 
Cells were imaged using a Nikon TE-2000-E inverted microscope with a Apo 
40x/NA 0.95 objective and Cascade II 512 camera (Photometrics), Lambda LS Xenon 
light source and Lambda 10-3 filter wheel control (Sutter Instrument) with a motorized 
stage (Prior Scientific). All imaging and parameters were set via the Nikon NIS Elements 
Imaging Software. Images were captured at 1 frame per second through a 89000ET filter 
set (Chroma Technology) with channels “DIC L”, “FITC” (Ex 490/20, Em 525/36). GFP 
fluorescence images were collected with an exposure time of 1s. DAPI images for the 





microscope with a Plan-Apochromat 63x/1.4 oil-immersion objective with standard 
DAPI (Ex 350/50, Em 455/50) wavelength setting and operated using Zeiss ZEN 
Microscope software. 
Cell size measurements were performed with a minimum of 10 fields of view and 
2000 cells per strain. Image analysis and quantification was performed using FIJI/ImageJ 
(Schindelin et al. 2012, 2015). For quantifying cell size, edge detection scripts were 
written as Python scripts and FIJI macros.  
3.3.6. Mating assays  
Since the genes assayed via CRISPR were tested in BY4741 (genotype MATa 
his3Δ1 leu2Δ0 met15Δ0 ura3Δ0), the humanized strains were mated to a BY4742 
derivative (genotype MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 mkt1-D30G rme1-ins308A 
tao3-E1493Q) so that diploids could be selected on SC-Lys-Met medium. Strains were 
first patched on a YPD plate. The humanized strain being assayed and its complementary 
mating strain were streaked perpendicular to each other and were grown overnight. These 
were then replica plated on SC-LYS-MET media to select for diploids. In cases of 
humanized septin mating assays, haploids were mated on YPD as described above and 
streaked on SC-Lys-Met to select for diploids following which they were incubated for 3 
days before imaging (Fig. 3.6.5B, S7B). For sporulation, diploids were grown overnight 
on GNA rich pre-sporulation medium. Individual colonies from this plate were inoculated 
into a liquid sporulation medium containing 0.1% potassium acetate, 0.005% Zinc 
acetate, and were incubated at vigorous shaking at 25˚C for 3-5 days. Spores were 





spores were replica plated on SC-Lys and SC-Met media to select haploid spores. This 
assay enabled subsequent mating of humanized haploids to each other and also 
generating homozygous diploids for the human genes via CRISPR-Cas9. All 
heterozygous diploids were scored for spore viability and 2:2 segregation of LYS, MET, 
and MAT loci.  
3.3.7. Gene tree construction 
Maximum likelihood trees for each cytoskeletal family were constructed with the 
Gamma LG protein model with the rapid hill-climbing algorithm bootstrapping 1000 
replicates on human and yeast protein sequences curated from the Uniprot database. All 
trees were computed using Geneious v10.2.6’s RAxML’s plugin (Stamatakis 2014) 
(v8.2.11). 
3.3.8. Human cytoskeleton RNA expression analysis  
RNA expression profiles across human tissue types were obtained from the 
Human Protein Atlas (Uhlén et al. 2015). We extracted the human cytoskeletal gene set 
from the available expression data normalized via FPKM. The normalized data was then 
processed in Rstudio and plotted with ggplot2 using the ggridges package. 
3.3.9. SCMD-SGD database searching and evaluations 
Genetic interaction data for each assayed yeast cytoskeletal gene was downloaded 
from the Saccharomyces Genome Database (Cherry et al. 1998, 2012) (SGD) to curate 
all the interaction partners for the assayed yeast cytoskeletal gene set. Imaging data and 
morphology parameter files were downloaded from the Saccharomyces Morphological 





observed in the case of actin and septin interactors, we specifically examined the long 
(C103) and short axis (C104) lengths of mother cells budded (SCMD cell types B and C) 
and unbudded cells (SCMD cell type A). C103/C104 ratios were calculated and ranked in 
ascending order. We reasoned that deletion strains resulting in small cells with round 
phenotypes (similar to our humanized actin yeast strains) would have ratios close to 1. In 
contrast, abnormally shaped cells (similar to our humanized septin yeast strains) would 
have larger (>1) C103/C104 ratios. We ranked the deletion collection phenotypes by the 
long to short axis ratios of the budded cells as a measure of circularity. Significance was 
determined by the hypergeometric test. 
 
3.4. RESULTS 
3.4.1. Human cytoskeletal genes can functionally replace their corresponding yeast 
orthologs 
Of the 324 cytoskeleton genes in yeast, 101 are essential for growth in standard 
laboratory conditions and possess identifiable human orthologs as determined by 
EggNOG (Huerta-Cepas et al. 2016) and InParanoid (Sonnhammer and Östlund 2015) 
(Fig. 3.6.S1). We focused on orthologs constituting major structural elements of the 
eukaryotic cytoskeleton, including actin, myosin, septin, and tubulin gene families 
identifying 106 testable human-yeast ortholog pairs. By restricting our tests to elements 
of the yeast cytoskeleton essential for cell growth in standard lab conditions, we could 
initially assay replaceability of human genes in yeast via simple growth rescue assays. 
Since human cytoskeletal gene families have undergone multiple duplication events, we 





yeast ortholog to assay if present day human genes could still complement the lethal loss 
of their yeast ortholog(s).  
Complementation assays in yeast were carried out in 3 different ways (Fig. 3.6.2), 
wherein orthologous yeast genes could be (i) genetically segregated away after 
sporulation of a heterozygous diploid deletion strain (Wach et al. 1994; Winzeler et al. 
1999; Giaever et al. 2002) (Fig. 3.6.S2A) (ii) inactivated via a temperature-sensitive 
allele(Li et al. 2011; Kofoed et al. 2015) (Fig. 3.6.S3A) or (iii) endogenously replaced by 
homologous recombination repair with the human ortholog(s) following CRISPR-Cas9 
cleavage (Kachroo et al. 2017; Akhmetov et al. 2018a) (Fig. 3.6.S4A).  
Each assayed human gene was sequence verified and either sub-cloned into a 
single-copy (CEN) yeast expression vector transcriptionally controlled by a constitutive 
GPD promoter [in assays (i) and (ii)] or PCR amplified with flanking homology to the 
yeast locus of interest [in assay (iii)]. In cases involving heterozygous diploid sporulation 
assays, we leveraged the heterozygous diploid deletion collection (Giaever et al. 2002), 
wherein one copy of the yeast ortholog being queried has been replaced with a KanMX 
resistance module thus enabling selection of haploids with either the null (conferring 
G418 antibiotic resistance) or the wild-type allele (susceptible to G418) post sporulation 
(Fig. 3.6.S2B, C). In cases of temperature-sensitive (ts) haploid strains, a single gene of 
interest is modified to carry mutations inactivating its corresponding gene product at 
restrictive temperatures (37°C) but permitting growth at lower temperatures (25°C), thus 
allowing for temperature-dependent growth rescue complementation assays (Fig. 





were assayed by natively substituting their yeast ORF mediated via CRISPR-Cas9 
(Akhmetov et al. 2018a) (Fig. 3.6.S4B, C).  
By taking advantage of full-length human cDNA clones from the human 
ORFeome(Rual et al. 2005; Lamesch et al. 2007; Temple et al. 2009) and existing yeast 
strains with null (or conditionally null) alleles for the relevant orthologs (Winzeler et al. 
1999; Giaever et al. 2002; Li et al. 2011; Kofoed et al. 2015), we could successfully 
assayed 89 of 109 human-yeast ortholog pairs, accounting for 50 of 62 (~81%) human 
genes across the 7 major cytoskeletal gene families. We observed that 13 (~26%) of the 
50 tested human genes could functionally replace their yeast orthologs in at least one of 
the three assay types, while 37 (~72%) could not (Fig. 3.6.2). In particular, we found that 
2 of 7 actin, 4 of 14 myosin (heavy chain), 4 of 13 septin, 2 of 9 β- and 1 of 2 ɣ-tubulin 
human genes complemented lethal growth defects caused by loss of their corresponding 
yeast orthologs, whereas genes from the human light chain myosin and α-tubulin families 
did not (Fig. 3.6.3). Since the septin family had expansions in both human and yeast 
lineages, we systematically assayed all human septins against 4 yeast deletion 
backgrounds (CDC3, CDC10, CDC11, and CDC12), observing that complementing 
human septins functionally replaced only CDC10. Thus, within 5 of these 7 essential 
cytoskeletal gene families, at least one extant human gene could substitute for its yeast 
ortholog, indicating that the yeast and human genes both still executed the essential roles 
of their shared opisthokont ancestor.  
To assay robustness of complementation and better measure the extent to which 
human orthologs complemented in standard laboratory conditions, we performed 





(where possible, temperature-sensitive strains were measured at 37°C) (Fig. 3.6.S5). 
Humanized strains assayed via plasmid-based complementation of the heterozygous 
diploid sporulation assay were assayed both in selective (SC-Ura) and rich medium 
(YPD). These strains while retaining the human gene encoding plasmid showed no major 
growth defects in YPD. However, they exhibited significantly slower growth rates in SC-
Ura medium compared to their wild-type yeast counterparts (Fig. 3.6.S5A). Besides Hs-
ACTBL2 and Hs-SEPT3, all other humanized strains showed drastically reduced growth 
rates in SC-Ura selective medium (Fig. 3.6.S5A (i)) compared to wild-type yeast. In 
particular, we found that strains with humanized heavy myosins and septins had mean 
doubling times over twice as long as wild-type (Fig. 3.6.S5A (i), Table 3.7.1). However, 
in rich medium (YPD) these fitness defects were substantially rescued (Fig. 3.6.S5A (ii)). 
We found that replacing Hs-MYH9 particularly affected growth to saturation phase in 
YPD with doubling time in these strains being twice the wild-type rate (Fig. 3.6.S5A (ii), 
Table 3.7.1). With respect to temperature sensitive growth rescue assays we found that 
humanized strains assayed in this manner generally exhibited slower growth rates with 
humanized ɣ-tubulin (Hs-TUBG2) strains in particular showing drastically slow growth 
rates, doubling at one-quarter the rate of wild-type lab strains and failing to reach 
comparable biomass at saturation (Fig. 3.6.S5B, Table 3.7.1). In contrast, we 
genomically replaced β-tubulins Hs-TUBB4 and Hs-TUBB8 both shared similar growth 
profiles to wild-type yeast strains (Fig. 3.6.S5C, Table 3.7.1). 
To probe growth effects of humanization in more detail, we subjected the strains 
(except those assays performed in a temperature-sensitive strain background) to 





humanized strains grew at wild-type rates at 25°C (Fig. 3.6.S11 bottom), we observed 
differential effects at 37°C (Fig. 3.6.S11 top). Specifically, yeast with human septins Hs-
SEPT6, Hs-SEPT9, and Hs-SEPT10 all reached stationary phase at a lower biomass 
compared to the wild-type yeast. Although septin genes complemented the lethal growth 
defect, they performed sub-optimally, especially under stress conditions, suggesting that 
they may be failing to complement other non-essential roles of the yeast orthologs, 
meriting a deeper examination of additional gene family specific phenotypes, especially 
in light of recent observations that cdc10Δ phenotype severity may also be modulated by 
altering plasma membrane properties (Michel et al. 2017). 
3.4.2. Sporulation and meiotic roles of human β-tubulin are regulated by their 
native regulation in yeast 
In yeast, β-tubulin (TUB2) is primarily associated with chromosome segregation 
during budding (Neff et al. 1983; Vogel et al. 2001; Bode et al. 2003) (asexual 
reproduction involving mitosis), mating (Bardwell 2005; Molk and Bloom 2006) (sexual 
reproduction) and sporulation (Neiman 2011) (starvation response involving meiosis). In 
our complementation assays, we observed that the human β-tubulins Hs-TUBB4 and Hs-
TUBB8 only complemented the loss of TUB2 when genomically inserted at the yeast 
TUB2 locus but failed to do so in plasmid-based segregation assays in heterozygous 
diploid knockout strains. Notably, plasmid expression was controlled transcriptionally by 
a constitutive GPD promoter; both human genes failed to rescue its corresponding 
heterozygous diploid yeast gene deletion leading to sporulation defects producing either 
mis-segregated (Fig. 3.6.4A - left panel) or inviable spores (Fig. 3.6.4B - left panel). 





TUBB8 at a minimum supported mitosis and asexual cell division via budding, but it was 
unclear if they supported meosis and sporulation. 
In order to determine whether replaceable human β-tubulins also rescued meiotic 
and sporulation specific roles of their yeast ortholog, we mated haploid humanized strains 
(harboring human genes at the corresponding yeast genes’ native genomic loci) with 
wild-type yeast. These humanized strains successfully mated with wild-type yeast strains 
to produce viable diploids. We assayed if these heterozygously humanized strains could 
successfully perform meiosis by sporulating the diploids generated from our mating 
assays. We observed high spore viability for both Hs-TUBB4 (~96.9%) and Hs-TUBB8 
(~84.4%) (Fig. 3.6.4A and 4B - right panel). Having shown that both replaceable β-
tubulins can mate with the wild-type strains (yielding high sporulation efficiency similar 
to the wild-type diploids) (Fig. 3.6.S6A - right panel), we next asked whether strains 
homozygous for human β-tubulins could behave similarly. We sporulated the humanized 
homozygous β-tubulin diploid strains assaying for proper progression through meiosis 
via sporulation and found that these diploid humanized yeast strains also sporulated in 
both Hs-TUBB4 (93.8%) and Hs-TUBB8 (84.4%) cases. (Fig. 3.6.4A and 4B - middle 
panel) similar to their heterozygous (Fig. 3.6.4A and 4B - right panels) and wild-type 
diploids (~87.5%) (Fig. 3.6.S6A - right panel including 2:2 segregation of the MAT, 
LYS and MET loci after dissecting tetrads, see Fig. 3.6.S6). These results reveal that 
native regulation of β-tubulin is more critical to yeast than the species origin of the gene. 
The functional replacement of TUB2 by two human orthologs, Hs-TUBB4 and Hs-





to successfully perform their roles in meiosis and sporulation successfully, similar to the 
yeast β-tubulin TUB2 (Fig. 3.6.S6) 
3.4.3. Human septin orthologs and their isoforms can carry out CDC10’s meiotic 
and mating role 
Next, we considered if human orthologs of yeast septins could also perform 
conditionally essential cytoskeletal roles in yeast. The yeast septin family is a particularly 
interesting case of gene family expansion as there have been duplications in both the 
human and yeast lineages, suggesting ancestral functions might have been distributed 
across paralogs in both species. Yeast possess 7 septin genes (CDC3, CDC10, CDC11, 
CDC12, SPR3, SPR28, and SHS1) while humans have 13 septin genes(Pan et al. 2007) 
(Fig. 3.6.1, 3). 3 of the 7 yeast septins (CDC3, CDC11, and CDC12) are essential for 
vegetative growth (budding) in standard lab conditions. We performed 39 of the 91 total 
possible septin complementation assays in each of the 3 septin null backgrounds, we 
found that none of the human orthologs assayed could complement CDC3, CDC11, and 
CDC12.  
While the remaining 4 septins (CDC10, SPR3, SPR28, and SHS1) are not 
essential for vegetative growth, CDC10 however, plays essential roles in meiotic cell 
division, mating, and spore health, with cdc10Δ strains exhibiting severe mating and 
sporulation defects (Douglas et al. 2005; McMurray et al. 2011; Neiman 2011; Kim and 
Rose 2015). Indeed, we also observed that the diploid strain heterozygously null for 






To identify human orthologs capable of rescuing sporulation defects caused by 
the loss of CDC10, we systematically assayed each of the 13 human septin orthologs. We 
observed that 4 of 13 septins (Hs-SEPT3, Hs-SEPT6, Hs-SEPT9, Hs-SEPT10) were 
capable of functionally complementing CDC10’s meiotic and sporulation roles (Fig. 
3.6.3). Since cdc10Δ strains additionally show severe mating defects(McMurray and 
Thorner 2008; McMurray et al. 2011) (Fig. 3.6.S7A), we next asked if the expression of 
individual human septin orthologs in a cdc10Δ strain could facilitate mating. We assayed 
this by cloning human septin genes into yeast expression vectors (Materials and 
Methods) and individually transformed cdc10Δ strains with each human septin clone. 
Subsequently, we mated each MATa transformant to a complimentary MATα strain (Fig. 
3.6.5A). While only 4 of 13 tested human septins, Hs-SEPT3, Hs-SEPT6, Hs-SEPT9, and 
Hs-SEPT10, rescued CDC10’s essential meiotic role, we found that all assayed septins 
were capable of performing CDC10’s role in mating (Fig. 3.6.5B). 
Unlike in yeast, human septins are known to exhibit a variety of different splice 
forms (Weems and McMurray 2017; Hall and Russell). Based on the availability of 
verified splice form (as per the Uniprot database) in the human ORFeome, we tested 
different isoforms of Hs-SEPT6 and Hs-SEPT10 observing contrasting results with both 
sets of isoforms. While the canonical isoform of Hs-SEPT6 functionally complemented 
its yeast ortholog CDC10, its testes isoform with an extended C-terminus failed to do so 
(Fig. 3.6.5C). However, when testing the uterine and canonical isoforms of Hs-SEPT10, 
the opposite was true, with only the truncated uterine form functionally complementing 
CDC10 (Fig. 3.6.5D). Thus for both, the presence of an extended C-terminus negatively 





results suggest that human septin orthologs can effectively rescue essential CDC10 
phenotypes in mating and meiosis.  
3.4.4. Humanized yeast strains differ in cell morphology 
Eukaryotic cytoskeletal proteins dynamically control cell shape and morphology. 
We next asked whether humanizing elements of the yeast cytoskeleton would result in 
any visually obvious phenotypic changes to cell morphology. Using light and 
fluorescence microscopy, we imaged the 13 humanized strains generated and quantified 
cell shape and size across >22,000 individual cells (Materials and Methods). In the case 
of humanized heavy myosins, Hs-MYH7B and Hs-MYH11, we did not observe any 
obvious defects in the cell morphologies, but introducing Hs-MYH1 and Hs-MYH9 
induced a slight size increase leading to more spherical cells (Fig. 3.6.6A, S7). However, 
the effect, while significant, was small, and their median sizes were within 1% of wild-
type (Fig. 3.6.6A, S8). In contrast, strains with humanized actins, tubulins, and septins 
had visibly different cell morphologies (Fig. 3.6.6A, S8). Humanizing actin visibly 
reduced cell size, resulting in round/spherical cells with small buds (Fig. 3.6.6A, S8). 
Complementing human ɣ-tubulin Hs-TUBG2 showed the opposite phenotype, resulting in 
enlarged and ovoid cells (Fig. 3.6.6A, S8). The endogenously replaced human β-tubulin, 
Hs-TUBB4, also showed reduced cell size (Fig. 3.6.6A, S8). Since α- and β-tubulins 
physically associate to form heterodimers we introduced human β-tubulins Hs-TUBB4 
and Hs-TUBB8 into a strain expressing GFP-tagged α-tubulin (Huh et al. 2003) (TUB1-
GFP), allowing us to visualize microtubules and observe if chimeric yeast-human αβ-
tubulin heterodimers were being assembled (Fig. 3.6.S10A). While we observed 





Hs-TUBB4 (Fig. 3.6.S10A), indicating a synthetic genetic interaction between the GFP 
tagged form of TUB1 and Hs-TUBB4, absent from the interaction of Hs-TUBB4 and 
native TUB1. Examining the distributions further, we observed a bimodal distribution of 
cell sizes (Fig. 3.6.S10B) for Hs-TUBB4 suggestive of cell cycle defects (as for TUB2 
Ser172 mutations (Caudron et al. 2010)). In contrast, the cell morphology and 
microtubule assembly of the Hs-TUBB8 TUB1-GFP strain appeared similar to wild-type. 
All replaceable septin strains (Hs-SEPT3, Hs-SEPT6, Hs-SEPT9, and Hs-
SEPT10) showed abnormal cell morphologies (Fig. 3.6.6A, B, S8), notably reminiscent 
of elongated pseudohyphal forms often observed in septin mutant strains as a function of 
improper activation of the morphogenesis checkpoint in the budding yeast cell cycle 
(Keaton and Lew 2006; McMurray et al. 2011). In order to verify if the replaceable 
human septins localized to the bud neck, we expressed C-terminal EGFP-tagged Hs-
SEPT4 (non-replaceable) and Hs-SEPT9 (replaceable) in heterozygous diploid deletion 
strains. We observed that when sporulated, the eGFP-tagged, Hs-SEPT9, can also rescue 
the sporulation defect induced by deletion of CDC10 (Fig. 3.6.S9A), whereas the mating 
defect in cdc10Δ haploids is rescued by both Hs-SEPT9 and Hs-SEPT4 eGFP-tagged 
genes (Fig. 3.6.S9B). We then tested the localization of both these human septins in 
haploid cdc10Δ strains. We did not see the localization at the bud neck (Fig. 3.6.S9C); 
rather, we observed the GFP fluorescence diffused throughout the cell. Therefore, we 
conclude that the likely mode of the rescue of yeast septin function is partial or indirect in 
nature. The assay also reveals that the strains do not have any major spore formation 
defect as we see several colonies growing on SC-Arg-His-Leu+Can-Ura-G418 medium 





reported that cdc10∆ null mutants do have aneuploid genomes (McMurray et al. 2011), in 
the conditions that we tested (heterozygous diploid deletion sporulation assay in SC-Arg-
His-Leu+Can-Ura+/-G418 with growth for 3 days), we rule out aneuploidy as a 
consequence of haploinsufficiency. However, we also observed that many cdc10Δ 
haploid colonies that grow in the presence of human gene (Hs-SEPT9) were able to also 
grow independent of the plasmid suggesting that the replaceability is not optimal and the 
expression of Hs-SEPT9 induces segregation defects in these cells that may likely induce 
aneuploidy (Figure 3.S9A). 
Taken together, these data suggest that human septins fail to fully complement the 
role of CDC10. The fraction of elongated cells differed across human septins, with Hs-
SEPT3 producing lower proportions of elongated cells (Fig. 3.6.6A, S8). To assay 
whether this effect arose from defective cytokinesis, we quantified the nuclei per cell by 
DAPI staining. We indeed observed that the cells were multinucleated (Fig. 3.6.6B). 
Despite this severe cell morphology defect, all replaceable human septins still enabled the 
strains to maintain growth rates comparable to wild-type strains (Fig. 3.6.3D). Taken 
together, we found that multiple human septins can rescue the essential meiotic and 
segregation roles of CDC10, but result in abnormal cell morphologies with delayed 
and/or defective cytokinesis.  
3.4.5. Humanized cytoskeletal orthologs phenocopy cell morphology defects 
observed by deleting interaction partners 
In spite of rescuing lethal growth defects, the humanized strains showed visible 
cell morphology defects consistent with the known roles of the humanized genes. These 





of the non-essential roles of the yeast cytoskeletal orthologs regulating cell shape and 
morphology. While the replaceable human cytoskeletal genes functionally complement 
the lethal growth defect caused by deletion of their yeast orthologs, we hypothesized that 
they failed to fully interface with their constituent interaction networks, thereby breaking 
key non-essential interactions regulating cell morphology. If true, this would imply that 
the humanization of a particular cytoskeletal yeast gene might phenocopy the deletion of 
its corresponding non-essential yeast interaction partner(s) (Fig. 3.6.7A).  
To test this hypothesis, we curated both physical and genetic interaction partners 
of all humanizable yeast orthologs from the Saccharomyces Genome Database (SGD) 
(Cherry et al. 1998, 2012) and mined the Saccharomyces Cerevisiae Morphological 
Database (SCMD) (Saito et al. 2004), a database cataloging the morphologies of ~1.9 
million cells across 4,718 haploid non-essential gene deletion backgrounds in yeast and 
measuring ~ 501 cell shape parameters. Specifically, we considered the humanized 
strains showing drastic morphology changes and computed the ratio of long to short cell 
axes as a measure of cell roundness or elongation. Deletion strains with elongated 
phenotypes (i.e., similar to humanized septin strains) would have higher axes ratios, and 
strains with round/spherical cells (i.e., similar to humanized actin strains) would have 
axes ratios centered around 1. To ensure stringency in curating interactors of both ACT1 
and CDC10, we restricted the interactions a priori to those reported at least twice in the 
literature. Additionally, we further restricted the interacting partners list to only those that 
contained SCMD cell morphology measurements for the corresponding deletion strain. 
To test our hypothesis, we next plotted the z-scores of the circularity index and asked 





circular morphologies (<2 standard deviations) and contrastingly an enrichment of 
CDC10 interactors in deletion strains with elongated morphologies (>2 standard 
deviations) (Fig. 3.6.7B). Indeed, we found a significant overlap, albeit not a very large 
one, between both the physical and genetic interactors of humanizable cytoskeletal genes 
and their observed phenotypes when deleted. In particular we found 3 physical (p ≤ 8.9 x 
10-4) and 11 genetic interactors (p ≤ 2.9 x 10-6) of ACT1 enriched for drastic cellular 
morphologies. In the case of yeast septins, we found 3 physical (p ≤ 4.3 x 10-4) and 10 
genetic (p ≤ 5.9 x 10-6) interactors of CDC10 enriched for elongated morphologies (Fig. 
3.6.7B & C). Taken together, these data suggest that the replaceable human orthologs 
may indeed fail to maintain non-essential physical interactions controlling cell shape and 
morphology and genetically perturb relevant morphology genes. It is possible that the 
amplification of cytoskeletal elements in the human lineage may have led to distribution 
of specific sub-functions and/or loss of interactions across duplicated human genes 
compared to the opisthokont ancestor. Our observations suggest that replaceable human 
cytoskeletal genes functionally complement the essential roles of their yeast ortholog, but 
simultaneously break key non-essential cytoskeletal associations, thereby phenocopying 
the deletion of their interaction partners. 
 
3.5. DISCUSSION 
Identifying how genes retain and/or distribute roles across their families is key to 
understanding the diversification of conserved genes across organisms. Cross-species 





orthologous genes even over large evolutionary timescales. While Saccharomyces 
cerevisiae (Baker’s yeast) and Homo sapiens (humans) diverged from their opisthokont 
ancestor nearly a billion years ago, both species still share thousands of orthologous 
genes and high-throughput humanization assays in yeast have found that many human 
genes are capable of substituting for their yeast orthologs with rates up to 47%, 
depending on strains and assays (Kachroo et al. 2015; Hamza et al. 2015; Laurent et al. 
2016, 2019; Sun et al. 2016; Yang et al. 2017). Most of these complementation tests until 
recently were performed in the absence of gene family expansions and revealed many 
humanizable systems, including the proteasome, and sterol and heme biosynthesis 
pathways (Kachroo et al. 2015, 2017; Hamza et al. 2015; Sun et al. 2016; Yang et al. 
2017; Laurent et al. 2019). In this study, we sought to better understand the functional 
equivalence of human and yeast orthologs that play key structural roles in the eukaryotic 
cytoskeleton, particularly focusing on how gene family expansions in cytoskeletal 
lineages might have diversified in function across their respective gene families. 
By systematically humanizing key structural components central to the yeast 
cytoskeleton, we determined that 5 of the 7 (~71%) assayed eukaryotic cytoskeletal gene 
families could be successfully humanized by at least one human ortholog within a family. 
In all, 13 (26%) out of 50 tested human cytoskeletal proteins could at least partially 
substitute for the corresponding yeast gene and complement a lethal growth defect caused 
upon loss of the yeast ortholog (Fig. 3.6.3A). Interestingly, these results are broadly 
consistent with our previous study, where 17 (~28%) of 60 tested regulatory genes of the 





It is noteworthy that we were unable to successfully humanize yeast with any 
member of the myosin light chain or α- tubulin gene families, suggesting extensive 
functional divergence in yeast-human ortholog pairs resulting in failure to substitute for 
each other across species. This variation in replaceability was not merely explainable by 
obvious patterns across human genes (at least as captured by the variation in their 
expression patterns across tissues; Fig. 3.6.S12A), nor was it explained by their degree of 
sequence similarity. As with previous yeast humanization studies (Kachroo et al. 2015), 
sequence conservation among replaceable and non-replaceable human cytoskeletal genes 
did not significantly predict replaceability (Fig. 3.6.S12B). While uncovering additional 
new properties predicting replaceability is beyond the scope of this study, future efforts at 
systematically constructing chimeric human/yeast genes have the potential to reveal 
which regions of the human/yeast orthologs are critical to maintain functional 
compatibility, perhaps enabling targeted humanization of specific domains and regions of 
genes (Barger et al. 2019).  
With only slight differences in mitotic growth between wild-type and most 
humanized strains observed under standard laboratory growth conditions, our results 
suggest robust complementation of essential cellular roles in most cases. However, we 
subsequently found incomplete complementation of multiple non-essential cellular roles. 
We found that human β-tubulins Hs-TUBB4 and Hs-TUBB8 remarkably complemented 
TUB2’s roles even in sexual reproduction, including sporulation and mating. However, 
this was contingent on genomic integration under the native yeast regulation, consistent 





et al. 2017) with overexpression of β-tubulin leading to toxicity, chromosome loss and 
cell cycle arrest (Burke et al. 1989; Weinstein and Solomon 1990; Abruzzi et al. 2002). 
For the septin gene family, which has expanded to consist of 7 yeast genes to 13 
in humans, we found evidence for functional divergence across family members in both 
human and yeast lineages, with human genes tending to only fulfill a subset of specific 
roles of their yeast ortholog(s). While none of the human septin orthologs individually 
rescued essential roles of the yeast CDC3, CDC11, and CDC12 genes, we found that 4 
human septin orthologs (Hs-SEPT3, Hs-SEPT6, Hs-SEPT9, Hs-SEPT10) complemented 
CDC10’s essential roles in meiosis and sporulation. However, severe mating defects 
caused by deleting CDC10 in a haploid strain background were completely rescued by 
every assayed member of the human septin family (Fig. 3.6.5A, B), indicating that all 
human septin orthologs executed the roles of their yeast counterparts to at least some 
extent. Extending this theme further, we saw that replaceability of Hs-SEPT6 and Hs-
SEPT10 differed based on their protein isoforms, demonstrating functional divergence 
not just across human septin paralogs but also within splice forms of a gene (Fig. 3.6.5C, 
D). Taken together, such specific complementation patterns suggest a complex 
evolutionary trajectory and delegation of function across the septin gene family in 
eukaryotes. It remains to be seen if human septin orthologs can individually complement 
their non-essential yeast counterparts SHS1, SPR3, and SPR28. While septin gene family 
expansions have been understood to predominantly bring functional redundancy and 
robustness within its interactome, recent studies have identified tissue specific roles 
within human septin orthologs (Fujishima et al. 2007; Tsang et al. 2008; Kaplan et al. 





to be remarkably conserved albeit their involvement in seemingly unrelated processes 
across species (Falk et al. 2019).  
Over the course of these complementation assays, we observed diverse cell 
morphologies among humanized strains that were broadly gene family specific, with 
complementing myosins and β-tubulins largely remaining unchanged, but actin, ɣ-
tubulin, septin families showing characteristic morphological differences as drastic as 
defective cytokinesis. Owing to the crucial role of the cytoskeleton in maintaining cell 
shape, we found that replaceable human cytoskeletal genes tend to perform its yeast 
ortholog’s essential roles equivalently while simultaneously breaking key non-essential 
cytoskeletal genetic interactions regulating cell morphology. In agreement with our 
findings, a recent study systematically determining cell size regulators in yeast found that 
145 genes of ~400 deletion strains were genetic interactors of actin (Soifer and Barkai 
2014). Replaceable human septin orthologs, in particular, represent interesting and rather 
extreme cases of abnormal cell morphology. Previously, a study showed that introducing 
the A. nidulans septin AspC in S. cerevisiae induces a similar pseudohyphal morphology 
observed when substituting for CDC12 in the septin ring (Lindsey et al. 2010). More 
recently, a report (Kim and Rose 2015) demonstrated that doubly deleting ELM1 and 
FUS3 (both genetic interactors of CDC10) in yeast produces the same filamentous 
elongated morphology with similar cytokinesis defects observed when humanizing 
CDC10. In agreement with these studies, our results suggest that human septins 
sufficiently complement CDC10’s roles by surpassing cellular thresholds for growth but 
not morphology. While in cases of both yeast actin and septin, we indeed find significant 





it is difficult to mechanistically interpret the consequences of genetic interactions or lack 
thereof. However, with significant enrichment in the physical interactors of ACT1 and 
CDC10 associated with the observed cell morphologies, our analyses suggest that human 
cytoskeletal orthologs in yeast may break at least some non-essential protein-protein 
interactions underlying normal cell morphology. It remains to be seen if humanization of 
their corresponding interaction partners can revert yeast cells to normal wild-type like 
morphologies. The genetic and biochemical mechanisms by which human orthologs 
regulate cytoskeletal interactions in yeast are yet to be explored. 
Systematic swaps of humanized cytoskeletal elements in yeast now provide a 
direct view of how compatible human orthologs likely are within their corresponding 
yeast interaction network(s), pointing to conserved and divergent interactions among 
eukaryotes. While our complementation assays tested the ability of human cytoskeletal 
orthologs to singly complement their yeast equivalents, combinatorial multi-gene swaps 
might enable humanization of entire yeast systems to study modularity and paralog-level 
cross-talk between different human cytoskeletal families in a genetically tractable 
eukaryote. Widening the scope of cytoskeletal humanization efforts to include accessory 
motors and chaperones, including kinesins and dyneins, could help advance our 
understanding of eukaryotic cytoskeletal evolution. It remains to be seen if constructing a 
fully human cytoskeleton in yeast would be feasible. 
These humanized strains can now serve as cellular reagents to study complex 
human cytoskeletal processes in a simplified eukaryotic context, allowing functional 
roles of distinct family members to be assayed individually. Screening allelic variants and 





variants in a high-throughput manner (Kachroo et al. 2015; Hamza et al. 2015; Sun et al. 
2016, 2018; Yang et al. 2017; Marzo et al. 2019), paving the way for a better 







Figure 3.6.1. Orthologs in cytoskeletal gene families have undergone extensive 
duplications in Bilaterians.  
(A) (Top) Species divergence across opisthokonts. (Bottom) Heatmap depicting the 
number of orthologs in eukaryotic cytoskeleton gene families (rows) across species 
(columns). Cytoskeletal ortholog counts for model organisms curated from The Alliance 






Figure 3.6.2. Overview of humanization assays.  
For each human-yeast ortholog pair (curated from inParanoid and EggNOG), 
complementation assays in Saccharomyces cerevisiae were performed using 3 strategies: 
(i) genomic replacement at the native yeast loci via CRISPR-Cas9, (ii) temperature-





deletion strain followed by tetrad dissection. Complementing human orthologs were 
further characterized using various phenotypic assays, including quantitative growth 






Figure 3.6.3. Human cytoskeletal genes replace their corresponding yeast orthologs. 
5 of 7 tested cytoskeletal families possess at least one functionally replaceable human 
ortholog. Neither of the tested human light myosin or α-tubulin genes could replace their 
corresponding yeast versions. Each human septin ortholog was tested for replaceability in 
4 yeast septin null backgrounds (CDC3, CDC10, CDC11, CDC12), however, human 
septins complemented only CDC10, non-essential for mitotic growth but essential in 
segregation and mating. (Orthology relationships between human genes and yeast septins 





protein sequences of their respective orthologs (see Materials and Methods). Scale bars 






Figure 3.6.4. Replaceability of human β-tubulins Hs-TUBB4 and Hs-TUBB8 is 
determined by their native yeast expression/regulation.  
Efficiency of sporulation and segregation of both (A) Hs-TUBB4 and (B) Hs-TUBB8 





expressed human β-tubulins Hs-TUBB4 and Hs-TUBB8 (controlled by a GPD promoter) 
fail to complement (left panel) whereas when replaced genomically could both grow and 
mate with wild-type yeast (middle panel). Diploids (both hetero- and homozygous) could 
also proceed through sporulation and meiosis similar to the wild-type yeast diploid strain 
(middle and right panel, see Materials and Methods). For population level 
complementation assays of the heterozygous diploid deletion strains see Fig. 3.6.S6. 






Figure 3.6.5. Human septins differentially rescue meiotic and mating roles of the 
yeast CDC10.  
(A) Mating rescue assay for BY4741 cdc10Δ. (B) All assayed human septins expressing 
strains can mate with BY4742, whereas the empty vector containing BY4741 cdc10Δ 
fails to rescue the mating defect caused by deleting CDC10. Plates were imaged after 3 
days of incubation on SC-Lys-Met (C) and (D) depict differential replaceability of human 
septin splice forms, Hs-SEPT6 and Hs-SEPT10, respectively. The top panels demonstrate 





while the bottom panels show the sequence alignment of the variation across the 







Figure 3.6.6. Yeast strains with humanized cytoskeletal components exhibit distinct 
cellular morphologies.  
(A) Humanized strains show varying cell sizes. Cell areas of humanized strains (in square 





indicate outliers. Humanized actin strains show reduced cell size while myosins and 
tubulins (except ɣ-tubulin) largely remain unchanged. However, humanized septin strains 
show drastically elongated cellular morphologies. Significance comparisons with wild-
type determined by standard t-test with ***, p ≤ 0.001; **, 0.001 < p ≤ 0.01; *, 0.01 < p ≤ 
0.05; NS, p > 0.05, not significant. Additional bright-field images are shown Fig. 3.6.S8. 
(B) Magnified bright-field and DAPI-stained images of humanized septin strains exhibit 
elongated morphologies and are multinucleated as a consequence of defective cytokinesis 






Figure 3.6.7. Humanized cytoskeletal yeast strains with abnormal cell morphologies 
phenocopy deletions of their corresponding yeast ortholog’s interaction partners. 
(A) Schematics of genetic interactions in the wild-type (Left), humanized (Middle), and 





shown to cause similar abnormal cell shapes. (B) Cell shape parameters calculated from 
SCMD and genetic interactors of the replaced yeast ortholog curated from SGD show 






Figure 3.6.S1. Humans and yeast share a substantial number of orthologous genes. 
(A) Global orthology relationships shared between human and yeast genes. Yeast genes 





orange and blue, respectively. (B) Replaceability distribution of human genes across 
structural and regulatory elements of the eukaryotic cytoskeleton. Data for regulatory 






Figure 3.6.S2. Representative heterozygous diploid deletion allele complementation 
assay.  
(A) Schematic outline of humanization assays performed in heterozygous diploid deletion 
yeast strains. (B) Complementation assay performed after sporulation and tetrad 
dissection shows examples of (i) replaceable, (ii) empty vector control, and (iii) non-






Figure 3.6.S3. Representative temperature-sensitive allele complementation assay. 
(A) Schematic outline of the assays performed in temperature-sensitive haploid yeast 
strains. (B) Bottom plate showing that Hs-ACTBL2 functionally replaces the temperature 
dependent lethal growth defect observed at 37ºC (left) as opposed to its empty vector 







Figure 3.6.S4. Representative CRISPR-Cas9 complementation assay.  
(A) Schematic outline of humanization of yeast genes at their native yeast loci using 





stranded breaks caused by the Cas9-sgRNA complex (center plate) by supplying a human 
ortholog containing repair template (right plate) with flanking sequence homology to 
yeast locus of interest. The left plate is a negative control (carrying the same selectable 
marker) without Cas9 and sgRNA expressing transcription units, performed to estimate 
competent cell transformation efficiency. (C) Colony PCR (top) and Sanger sequencing 
(bottom) to confirm the integration of the human ortholog Hs-TUBB4 (Lanes 1 & 3) into 
the corresponding yeast TUB2 genomic locus (Lanes 2 & 4) using primers binding 






Figure 3.6.S5. Growth profiles of humanized strains.  
In all, 89 of 109 possible human-yeast complementation pairs were tested, amounting to 
50 of 62 human genes. We observe that 13 human genes complement the lethal loss of 
the corresponding yeast ortholog. Quantitative growth assays of humanized strains 
measuring absorbance at 600nm assayed via (A) Plasmid based complementation of 
(haploid) humanized yeast strains after sporulation, tetrad dissection and 5-FOA/G418 
screening of heterozygous deletion diploids in (i) SC-Ura or (ii) YPD rich medium at 
30ºC. We observe substantial growth rate differences across both media even though the 





based complementation of temperature-sensitive strains performed at 37ºC. (C) Growth 
profiles of haploid yeast strains at 30ºC after humanization of yeast genes at their native 
genomic loci via CRISPR-Cas9. Solid lines represent the mean of Wild-type (black) and 
humanized (magenta) and shaded boundaries demonstrate +/- standard deviation of 3 






Figure 3.6.S6. Tetrad dissection and analysis of humanized β-tubulin strains.  
(A) Sporulation and tetrad dissection of BY4743 TUB2/tub2::KanMX heterozygous 





strain harboring plasmid borne copy of the yeast TUB2 gene (center panel). Wild-type 
homozygous diploid (right panel) serves as a positive control. Plasmid borne TUB2 
rescues the loss-of-function of the yeast gene at the native locus. (B) Plasmid 
complementation assays of yeast TUB2 by TUB2 (left), Hs-TUBB4 (center), Hs-TUBB8 
(right) on SC-Arg-His-Leu+Can-Ura +/- G418. As in the case of TUB2 (left), a 
complementation consists of spores able to proliferate both in the presence and absence 
of G418. In the case of Hs-TUBB4 (center) selecting for spores harboring the TUB2 null 
allele (+G418 condition) is lethal as the human gene on the plasmid does not 
complement. However, in the case of Hs-TUBB8 (right) the expression of the gene tends 
to be toxic and suggestive of defective sporulation since no spores are able to grow even 
in the -G418 condition. (C) Analysis of segregation of genetic markers in humanized 
tubulin strains. Humanized strains heterozygous diploid for Hs-TUBB4 (left panel) and 
Hs-TUBB8 (right panel) were sporulated, tetrad-dissected, and selected on MET- 
(harbored by BY4741) and LYS (harbored by BY4742) media to check individual loci 
for 2:2 independent segregation. Since we performed tubulin humanizations in a BY4741 







Figure 3.6.S7. Humanized septin mating assays.  
(A) Mating assays performed with BY4741 cdc10Δ strains show severe mating defects 
resulting from deletion of the yeast septin CDC10. BY4741 cdc10Δ strains show severe 
mating defects taking ~10 days to produce diploids, while complementation with human 





with other septins, Hs-SEPT6 and Hs-SEPT10 can individually rescue the mating defect 
caused by the deletion of the yeast ortholog, CDC10. Plate images depict diploids 






Figure 3.6.S8. Yeast strains with replaceable human cytoskeletal genes exhibit 
abnormal cell morphologies.  






Figure 3.6.S9. GFP tagged septins also functionally complement CDC10.  
(A) Complementation assays of GFP-tagged human septins. Plasmid complementation 





SEPT9-eGFP (right) on SC-Arg-His-Leu+Can-Ura-G418 (top) and +G418 (bottom). A 
complementation consists of spores able to proliferate both in the presence and absence 
of G418. In the case of the empty vector control (left) and Hs-SEPT4-eGFP (center) 
selecting for spores harboring the CDC10 null allele (+G418 condition) is lethal as both 
the empty vector and human gene on the plasmid fail to complement. However in the 
case of Hs-SEPT9-eGFP (right), expression of the human gene rescues the sporulation 
defect since colonies are able to proliferate on both + and -G418 conditions. The inset 
shows the replica-plating of the +G418 Hs-SEPT9-eGFP colonies also growing on 5-
FOA indicating segregation defects induced by human gene expression. (B) GFP tagged 
versions of both Hs-SEPT4 and Hs-SEPT9 can rescue the mating defect observed in 
cdc10Δ strains similar to their untagged versions. But Hs-SEPT4-eGFP similarly fails to 
rescue the sporulation defect observed with its untagged version (C) GFP-tagged human 
septins Hs-SEPT4 and Hs-SEPT9 do not localize to the bud neck as seen in the case of 
yeast CDC10. Left panels indicate the DIC (brightfield) channel and right panels indicate 
GFP channel with 20 micron scale bar width. Orange boxes depict zooms of the 






Figure 3.6.S10. Human β-tubulins are successfully incorporated into the 
microtubule structure.  
(A) GFP-fluorescence imaging of the wild-type haploid yeast strain with yeast α-tubulin 
TUB1 tagged with GFP (left panel) and harboring human β-tubulins, Hs-TUBB4 (center 





(A) reveal an obvious cell size increase when replacing Hs-TUBB4 in a TUB1-GFP 
background. Grey violins indicate size distributions. Significance comparisons were 






Figure 3.6.S11. Humanized cytoskeletal strains demonstrate temperature dependent 
fitness defects.  
Quantitative growth assays on humanized strains subjected heat (37°C) and cold (25°C) 







Figure 3.6.S12. Tissue expression patterns and sequence divergence of human 
cytoskeletal genes do not explain replaceability.  
(A) Tissue expression data was curated from Human Protein Atlas for available human 





Ridgeplots are binned by complementation status. (B) Patristic distance between human 
and yeast ortholog pairs does not predict replaceability. Boxplot comparing patristic 
distances of a human-yeast ortholog pair in cytoskeletal families. Patristic distance 







Strain Growth rate in 
YPD (/hrs) 
Growth rate in 
URA (/hrs) 
Doubling time 
in YPD (hrs) 
Doubling time 
in URA (hrs) 
Hs-TUBB4 0.5387127 NA 1.286673 NA 
Wild-type 0.5349355 0.31743107 1.295758 2.183615 
Hs-TUBB8 0.5306934 NA 1.306116 NA 
Hs-SEPT3 0.5014354 0.17186381 1.382326 4.033119 
Hs-SEPT9 0.4563149 0.0981111 1.519011 7.064921 
Hs-SEPT6 0.3638143 0.11498014 1.905223 6.028408 
Hs-MYH11 0.342426 0.12376502 2.024225 5.60051 
Hs-MYH7B 0.3265971 0.10264045 2.122331 6.753158 
Hs-SEPT10 0.324499 0.05488795 2.136053 12.628404 
Hs-MYH1 0.3105858 0.13957244 2.231741 4.966218 
Hs-ACTBL2 0.2970452 0.22531536 2.333473 3.076342 
Hs-MYH9 0.2470456 0.13523041 2.805746 5.125675 
Hs-ACTG2 0.2295563 NA 3.019508 NA 
Hs-TUBG2 0.1349441 NA 5.13655 NA 
 





Chapter 4: Antifungal benzimidazoles disrupt vasculature by targeting 
one of nine β-tubulins3 
 
This final chapter encapsulates what is arguably the most exciting and favorite 
years of my graduate work because it tied together multiple different threads in the lab 
and synthesized in an exciting discovery. The origin of this project dates back 8-10 years 
before I started my Ph.D. As with most projects in the Marcotte lab, this too was 
motivated by understanding how orthologous modules between species functionally 
diverge over time. Over the past several years, the lab established “phenologs” a concept 
that defines orthologous phenotypes between organisms by systematically overlapping 
sets of orthologous genes associated with each organism-specific phenotype (McGary et 
al. 2010). In other words, two phenotypes (between species) are said to be phenologs if 
they are linked by a set of orthologous genes. Most interestingly, this approach supplies 
links between conserved gene modules and how they likely work in organism-specific 
contexts. Besides mapping these seemingly non-obvious phenotypic associations between 
pairs of organisms, this novel approach allows for the identification of new candidate 
genes that are likely implicated in disease. A couple of notable examples include a 
Saccharomyces cerevisiae (Baker’s yeast) model for angiogenesis and an Arabidopsis 
thaliana (thale cress plant) model for Waardenburg syndrome. Obviously, yeast lack 
blood vessels (and angiogenesis) and Arabidopsis thaliana lack ears (to suffer from 
congenital hearing loss) but such orthologous gene sets involved in their corresponding 
 
3This chapter was published as Garge, R.K., Cha, H.J., Lee, C., Gollihar, J.D., Kachroo, A.H., Wallingford, 
J.B., and Marcotte, E.M. (2020). Antifungal benzimidazoles disrupt vasculature by targeting one of nine β-
tubulins. BioRxiv. This work was co-led by Hye Ji Cha and myself. My contributions were performing the 





phenotypes (i.e., cell wall development in yeast and gravitropism) provide unexplored 
routes to study angiogenesis and Waardenburg syndrome respectively. Extending this 
principle further, combining chemical screens with these phenotypic relationships can be 
fruitful in discovering and developing therapies against human diseases. In 2014, by 
leveraging the yeast model of angiogenesis, Hye Ji Cha found that the widely used FDA-
approved antifungal Thiabendazole inhibited angiogenesis functioning as a vascular 
disrupting agent (Cha et al. 2012).  
While this phenolog-driven approach resulted in an exciting discovery, 
Thiabendazole’s molecular target and mechanism of vascular action still remained 
unknown. This chapter describes how Thiabendazole’s target was uncovered using a 
combination of in silico homology modeling with docking, tissue culture, model 
organisms, humanized yeast, and mining chemical properties of benzimidazoles with 
epidemiological signatures of pesticide resistance. This chapter is the synthesis of 
multiple research threads that resulted in an even more exciting discovery of 5 more 
compounds (similar to Thiabendazole) all functioning as vascular disrupting agents. Most 
interestingly, this group included two human intestinal antihelminthics prescribed by the 
World Health Organization making a case to reevaluate their use in young children and 
pregnant women. Finally, this chapter is a poster child to the power that model 







Thiabendazole (TBZ) is an FDA-approved benzimidazole widely used for its 
antifungal and antihelminthic properties. We showed previously that TBZ is also a potent 
vascular disrupting agent and inhibits angiogenesis at the tissue level by dissociating 
vascular endothelial cells in newly formed blood vessels. Here, we uncover TBZ’s 
molecular target and mechanism of action. Using human cell culture, molecular 
modeling, and humanized yeast, we find that TBZ selectively targets only 1 of 9 human 
β-tubulin isotypes (TUBB8) to specifically disrupt endothelial cell microtubules. By 
leveraging epidemiological pesticide resistance data and mining chemical features of 
commercially used benzimidazoles, we discover that a broader class of benzimidazole 
compounds, in extensive use for 50 years, also potently disrupt immature blood vessels 
and inhibit angiogenesis. Thus, besides identifying the molecular mechanism of 
benzimidazole-mediated vascular disruption, this study presents evidence relevant to the 
widespread use of these compounds while offering potential new clinical applications.  
 
4.2. INTRODUCTION 
The vascular system is built by the combination of de novo formation of blood 
vessels by vasculogenesis and the sprouting of new vessels from existing vessels via 
angiogenesis (Carmeliet 2005; Herbert and Stainier 2011). Imbalances in angiogenesis 
underlie a variety of physiological and pathological defects, including ischemic, 





Indeed, angiogenesis is central to tumor malignancy and cancer progression, as new 
blood vessels must be established to supply oxygen and nutrients to the growing tumor. 
Accordingly, inhibition of angiogenesis is now a well-recognized therapeutic avenue 
(Folkman 2004, 2007; Carmeliet 2005; Kerbel 2008; Herbert and Stainier 2011). Defined 
angiogenesis inhibitors such as Avastin (FDA approved since 2004) are now in wide use 
in the clinic and, over the past 30 years, several dozen drugs have been approved or 
entered clinical trials as angiogenesis inhibitors (O’Reilly et al. 1994, 1997; Folkman 
2004; Nyberg et al. 2005; El-Kenawi and El-Remessy 2013). 
In recent years, a new class of anti-vascular drugs, termed vascular disrupting 
agents (VDAs), have gained attention as potential alternative therapeutics operating by 
distinct mechanisms (Lippert 2007; Hinnen and Eskens 2007; Heath and Bicknell 2009; 
Mason et al. 2011). Unlike angiogenesis inhibitors which selectively prevent the 
formation of new blood vessels, VDAs function by dismantling existing vasculature, 
making them potentially effective for therapies beyond cancer, for example in the 
treatment or control of macular degeneration and diabetic retinopathies (Ibrahim et al. 
2013; Nowak-Sliwinska et al. 2013). While several VDAs have shown therapeutic 
potential, none have yet been approved, with several candidates still in clinical trials 
(Tozer et al. 2005; Cai 2007; Hinnen and Eskens 2007).  
Given the lengthy approval process, the failure of many drugs to succeed in 
clinical trials, and the high costs involved with developing new compounds, drug 
repurposing offers an attractive alternative for developing new therapies more quickly. 





identify both deeply conserved genetic networks as well as small molecules that may 
manipulate them (McGary et al. 2010; Cha et al. 2012; Woods et al. 2013). This effort 
identified thiabendazole (TBZ) as both a novel angiogenesis inhibitor and VDA (Cha et 
al. 2012). 
TBZ is one of a large class of biologically active benzimidazole compounds that 
are widely used commercially or clinically, with applications ranging from photographic 
emulsions and circuit board manufacturing, to serving as one of the most common 
heterocyclic ring systems used for small molecule drugs (Taylor et al. 2014). The FDA 
approved TBZ in 1967 for human use for treating systemic fungal and helminthic 
infections, but it is more widely used in veterinary settings and in agricultural pesticides 
and preservatives. However, we found that TBZ also possesses potent vascular disrupting 
ability, demonstrated in vitro in human cell culture and in vivo in mice and frogs, 
including for retarding tumor growth and reducing intratumoral vessel density in 
preclinical murine xenograft models (Cha et al. 2012). 
Several other VDAs have been reported to collapse the vasculature by inhibiting 
microtubule polymerization dynamics via binding β-tubulin (Tozer et al. 2005; Hinnen 
and Eskens 2007). Indeed, though the basis for TBZ’s vascular disrupting action is 
unknown, it is proposed that TBZ’s fungicidal action is mediated via disrupting fungal 
microtubule assembly and dynamics (Davidse and Flach 1978; Skuce et al. 2010). In 
particular, mutations in β-tubulin have been frequently found to confer resistance to TBZ 
in parasitic/invasive fungal and nematode species(Davidse and Flach 1978; Driscoll et al. 





et al. 2013; Taylor et al. 2014; Vela-Corcía et al. 2018; Hahnel et al. 2018). However, in 
humans, TBZ does not generally disrupt cell growth, and even in human umbilical vein 
endothelial (HUVEC) cells , while it somewhat reduced tubulin protein abundance it did 
not elicit gross defects in the microtubule cytoskeleton (Cha et al. 2012). At 
angiogenesis-inhibiting doses, the overall development of TBZ treated animals is normal 
(Cha et al. 2012), consistent with TBZ’s safety record in humans and veterinary settings 
(EPA 2002). Therore, we hypothesized that only certain types of human cells, such as 
subsets of endothelial cells involved in forming the vasculature, might be uniquely 
susceptible to TBZ. 
Here, we experimentally determined TBZ’s specific molecular target and cellular 
mechanism of vascular disrupting activity. We find that TBZ disrupts microtubule 
growth, with increased potency in endothelial cells. Using predictive molecular 
modeling, human cell culture, and humanized yeast, we find TBZ predominantly targets 
only one of nine human β-tubulins, suggesting an explanation for its cell-type specificity. 
Finally, based on epidemiological data mining and chemical structures, we discovered 
that a larger family of benzimidazoles—in clinical and commercial use for >50 years—all 
act as VDAs, disrupting the vasculature in a vertebrate animal model. These newly 
discovered VDAs include two World Health Organization (WHO) antihelminthics 
(albendazole and mebendazole) administered for the treatment of human intestinal 
infections, one broad-spectrum antifungal/antihelminthic (fenbendazole) used to treat 
farm animal infections, and two banned pesticides (benomyl and carbendazim) used to 





vascular disrupting activities should thus inform their use in at-risk individuals (such as 
during pregnancy) and opens new clinical applications for these compounds. 
 
4.3. MATERIALS AND METHODS 
4.3.1. Multiple sequence alignment 
Human gene sequences were downloaded from the Uniprot database. The 
multiple sequence alignment for S. pombe, S. cerevisiae, and 9 human β-tubulin genes 
was constructed using MAFFT v7 (Katoh and Standley 2013) and visualized in Geneious 
v10 (https://www.geneious.com). 
4.3.2. Molecular modeling of β-tubulins 
Homology models of human and fungal β-tubulins were constructed using as a 
reference structure the previously determined Ovis aries β-tubulin crystal structures 
(PDB: 3UT5 and 3N2G) (Barbier et al. 2010; Ranaivoson et al. 2012). The template was 
prepared using the Molecular Operating Environment (MOE.09.2014) software package 
from Chemical Computing Group. The structure was inspected for anomalies and 
protonated/charged with the Protonate3D subroutine (310K, pH 7.4, 0.1 M salt) (Labute 
2009). The protonated structure was then lightly tethered to reduce significant deviation 
from the empirically determined coordinates and minimized using the Amber10:EHT 
forcefield with R-field treatment of electrostatics to an RMS gradient of 0.1 kcal mol-1 Å-
1. Homology models of the wild-type fungal β-tubulin were prepared by creating 25 main 





were refined to an RMS gradient of 1 kcal mol-1 Å-1, scored with the GB/VI 
methodology, minimized again to an RMS gradient of 0.5 kcal mol-1 Å-1 and protonated. 
The final model for each variant was further refined by placing the protein within a 6 Å 
water sphere and minimizing the solvent enclosed structure to an RMS gradient of 0.001 
kcal mol-1 Å-1. Models were evaluated by calculating Phi-Psi angles and superimposed 
against the reference structure. Homology models for each human β-tubulin were 
prepared similarly, based on generating a total of 625 models and averaging to make a 
final model for each β-tubulin isotype.  
4.3.3. In silico docking of TBZ into β-tubulins 
Potential binding sites were evaluated using the Site Finder application and recent 
computational work on benzimidazole binding to parasitic β-tubulins (Aguayo-Ortiz et 
al. 2013). Conformational variants of TBZ were created in 3-D within MOE. A database 
of conformations was then used to dock TBZ to the wild-type homology model using 
induced fit and template similarity protocols. The placement was scored with Triangle 
Matcher and rescored with London dG. Poses were refined with the Amber10:EHT 
forcefield with GVBI/WSA dG scoring. Candidate poses were then identified by 
inspecting polar contacts. Geometry optimization was carried out with MOPAC 7.0 using 
AM1. Conformational analysis of the bound structure was evaluated with LowModeMD 
(Labute 2010). 2-D contact maps were created using Ligand Interactions (Clark and 





4.3.4. Cell culture 
HUVEC cells were purchased from Clonetics and were used between passages 4 
and 9. HUVECs were cultured on 0.1% gelatin-coated (Sigma) plates in endothelial 
growth medium-2 (EGM-2; Clonetics) in tissue culture flasks at 37 °C in a humidified 
atmosphere of 5% CO2. NIH-3T3 cells were obtained from Vishy Iyer at the University 
of Texas at Austin and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 
10% bovine calf serum. 
4.3.5. Immunohistochemistry 
Cell lines were cultured in 6-well plates and treated with thiabendazole dissolved 
in 1% DMSO. Control cells received 1% DMSO. After 24 h, cells were fixed with 
methanol at -20 °C for 10 min and subsequently with 4% paraformaldehyde in PBS at 
room temperature for 10 min. Cell membranes were permeabilized with 0.2% Triton X-
100 in PBS, and nonspecific antibody binding sites were blocked with 5% goat serum for 
1 h at room temperature. Cells were incubated with primary antibodies to EB1 (BD 
Bioscience) and α-tubulin (Sigma) at 4 °C overnight. After washing with PBST, primary 
antibodies were detected by Alexa Fluor-488 or 555 goat anti-rabbit or mouse 
immunoglobulin (IgG). 4′,6-Diamidino-2-phenylindole (DAPI dye, Sigma) was added as 
needed to visualize nuclei. 
4.3.6. Cell transfection and perfusion 
EB3-eGFP cDNA obtained from Anna Akhmanova was cloned into the vector 
CS2+(Stepanova et al. 2003). TUBB4 (Origene, RG203945) and TUBB8 (Origene, 





HUVEC cells were transfected by nucleofection (Lonza) according to the manufacturer’s 
instructions. To analyze the effect of TBZ in living cells, we used a closed perfusion 
system (POC-R2, Pecon) connected to a peristaltic pump (Ismatec). 1% DMSO, 250 μM 
TBZ or 1% DMSO diluted in EBM-2 medium was flowed at 100 μl/min rate for the 
indicated times. 
4.3.7. Western blotting 
HUVECs were cultured in 6-well plates and treated with 1% DMSO or 1% 
DMSO, 250 µM TBZ for 24 hours. Cells were lysed in cell lysis buffer (Cell Signaling 
Technology) containing 1 mM PMSF and analyzed by SDS-PAGE and western blotting 
using anti-EB1 (BD Bioscience) or anti-EB3 (Millipore) or anti-Clip170 (Santa Cruz) 
antibodies. 
4.3.8. Imaging and image analysis 
Immunohistochemistry experiments, live HUVECs, and live KDR:GFP 
transgenic Xenopus laevis were imaged using an inverted Zeiss LSM5 Pascal and Zeiss 
LSM700 confocal microscope, and super-resolution structured illumination (SR-SIM) 
combined with Zeiss LSM710 microscope. Comet lengths were measured using the 
software Fiji. Confocal images were cropped and enhanced in Adobe Illustrator and 
Adobe Photoshop for the compilation of figures.  
4.3.9. Benzimidazole clustering analysis 
81 commercially used benzimidazole compounds spanning a wide range of 





(http://joelib.sourceforge.net), OpenBabel (O’Boyle et al. 2011), and Chem Mine features 
were computed using ChemMine tools (Backman et al. 2011). Heatmaps were visualized 
using Morpheus (https://software.broadinstitute.org/morpheus). Clustergrams were 
generated by hierarchical clustering on the one minus Pearson correlation coefficient with 
average linkage. 
4.3.10. Humanizing yeast β-tubulin using CRISPR-Cas9 
The human TUBB4 and TUBB8 open reading frames were integrated 
chromosomally (from start to stop codon) into Saccharomyces cerevisiae in place of the 
endogenous TUB2 open reading frame using CRISPR/Cas9 genome editing as described 
previously. (Akhmetov et al. 2018a). Two sgRNAs were designed targeting the yeast 
TUB2 locus using the Geneious (v10.2.6) CRISPR-Cas9 tools suite, purchased as oligos 
from IDT, and cloned into yeast CRISPR-K/O vectors using the yeast toolkit (YTK) (Lee 
et al. 2015) to express a synthetic guide RNA sequence, Cas9 nuclease, and a selectable 
marker (URA3) (Akhmetov et al. 2018b; Garge et al. 2020). Repair templates were 
constructed by PCR amplification of the human β-tubulin ORF (from the human 
ORFeome (Lamesch et al. 2007)) flanked by 75 bp of target chromosomal boundary at 
the TUB2 locus to facilitate recombination via homology directed repair. BY4741 
(S288C) yeast strains were co-transformed with the CRISPR/Cas9 vector and repair 
template using Zymo Research Frozen-EZ Yeast Transformation II Kit. Transformants 
were selected on SC-URA media. Surviving colonies were screened by colony PCR, and 





4.3.11. Humanized yeast growth assays 
Assayed benzimidazole compounds were all dissolved in 100% DMSO to prepare 
stock solutions of 5 or 10 mg/ml based on solubility. Candidate VDA compounds were 
titrated in ranges of 5-1000 µg/ml into growth medium depending on solubility (Fig. 
4.6.S5 lists specific concentrations) for subsequent growth assays. Liquid growth assays 
were performed in triplicate in 96-well format using a Biotek Synergy HT incubating 
spectrophotometer. Humanized tubulin strains were pre-cultured to saturation in YPD 
and diluted into 150 µL of media to have 0.05-0.1 x 107 cells/ml. Assays were typically 
run for 48 hrs with absorbance measured every 15 min. 
4.3.12. Xenopus embryo manipulations and VDA assays 
Xenopus embryos were reared in 1/3× Marc’s modified Ringer’s (MMR) solution. 
Each drug was treated to embryos from stage 31 until stage 38 with 10 μg/ml or 20 μg/ml 
in 1% DMSO diluted in 1/3X MMR. Embryos were fixed at stage 38 with MEMFA, and 
whole mount in situ hybridization for erg was performed as described in Sive et al.87.  
 
4.4. RESULTS 
4.4.1. Thiabendazole disrupts microtubule plus ends in endothelial cells 
Thiabendazole exhibits broad-spectrum activity against fungal and nematode crop 
pests (Lubega and Prichard 1990), but prior to demonstration of its VDA activity, it was 





mechanism of vascular action remains poorly understood (Lacey and Gill 1994), although 
in vitro studies have suggested various benzimidazole compounds inhibit cell growth by 
interfering with microtubule polymerization (Davidse and Flach 1978; Lacey and Gill 
1994; Aguayo-Ortiz et al. 2013; Vela-Corcía et al. 2018). Benzimidazole suppressor 
screens in both Saccharomyces cerevisiae and Caenorhabditis elegans have 
independently identified resistance mutations occuring in β-tubulin genes, giving some 
insight into the binding site (Driscoll et al. 1989; Hahnel et al. 2018). The case for a β-
tubulin binding site is strengthened by numerous animal and agricultural studies also 
demonstrating resistance mutations arising repeatedly and independently across multiple 
parasitic nematode and fungal species infecting farm livestock and crops (Brown et al. 
1984; Tolliver et al. 1993; Nakaune and Nakano 2007; Zhang et al. 2009; Skuce et al. 
2010; Carter et al. 2013; Aguayo-Ortiz et al. 2013; Furtado et al. 2014; Furtado and 
Rabelo 2015; Zhu et al. 2016; Ramünke et al. 2016; Yilmaz et al. 2017; Yang et al. 
2018; Ali et al. 2018; Baltrušis et al. 2018).  
To examine the effects of the microtubule cytoskeleton and dynamics in the 
presence of TBZ, we examined the localization of GFP-tagged EB1, which labels 
growing microtubule plus ends and provides a proxy for microtubule dynamics in both 
endothelial (HUVEC) and non-endothelial (NIH3T3) human cells. Despite the grossly 
normal architecture of microtubules in TBZ-treated HUVECs, TBZ significantly reduced 
the accumulation of EB1 at microtubule plus ends (Fig. 4.6.1A’, B’) as compared to its 
control (Fig. 4.6.1A, B). Importantly, and consistent with the overall normal morphology 
and patterning of TBZ-treated embryos (Cha et al. 2012), we found that TBZ had a 





fibroblasts as compared to endothelial cells (Fig. 4.6.1C-E). These data are consistent 
with, and provide new insights into, previous studies showing that TBZ’s interaction with 
tubulin interferes with microtubule polymerization in nematodes and fungi (Dawson et al. 
1984; Davidse 1986). 
4.4.2. Thiabendazole selectively targets TUBB8 among human β-tubulins 
Three commonly observed mutations in fungal and nematode β-tubulins (F200Y, 
E198A, and F167Y) confer resistance to TBZ (Fig. 4.6.2A, B), suggesting that its 
binding site is in the vicinity of these residues (Brown et al. 1984; Tolliver et al. 1993; 
Nakaune and Nakano 2007; Zhang et al. 2009; Skuce et al. 2010; Carter et al. 2013; 
Aguayo-Ortiz et al. 2013; Furtado et al. 2014; Furtado and Rabelo 2015; Zhu et al. 2016; 
Ramünke et al. 2016; Yilmaz et al. 2017; Yang et al. 2018; Ali et al. 2018; Baltrušis et 
al. 2018) (Table 4.7.1). Based on the previously observed benzimidazole suppressor 
mutations, we used 3D structural modeling to evaluate TBZ’s potential binding sites in a 
fungal β-tubulin. We first constructed 3D homology models of the Schizosaccharomyces 
pombe (fission yeast) wild-type and TBZ-resistant F200Y β-tubulins, based on the 
previously determined Ovis aries β-tubulin crystal structures (PDB: 3UT5 (Ranaivoson et 
al. 2012) and 3N2G (Barbier et al. 2010)) as templates. We computationally refined the 
structures and then evaluated potential binding modes of TBZ, as detailed in the 
Methods, using computational docking algorithms to localize TBZ’s potential binding 
sites within the fungal β-tubulin structures (Fig. 4.6.S1). We identified a binding site 
around F200 to be the most probable (Table 4.7.2). We found that the preferred binding 
conformations of TBZ in both models (Fig. 4.6.S1) situated close to (but distinct from) 





computational predictions made on parasitic β-tubulins binding benzimidazoles (Aguayo-
Ortiz et al. 2013) and recent crystal structures of other benzimidazole derivatives binding 
to bovine brain β-tubulins (Wang et al. 2016) .  
On measuring the polar contacts and clashing energies of TBZ with tubulin, we 
found that the wild-type β-tubulin bound to TBZ more favorably with contact energy (-
9.9 kcal/mol) as compared to its F200Y counterpart, which showed unfavorable 
repulsions (+27.6 kcal/mol) (Table 4.7.2, S3). For the wild-type protein, TBZ’s polar 
contacts included E198 and Q134 (Fig. 4.6.2C, S1). Arene-hydrogen interactions 
between the drug and protein included contributions from F200, L250, and L253. 
However, for our F200Y mutant, repulsion was observed in our fixed ligand experiments 
predominantly caused by unfavorable contacts made with Y200, F240, L250, and L253 
(Fig. 4.6.S1). Our analyses suggest F200Y likely forms a hydrogen bond to E198 in the 
TBZ-resistant mutant, thus constricting the pocket and occluding binding. 
Unlike fungi, tetrapods have multiple β-tubulin isotypes (here, we use the term 
isotype to denote the protein products of paralogous genes, in accordance with prior 
tubulin literature), and their expression varies in different cells and tissue types. For 
example, human tubulin βI (TUBB/TUBB5) is constitutively expressed in many cells and 
tissues, whereas βIII (TUBB3) is exclusively enriched in neurons and the brain 
(Kavallaris 2010; Leandro-García et al. 2010). The specific roles of different β-tubulin 
isotypes are not yet fully understood, but recent studies indicate that their sequence 
diversity modulates binding affinity to tubulin-binding drugs and influences microtubule 





Sirajuddin et al. 2014). The recurrence of TBZ resistance mutations at the same three loci 
across diverse fungi and nematodes (Table 4.7.1) led us to hypothesize that human β-
tubulin isotypes might have differential sensitivities to TBZ by virtue of incorporating 
resistant residues at positions 167, 198, and 200, potentially explaining both its tissue-
specific effects and generally low toxicity in humans. 
Indeed, multiple sequence alignment of human and yeast β-tubulin genes 
indicated that while F167 remained conserved across all the human isotypes, positions 
198 and 200 were variable (Fig. 4.6.2B). Moreover, all human β-tubulin isotypes except 
TUBB1 and TUBB8 contain the F200Y resistance mutation. Because TUBB1 also 
harbors the other commonly observed E198A suppressor (Fig. 4.6.2B), TUBB8 is the 
only human β-tubulin isotype predicted by sequence to be TBZ-sensitive. Given this 
variability across isotypes, we next asked how the E198A and F200Y mutations would be 
expected to affect TBZ’s ability to bind at its predicted site in human isotypes.  
We first evaluated this hypothesis computationally, by constructing 3D homology 
models for each of the human β-tubulin isotypes in the same manner as for the fungal 
model (see Methods). We then performed induced-fit docking with TBZ across our 
human β-tubulin models. Using a TBZ-wild-type fungal β-tubulin complex as a template, 
we docked TBZ into the same pocket in each of the human isotypes and measured 
protein-ligand interactions in the superimposed structures. In agreement with our primary 
sequence based predictions, TBZ fit well into the predicted binding pocket of only 
TUBB1 and TUBB8, which lack the F200Y mutation. Both showed favorable binding 





contact energy among these isotypes could be explained by position 198. In TUBB1, 
alanine occupies position 198, whereas TUBB8 has glutamate, which contributed heavily 
to the binding energy in all of our simulations when both F200 and E198 were present. 
Our data suggest that TBZ binding is stabilized by hydrogen bonds with residues Q134 
and E198 in the presence of F200 (Fig. 4.6.S1, S2). Taken together, our in silico studies 
predicted that TBZ should strongly bind TUBB8 and weakly bind TUBB1, but should not 
bind any other human β-tubulin isotypes. 
4.4.3. Functional assays in human endothelial cells and humanized yeast confirm 
TBZ specificity to human TUBB8 
Given TBZ’s effects on human vascular endothelial cells and in vivo vascular 
disruption in Xenopus embryos (Cha et al. 2012), we wished to test directly if TUBB8-
specific binding could explain the compound’s effects. We thus asked whether resistance 
to TBZ could be acquired by simply supplying human β-tubulin isotypes predicted to be 
resistant. We tested this by two independent assays: (i) by overexpressing specific 
sensitive or resistant human β-tubulin isotypes in human endothelial cells and (ii) by 
humanizing Baker’s yeast’s β-tubulin TUB2 to enable assays of individual human β-
tubulin isotypes.  
To test if microtubule dynamics in human cells could be significantly restored by 
supplying resistant β-tubulin isotypes, we singly transfected HUVEC cells with plasmids 
overexpressing either TUBB4 or TUBB8 and assayed microtubule dynamics by 
measuring the comet lengths of end-binding protein EB3 (Fig. 4.6.3A). Compared to 
untransfected HUVECs, we saw that overexpressing TUBB4 significantly rescued the 





TUBB8, by contrast, had no effect (Fig. 4.6.3B). The differences became very significant 
after 30 minutes of exposure (Fig. 4.6.3B).  
As an independent assay of TBZ action on human tubulins, we turned to 
humanized yeast, as our previous work showed that of the nine human β-tubulins, only 
TUBB4 and TUBB8 could functionally replace TUB2 in Saccharomyces cerevisiae 
(Garge et al. 2020). From our modeling and docking data, we hypothesized that yeast 
strains humanized with TUBB8 would be susceptible to TBZ while humanizing with 
TUBB4 would confer TBZ resistance. Saccharomyces cerevisiae possesses 2 α-tubulins 
(TUB1 and TUB3) that interact with TUB2 to form tubulin heterodimers, which in turn 
oligomerize to form microtubules. Wild-type BY4741 haploid strains are TBZ-resistant. 
However, previous studies have shown that on deleting TUB3, yeast strains become 
susceptible to benzimidazoles (Schatz et al. 1986b) likely due to reduced overall α-
tubulin stoichiometry or possibly by TBZ occluding TUB2’s dimerization with TUB1 but 
not TUB3. Therefore, we performed all our yeast replacement assays in a tub3Δ 
background, which yielded a clear growth defect in the presence of TBZ (Fig. 4.6.S3). In 
order to test the effect of TBZ on human β-tubulin isotypes TUBB4 and TUBB8, we used 
CRISPR/Cas9 to construct yeast strains with these human isotypes in place of the 
endogenous TUB2 and tested them in the presence or the absence of the drug (Fig. 
4.6.3A). We found that strains possessing wild-type TUB2 and human TUBB8 exhibited 
slow growth in the presence of TBZ (at conc. 20 µg/ml). By contrast, the strain 
humanized with TUBB4, which is predicted to be resistant to TBZ, grew normally in the 





Together with our in silico docking data, our results in HUVECs and humanized 
yeast indicate that TUBB8 is uniquely TBZ-sensitive, suggesting in turn that vascular 
endothelial cells are selectively sensitive to its loss. 
4.4.4. Benzimidazole resistance patterns and chemical similarities suggest additional 
VDAs 
Given the plethora of fungal and nematode studies on benzimidazole pesticide 
resistance in agriculture (Jambre et al. 1979; Middelberg and McKenna 1983; Brown et 
al. 1984; Dawson et al. 1984; Tolliver et al. 1993; Romero and Sutton 1998; Gossen et 
al. 2001; Saeed et al. 2007; Nakaune and Nakano 2007; Banno et al. 2008; Cabañas et al. 
2009; Zhang et al. 2009, 2016a; b; Skuce et al. 2010; Niciura et al. 2012; Xu et al. 2015; 
Zhu et al. 2016; Kumar et al. 2016; Liu et al. 2016, 2018; Chagas et al. 2016; Ramünke 
et al. 2016; Rupp et al. 2017; Keegan et al. 2017; Yilmaz et al. 2017; Santos et al. 2017; 
Yang et al. 2018; Ali et al. 2018) (Fig. 4.6.4A), we reasoned that TBZ's molecular 
mechanism may extend to other commercially used benzimidazole compounds. Indeed, 
based on our experiments, a simple epidemiological signature should be sufficient to 
identify other pesticides that likely to function as vascular disrupting agents and 
angiogenesis inhibitors: (i) the compounds should be selectively toxic to fungal and 
nematode clades but demonstrate low toxicity in tetrapods, and (ii) sensitive species 
should specifically gain benzimidazole resistance from F167Y, E198A or F200Y β-
tubulin mutations.  
In order to understand how extensively distributed benzimidazole resistance was, 
we mined ~40 years of literature to identify reported cases of pesticide resistant species 





phenomenon (Fig. 4.6.4A); across 9 major commercial benzimidazole-based pesticides, 
we found multiple independent instances of reported resistance across 27 (12 nematodes 
and 15 fungal) parasitic species (Table 4.7.1), all of which exhibited at least 1 of the 3 
signature β-tubulin mutations. These widespread patterns of benzimidazole pesticide 
resistance suggested at least 9 new candidate VDAs. 
As a complement to the epidemiological data, we also considered chemical 
properties by asking if pesticide benzimidazoles shared similar chemical feature profiles 
relative to other benzimidazoles. We curated >80 commercially available compounds in 
the benzimidazole class spanning a diverse range including pesticides, fungicides, 
therapeutics, and preservatives. Upon hierarchical clustering of these benzimidazoles 
based on their chemical properties computed from JOELib’s features matrix (Cao et al. 
2008; Backman et al. 2011) (Table 4.7.5), we found that pesticide benzimidazoles 
generally shared similar chemical properties and clustered together (Fig. 4.6.4B).  
4.4.5. Numerous commercially used benzimidazoles also function as vascular 
disrupting agents 
We next tested if pesticides exhibiting the epidemiological signature and 
clustering in the same clades by virtue of their chemical features would also specifically 
inhibit TUBB8 and function as VDAs. We selected 12 commercially used benzimidazole 
compounds across 2 clusters (Fig. 4.6.4B). Our list included 2 anthelmintics, both World 
Health Organization essential medicines (albendazole and mebendazole) prescribed to 
treat broad-spectrum human intestinal nematode infections; fenbendazole, an 
anthelmintic prescribed specifically for animals against gastrointestinal nematode 





agriculture; triclabendazole, specifically used to treat liver fluke infections; and 5 proton-
pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, and 
rabeprazole) used to treat gastrointestinal and stomach acid disorders. The latter set were 
from a different clade and did not exhibit the epidemiological signature, serving as 
negative controls. 
We first took advantage of our humanized yeast strains to rapidly discriminate 
TUBB8-specific inhibition from general β-tubulin inhibition. We found that 5 of the 12 
compounds tested selectively inhibited TUBB8, as evidenced by the growth profiles 
observed for the humanized strains when cultured in the presence of the drugs (Fig. 4.6.5, 
S4). Notably, none of the 5 proton pump inhibitors or colchicine exhibited any tubulin 
inhibition (Fig. 4.6.S4, S5A), confirming the specificity of the epidemiological signature 
as a predictor of TUBB8 inhibition. In contrast, triclabendazole was generally toxic, 
behaving as a pan-isotype inhibitor (Fig. 4.6.S5B).  
Testing the 5 positive TUBB8-inhibiting compounds in Xenopus laevis embryos 
showed strong vascular disrupting activity for all 5 compounds (Fig. 4.6.5). As we 
observed previously for TBZ (Cha et al. 2012), the gross morphology of the treated 
embryos was largely normal (Fig. 4.6.5). Thus, this broader class of benzimidazoles do in 







In the >30 years of therapeutic research efforts in the angiogenesis field only a 
highly restricted set of drugs have yet been approved (Hinnen and Eskens 2007). Given 
the frequent failure to successfully make it through clinical trials and the high costs and 
lengthy process associated with developing new compounds, drug repurposing can offer 
efficient alternatives in developing new patient therapies with accelerated timeframes. 
This study represents a rather unconventional path to drug repurposing, leveraging a 
combination of model organisms, humanized yeast, cell culture, molecular modeling, and 
epidemiological data mining to determine TBZ’s molecular target and mechanism of 
vascular action. Indeed, TBZ was initially identified as a VDA and angiogenesis inhibitor 
by using a Baker’s yeast model of angiogenesis discovered in a computational search for 
orthologous phenotypes, or phenologs, aimed at exploiting deep evolutionary 
conservation to prioritize yeast processes relevant to human diseases (McGary et al. 
2010; Cha et al. 2012; Woods et al. 2013). Although obviously lacking blood vessels and 
a circulatory system, yeast nonetheless retains conserved biological pathways and 
processes relevant to vertebrate angiogenesis genes, and it was on the basis of these 
conserved processes that the antifungal compound TBZ was initially suspected, later 
confirmed, to be an angiogenesis inhibitor (Cha et al. 2012).  
While TBZ somewhat reduced the abundance of tubulin proteins in human cells 
(Cha et al. 2012), at angiogenesis-inhibiting doses, the overall morphology of TBZ 
treated animals was normal, suggesting that only certain cell types, specifically those 





TBZ. Here, we find that TBZ does indeed specifically modulate the microtubules in 
vascular endothelial cells. Several currently identified microtubule targeting drugs have 
been reported to interfere with polymerization dynamics by binding β-tubulin (Tozer et 
al. 2005; Hinnen and Eskens 2007) close to or at the colchicine binding site. Building on 
previous work(Aguayo-Ortiz et al. 2013; Wang et al. 2016), our in silico modeling 
results suggest that TBZ’s binding site, while in close proximity to the colchicine binding 
site, is distinct from it, thereby uncovering a novel β-tubulin effector site likely specific to 
other benzimidazoles and TBZ analogs. 
In contrast to β-tubulin anticancer drugs, which have largely shown pan-isotype 
activity, to our knowledge, this study presents an unusual case of isotype-specific drug 
targeting in the β-tubulin gene family. Fungal suppressor studies on benzimidazole 
resistance have repeatedly found resistant mutations in β-tubulin; we found that 8 of 9 
human β-tubulins natively harbor the same suppressor mutations and consequently 
exhibit unfavourable steric clashes interfering with TBZ binding. We demonstrate both 
via human cell culture microtubule assays and humanized yeast drug sensitivity tests that 
TBZ selectively targets only TUBB8 among the nine human β-tubulins, thus disrupting 
microtubule dynamics and reducing end-binding protein accumulation at the plus ends of 
microtubules in susceptible cells.  
With TUBB8 thus acting as the specific target, it follows that of all human cell 
types, vascular endothelial cells must in turn be particularly sensitive to inhibition of 
TUBB8, leading to selective disruption of the vasculature relative to other human tissues. 





newly forming blood vessels, but we speculate that this subset of the vasculature lacks 
reinforcing cell-cell contacts typical of larger, more established vasculature, leading to 
greater sensitivity to TBZ-induced microtubule disruption. As β-tubulin isotypes tend to 
be broadly expressed and often substitute for one another in microtubule structures 
(Uhlén et al. 2015; The UniProt Consortium 2019), one possibility is that TUBB8 
inhibition simply leads to the loss of interactions with endothelial cell-specific 
components, thus specifically impacting vasculogenesis/angiogenesis. However, gene-
gene and gene-drug interactions can often proceed by less obviously direct mechanisms 
to selectively impact cell types or phenotype penetrance via conditional cell-specific or 
dosage-dependent synthetic interactions (Burga et al. 2011; O’Neil et al. 2017). It would 
thus not be surprising for the consequences of inhibiting TUBB8 in vascular endothelial 
cells to be similarly indirectly mediated by endothelial cell-specific synthetic interactions. 
Further experiments characterizing TBZ’s selective activity against newly 
forming/formed vasculature and the vascular-specific roles of TUBB8 in tetrapods could 
offer valuable insights into the cytoskeletal dynamics underlying vasculogenesis and 
angiogenesis.  
Based on chemical properties and signature resistance mutations observed against 
benzimidazole compounds, we identified a larger class of extensively used fungicides and 
pesticides that all exhibit vascular disruption activity. While our results suggest possible 
new clinical applications for these compounds, they also highlight the potential caveats of 
their use in at-risk populations, especially for the two compounds (albendazole and 
mebendazole) that are FDA approved for human use. The WHO recommends the use of 





up to the age of 14 against soil-transmitted helminth infections. Moreover, these 
compounds are widely used as public health interventions in pregnant women after the 
first trimester in regions where hookworm and whipworm infections exceed 20% (World 
Health Organization 2018). While in the US, the risk of mebendazole use during 
pregnancy has not been assigned, our data add weight to WHO recommendations that 
these drugs should not be administered in the first trimester of pregnancy and suggest 
their use be carefully evaluated in patients in which angiogenesis inhibition might pose 
risks, including using caution later in pregnancy in light of the evidence that the 
compounds disrupt immature vasculature and might prove harmful to a developing fetus. 
Conversely, while efforts in the angiogenesis field have been often motivated towards 
developing anticancer therapies, the wide use of the compounds discussed here and their 
FDA-approved status could open alternative paths to treating other angiogenesis and/or 
vascular related diseases, such as diabetic retinopathy, macular degeneration, and 
hemangioma. It remains to be seen if other benzimidazoles sharing similar chemical 
profiles to those tested in our work (such as ciclobendazole, nocodazole, oxibendazole, 
and oxfendazole) also exhibit vascular disrupting activity.  
More broadly, our framework of leveraging phenotypic relationships between 
species and repurposing model organisms to systematically explore drug mechanisms 
opens new routes for drug repurposing and discovery and highlights the power of systems 
biology and evolution-guided approaches in advancing our knowledge of conserved 
genetic modules and how their disruption manifests in disease. This work also illustrates 
how duplicated genes diversify their functions and reinforces the therapeutic benefits of 





degree of replaceability of conserved genes from cross-species complementation assays 
(Kachroo et al. 2015; Laurent et al. 2016, 2020), we anticipate that the combination of 
humanized yeast and phenolog-based disease modeling can be extended beyond vascular 








Figure 4.6.1. Thiabendazole (TBZ) significantly reduces EB1 comet length at 
microtubule plus ends in cultured human cells.  
Immunohistochemical analysis of α-tubulin in two human cell lines using confocal 





C) and 1% DMSO, 250 μM TBZ-treated cell lines (B, D), but images from super-
resolution microscopy reveal that the accumulation of end-binding (EB) protein 1 at the 
plus end of microtubules is significantly reduced with TBZ treatment (B) compared to the 
control (A) in HUVECs. In NIH-3T3 cells, the reduced EB1 comet length following TBZ 
treatment (D) compared to control (C) is not as pronounced as in HUVECs, as quantified 







Figure 4.6.2. Uncovering the molecular mechanism of thiabendazole.  
(A) TBZ elicits varying activity across different clades of life being toxic to fungal and 





human β-tubulins, 8 have amino acids at positions 167, 198, and 200 that confer TBZ 
resistance to fungal tubulins , as seen in a multiple sequence alignment of human and 
Schizosaccharomyces pombe β-tubulins; only TUBB8 lacks resistance mutations. (C) In 
silico docking of TBZ (orange) into a homology modeled yeast β-tubulin 3D structure 
(see Methods) indicates TBZ is well-accommodated by a binding pocket in wild-type 
yeast NDA3 that abuts the 3 major β-tubulin TBZ resistance mutation sites. In contrast, 
docking of TBZ into homology models of human TUBB4 and TUBB8 indicates the 
potential for differential binding, with TUBB8 accommodating TBZ whereas, in the case 
of TUBB4, TBZ is sterically blocked. Polar contacts are illustrated via dashed lines, and 
residues lining the proposed binding pocket are shown in cyan. Intramolecular hydrogen 
bonding between E198 and Y200 in TUBB4 reorganizes the geometry of the binding 
pocket. Residues involved in steric clashing are depicted with a partial mesh surface. 
(Note that due to steric clashes between TBZ and TUBB4 at the proposed binding pocket, 







Figure 4.6.3. TBZ specifically inhibits the human β-tubulin TUBB8, not TUBB4, in 
humanized yeast and HUVEC cell culture.  
(A) Overview. TBZ’s isotype specificity was identified in 2 ways. (Left) Recombinant 





culture to monitor comet lengths in the presence of TBZ. (Right) Using humanized yeast 
wherein yeast TUB2 was singly humanized by either of 2 replaceable human β-tubulins 
TUBB4 or TUBB8 to screen for differential sensitivity towards TBZ. (B) Reduced EB3 
comet length after 1% DMSO, 250 μM TBZ treatment compared to 1% DMSO treated 
control. A. Comet length is similar in EB3, TUBB8 transfected HUVECs compared to 
EB3 transfected controls expressing native tubulins, but comets are longer in most EB3, 
TUBB4 transfected cells. B. Comet length is statistically similar between cells treated 
with 1% DMSO; however, following 30 minutes of 1% DMSO, 250 μM TBZ treatment 
TUBB4 transfected cells have significantly longer EB3 comets than HUVECs with 
TUBB8 or expressing native tubulins. (C) Growth profiles of humanized yeast strains 
show TBZ’s isotype specificity to TUBB8. When grown in the presence of TBZ, Strains 
carrying the wild-type TUB2 (blue) and human TUBB8 (green) genes are sensitive to 
TBZ while humanized TUBB4 strains (orange) are resistant. Mean +/- standard deviation 







Figure 4.6.4. Global trends in benzimidazole resistance mutations and chemical 
structural similarities suggest numerous potential vascular disrupting agents.  
(A) 3 β-tubulin mutations, (F167Y, E198A, F200Y) conferring benzimidazole resistance 





represents an instance of β-tubulin suppressor mutations occurring in benzimidazole 
resistant parasitic fungal or nematode species (See Table 4.7.1 for list of species showing 
benzimidazole resistance). (B) Commonly used benzimidazoles hierarchically clustered 
by their chemical properties suggest new vascular disrupting agents with similar 
molecular mechanisms to TBZ. (Left) Clustergram of 81 widely used benzimidazole 
compounds spanning a wide range of drug classes grouped by chemical features (See 
Table 4.7.5 for the full list of compounds and features analysed). (Right) Zooms of black 
boxes indicate 3 clades containing TUBB8 specific VDA candidates (top) and proton-







Figure 4.6.5. Commercially used benzimidazole pesticides, antifungals, and 
antihelminthics are also TUBB8-specific and disrupt vasculature.  
(A-D) In situ hybridization of blood vessels (using the erg/flk1 probe(McGary et al. 





intersomitic (ISV, yellow arrows) and posterior cardinal veins (PCV, black arrows) 
caused by the presence of human and animal antihelminthics and broad-spectrum 
pesticides as compared to the DMSO control. Insets show growth profiles for yeast 
strains with humanized β-tubulin TUBB4 (orange) and TUBB8 (green) compared to 
wild-type (blue) when grown in the presence of each compound. Mean +/- standard 






Figure 4.6.S1. Homology modeling and in silico docking studies predict the TBZ 
binding site in the fungal β-tubulin NDA3 structure.  
TBZ is well accommodated in wild-type NDA3’s predicted binding pocket (A) as 
opposed to its F200Y mutant (B). 3D structures and 2D contact maps shown on the left 
and right respectively indicate the steric clashes TBZ faces in the F200Y binding pocket. 
Cyan meshes (in 3D structures) and red highlights on the ligand (in 2D contact maps) 






Figure 4.6.S2. Only TUBB8 favorably binds TBZ among the 9 human β-tubulins. 
(A) 2D contact maps highlight ligand interactions between TBZ and TUBB4 (left) or 





TUBB8. In TUBB4, reorientation of the proposed binding pocket is observed. Substantial 
steric clashing is shown in red on TBZ. (B) In silico docking of TBZ into other human β-
tubulin homology models suggests substantial steric clashes due to unfavorable binding 
pockets among 8/9 human β-tubulin isotypes. Cyan meshes (in 3D structures) and red 








Figure 4.6.S3. Yeast strains with modified β-tubulin are differentially sensitive to 
TBZ.  
(A) Deletion of yeast α-tubulin TUB3 makes Saccharomyces cerevisiae (Baker’s yeast) 





humanized β-tubulins TUBB4 (orange), or TUBB8 (green) in increasing concentrations 






Figure 4.6.S4. Growth profiles of benzimidazole treated yeast strains.  
Plots depict varying doses of albendazole, benomyl, carbendazim, and colchicine. Our 
data show that colchicine is a pan-isotype inhibitor whereas albendazole, benomyl, and 






Figure 4.6.S5. Proton-pump inhibitors do not elicit growth defects in humanized 
strains.  
(A) Yeast strains harboring the beta-tubulin gene TUB2 (blue), TUBB4 (orange), and 
TUBB8 (green) are not inhibited by proton pump inhibitors (drug conc. 40 µg/ml). (B) 





humanized yeast strains (Left) and lethal to developing Xenopus laevis embryos at stage 






Since the tables are very large, they are provided in the supplementary materials.  
Online versions are also available with this link. 
Table 4.7.1. β-tubulin mediated resistance mutations seen in species curated from 
literature. 
Table 4.7.2. Yeast site finder statistics for wild-type and F200Y. 
Table 4.7.3. Docking free energy scores across β-tubulin isotypes. 
Table 4.7.4. Yeast wt β-tubulin induced fit TBZ docking scores. 






Chapter 5: Conclusions and Future Directions4 
 
The central theme throughout this thesis is understanding the divergence in core 
biological systems over vast timescales using cross-species gene swaps in Baker’s yeast. 
Chapter 2 systematically surveys the ability of orthologous (and paralogous) human 
genes in expanded gene families to functionally complement their yeast counterparts. 
Besides providing direct tests of function complementarity, it also reveals the extents to 
which ancestral roles are retained and/or distributed across gene families and the 
principles that underlie them. These assays with when combined with previous 
humanization efforts now include nearly all assayable essential yeast genes. Chapter 3 
addresses functional divergence in gene families constituting a core eukaryotic module, 
the cystoskeleton. Expanding the scope of complementation assays in yeast beyond 
essential roles, these humanization experiments uncover the divergence of ancestral 
function in context-dependent and conditionally essential roles. Chapter 4 marks the 
intersection of multiple research threads including phenologs, cross-species gene swaps, 
and model organisms to discover the mechanism of vascular disruption underlying a class 
of widely used antifungal compounds. In Chapter 5, I discuss the directions that I 
anticipate being most interesting and present some preliminary work in humanizing entire 
yeast systems and their utility to understanding human health and disease. 
 
 
4Most of the sterol pathway replacements in yeast were performed by Sophie Curie. The mass-spectrometry 
experiments of the humanized strains were performed by Daniel Boutz. The mu-opioid receptor signaling 





5.1. THE FUTURE OF HUMANIZED YEAST 
Human gene complementation assays have been around for over 30 years now. 
Humanizing yeast genes is but a starting point. These assays are not new, however their 
utility to human biology (especially when paired with high-throughput yeast 
technologies) is. While this thesis predominantly uses humanized yeast to study 
divergence across evolutionarily conserved biological systems, its application to human 
functional genomics and systems biology is only in its infancy.  
It is remarkable that on average roughly half of the human orthologs assayed are 
replaceable in yeast. This observation marks as a starting point for many research 
directions all worthy of pursuing. It begs the question of why the remaining genes were 
unable to. There may be several reasons for this. Most complementation assays in this 
thesis particularly assay essential roles of the yeast genes being queried. These assays 
while simple, may often fail to test the ability of human genes to rescue context-
dependent and/or conditionally essential roles. For example, in Chapter 3 we found that 
despite only 4 human septins being replaceable, but all of them complemented the mating 
and meiotic roles of their yeast ortholog. Such findings are important as they point to 
fractional complementation of specific roles. Therefore, to exhaustively test 
replaceability, it is crucial to expand the scope of humanization assays in yeast to include 
non-essential roles as well. Another important caveat of humanization is recognizing the 
biological and technical limits of the available complementation assays. For example, 
sporulation-based assays inherently have an added layer of stringency in that they require 
human genes to appropriately function through meiosis while temperature sensitive 





significant challenges in constructing robust reagent strains, curating accurate human 
clones and the cost of performing large-scale humanization in yeast. I foresee these 
challenges being overcome as the suite of yeast genome engineering tools continues to 
expand and the cost of large-scale DNA synthesis continues to drop. 
 
5.2. BUILDING ENTIRE HUMAN SYSTEMS IN YEAST 
Possessing a census of swappable genes in yeast now provides a global view of 
the human processes that can be studied in yeast. The first large-scale humanization 
assays provide reagent strains to study human genes individually. However, it is 
important to understand how multiple human genes interface with each other to execute 
their molecular and cellular roles. In the next phase, I anticipate multi-gene 
humanizations becoming common to study gene-gene interactions and epistasis. The 
efficiency of CRISPR-Cas9 based genome editing tools in yeast means that these gene 
replacements can now be multiplexed and even be performed iteratively. Perhaps it is not 
an unachievable goal to humanize every replaceable yeast gene natively under the 
influence of their respective loci. The advent of DNA synthesis technologies allows for 
testing human genes that were previously hard to assay and additionally enables large-
scale testing of allelic variants for pathogenicity.  
In recent years, we (Laurent 2016; Kachroo et al. 2017; Curie 2019) and others 
(Agmon et al. 2020) have pursued this direction. For example, we have systematically 
humanized ~80% of the yeast sterol biosynthesis pathway natively using CRISPR-Cas9 





combinations, these multi-gene humanized strains offer reagents to directly study 
feedback, epistasis and pathogenic allelic variants in the context of in the background of a 
full human module. I anticipate that such efforts building entire human systems in yeast 
becoming a fertile area of research in the years to come. 
 
5.3. NON-ORTHOLOGOUS GENE SWAPS AND SURROGATE HUMAN SYSTEMS 
Replacements need not be restricted only to orthologous genes. Genes (and even 
systems) may be replaceable without being orthologous. While I predict these instances 
to be few and far between, they may still yet prove useful. One example was the 
replacement of the yeast ergosterol biosynthesis enzyme ERG8 by the human PMVK 
gene. Previously, a study found that the human SEC61A1 was able to complement yeast 
strains lacking RFT1 (Hamza et al. 2015). Recently, Luongo et al. found that the human 
gene SLC25A51 complements NDT1 and NDT2 deficient yeast strains by functioning as 
a mitochondrial NAD+ transporter (Luongo et al. 2020). With the widespread availability 
of large-scale yeast mutant libraries and human clones, such non-orthologous gene 
replacement warrants further exploration.  
Perhaps our most exciting of non-orthologous replacements yet has been 
engineering cholesterol production in yeast. Zymosterol is the last common intermediate 
sterol between yeast and humans. Yeast and humans produce ergosterol and cholesterol 
as their terminal sterols (Fig. 5.6.2A). Ergosterol is a non-essential metabolite but strains 
lacking two or more genes in this pathway tend to elicit growth defects. We found that 





showed strong fitness defects which could be rescued significantly when completely 
humanized (Fig. 5.6.2B). On assaying the protein expression levels, we find that these 
strains upregulate genes upstream of the pathway pointing to feedback and regulation 
(Fig. 5.6.2C). It begs the question of whether the upregulation of yeast enzymes at the 
feedback points is a modular property that can be restored when those enzymes are 
humanized too. Surprisingly, when engineered with appropriate enzyme expression, these 
strains produce cholesterol (Fig. 5.6.3A & B). It is interesting that when the pathway is 
natively replaced yeast strains do not produce cholesterol despite being viable offering 
interesting insights into replaceability beyond genes to metabolites. I believe that such 
engineering efforts in yeast will offer valuable eukaryotic surrogates to study human 
systems. 
Perhaps the most promising direction with building non-orthologous human 
systems in yeast is repurposing these reagents as therapeutic platforms (as seen in 
Chapter 4) for human biology including drug discovery and modeling disease states. One 
direction we have pursued over the past several years is applying humanized yeast to 
understand G-Protein Coupled Receptor (GPCR) signaling. GPCRs play a crucial role in 
sensing external stimuli and constitute the largest class of membrane proteins in humans. 
About 34% of all FDA approved drugs target GPCRs (Hauser et al. 2018). Studying 
GPCR function in yeast proved challenging for a number of reasons including improper 
folding, expression, and different signaling environments. We found that modulating 
membrane sterol compositions in yeast through humanization was sufficient to enable 
human mu-opioid receptor signaling (Fig 5.6.3C & D). This is an exciting result because 





additionally examine the genetic tolerance in the receptors, discover ligands and small 
molecules capable of triggering orphan receptors whose mode of action is unknown. 
With the fast pace of large-scale pathway engineering in yeast, I believe that these studies 
will become more common and insightful for human health. 
More broadly, non-orthologous gene swaps present opportunities to test 
hypotheses akin to The Ship of Theseus. As previously described, with the plummeting 
cost of DNA synthesis and advances in artificial chromosome assembly, extending 
humanization to include non-coding and regulatory regions is an achievable goal and 
would massively advance the field. 
 
5.4. SACCHAROMYCES SAPIENS AND PERSONALIZED MEDICINE 
The most exciting of directions for humanized yeast involve the ability to now 
personalize strains with an individual’s allelic variant(s) either singly or in combination 
with interacting genes to better understand epistasis, pathogenicity and gene-drug 
interactions. It has been well established for a few years now that pathogenic variants and 
disease alleles can be efficiently discerned just by simple growth assays in yeast 
(Kachroo et al. 2015; Hamza et al. 2015, 2020; Sun et al. 2016, 2018; Yang et al. 2017). 
Humanizing libraries of gene variants en masse through deep mutational scanning 
(Fowler and Fields 2014; Fowler et al. 2014; Amorosi et al. 2021) coupled with 
functional screens in the context of partially or entirely humanized modules will 
significantly advance our understanding of genetic variance in populations and even offer 






5.5. EVOLUTIONARY SYSTEMS BIOLOGY AND THE FUTURE OF MODEL ORGANISMS 
Humanization of yeast is a lucid and effective approach to understanding and 
characterizing human biology. However, zooming out, cross-species gene swaps offer the 
opportunity to test multiple evolutionary questions. The obvious one that goes beyond 
humanization is the extent to which the trends and rules underlying replaceability are 
translatable to other species. When and how do orthologous genes lose the ability to work 
between species? Recent work from our lab has shown that yeast processes can be 
“plantized” and even “bacterialized” demonstrating that the rules of replaceability do 
indeed transcend domains (Kachroo et al. 2017). The extent of functional plasticity in 
core conserved biological machinery across the domains of life still remains to be seen. 
All gene swaps discussed up to this point have been performed in yeast, testing the 
orthologous gene of interest to function in a yeast cellular environment. An understudied 
aspect of complementation is the reciprocity of gene swaps. With mammalian cell culture 
and tissue engineering techniques advancing at a quick pace, perhaps yeastizing, 
plantizing and bacterializing human cells and/or other model organisms are all interesting 
and conceivable avenues worth pursuing. While cross-species gene swaps are strong tests 
of functional divergence, extending such approaches beyond genes to non-coding 
regions, chromosomes, cells, tissues offer far greater value especially when coupled with 
systems biology. The comparative nature of omics and systems biology along with the 
ever-expanding trove of phenotyping data available in model organisms altogether form 





Finally, contemporary research is soaring to greater heights every day and at an 
unprecedented pace. This is largely due to the fact that science now lives in the data-
driven age wherein multiple groups are parallelly generating a plethora of datasets from 
their experiments. Therefore, addressing challenges in data curation and consolidation 
will be key in devising and guiding future high-throughput experimental studies. The 
Saccharomyces Genome Database (SGD) has been at the forefront of database 
maintenance and management ever since its inception some 30 years ago including 
curating human complementation assays in yeast (Cherry et al. 1998, 2012). Recently, 
there has been a joint effort involving several model organism databases to consolidate 
functional gene annotations across multiple species (including model organisms) by The 
Alliance of Genome Resources (Agapite et al. 2020). Databases have been around for a 
couple of decades and it is crucial for us to recognize the roles that they play in shaping 
and guiding research. Therefore, in the era of big-data and multi-omics, model organisms 
are arguably more important than they have ever been. While there are exciting and 
promising efforts to shift large-scale genetic and biochemical studies into human cells, it 
is important to appreciate the roles model organisms have played in advancing our 
understanding of human health and disease over the decades. So, it is imperative that 
these databases be actively supported, and future curation efforts consider effective 











Figure 5.6.1. Entirely humanizing sterol biosynthesis in yeast.  
The 19 enzymes from acetyl-CoA to zymosterol are conserved between humans and 
yeast. Majority of the pathway is replaceable (yellow). Using CRISPR-Cas9 genome 
editing 16 steps of yeast sterol biosynthesis have been genomically replaced with their 
human counterparts (Green stars). Further, using genome editing iteratively several multi-






Figure 5.6.2. Humanizing yeast genes downstream of zymosterol.  
(A) Yeast use 5 enzymes downstream of zymosterol to make ergosterol while humans 
use 4 to make cholesterol. The pathway was humanized in place their corresponding 
yeast genes i.e., DHCR24 in place of ERG6 and so on. (B) Yeast growth profiles 
containing combinations of the cholesterol biosynthesis pathway. Singly humanized 





wild-type (black). Doubly humanized strains with SC5DL and DHCR24 have strong 
growth defects (purple). Interestingly, despite having slower lag phase, humanizing the 
entire cholesterol biosynthesis pathway (red) restores doubling time close to wild-type. 
Lines and shades indicate mean and standard deviation respectively (n=3). (C) 
Proteomics of humanized yeast strains pathway uncovers feedback upstream of 
zymosterol. Heatmap depicting ratio of protein abundances (rows) in sterol biosynthesis 
across fractionation experiments (columns). Expression of human enzymes upregulates 
genes upstream of zymosterol. Particularly, enzymes ERG11, ERG24, ERG25, ERG26, 






Figure 5.6.3. Repurposing humanized yeast as a platform to study GPCR signaling. 
(A) Yeast sterol profiles analyzed by gas-chromatography mass-spectrometry (GC-MS). 
Top row indicates standards cholesterol (red), zymosterol (light blue), and ergosterol 
(blue). Wild-type strains (middle row) predominantly produce ergosterol while 
humanized strains (bottom row) produce cholesterol. (B) Mass spectra of ergosterol and 
cholesterol extracted from the labeled peaks from wild-type (star) and humanized strains 





5C1M). (D) Signaling of human mu-opioid receptor with its peptide ligand DAMGO in 
wild-type (black) and humanized (red) sterol biosynthesis backgrounds. EC50 for  the 







Appendix A: Single-step Precision Genome Editing in Yeast Using 
CRISPR-Cas95 
 
One of the main tools I have used over the course of my graduate work has been 
CRISPR-Cas9 which in recent years has become ubiquitous with synthetic biology and 
genome engineering especially in Baker’s yeast. This project started to gain momentum 
right at the end of my first year of graduate school. Systematically screening the 
replaceability of hundreds of human genes in yeast warranted powerful tools to 
efficiently edit yeast genomes in a scalable fashion. Here we describe a one-step, scarless 
and marker-free method that was developed between the Gollihar, Ellington, and 
Marcotte labs to swap genes/ORFs in yeast. The most interesting aspect of this approach 
was its robustness to natively edit yeast genomes in a single step. Further, this method 
opens up avenues to engineer combinatorial and iterative multi-gene swaps to study 
epistasis via gene-gene interactions and entire modules in yeast.  
 
A.1. ABSTRACT 
Genome modification in budding yeast has been extremely successful largely due 
to its highly efficient homology-directed DNA repair machinery. Several methods for 
 
5This chapter was published as Akhmetov, A., Laurent, J.M., Gollihar, J., Gardner, E.C., Garge, R.K., 
Ellington, A.D., Kachroo, A.H., and Marcotte, E.M. (2018). Single-step Precision Genome Editing in Yeast 
Using CRISPR-Cas9. Bio-Protocol 8. My contributions were performing the experiments and helping with 





modifying the yeast genome have previously been described, many of them involving at 
least two-steps: insertion of a selectable marker and substitution of that marker for the 
intended modification. Here, we describe a CRISPR-Cas9 mediated genome editing 
protocol for modifying any yeast gene of interest (either essential or nonessential) in a 
single-step transformation without any selectable marker. In this system, the Cas9 
nuclease creates a double-strand break at the locus of choice, which is typically lethal in 
yeast cells regardless of the essentiality of the targeted locus due to inefficient non-
homologous end-joining repair. This lethality results in efficient repair via homologous 
recombination using a repair template derived from PCR. In cases involving essential 
genes, the necessity of editing the genomic lesion with a functional allele serves as an 
additional layer of selection. As a motivating example, we describe the use of this 
strategy in the replacement of HEM2, an essential yeast gene, with its corresponding 
human ortholog ALAD. 
 
A.2. INTRODUCTION 
Saccharomyces cerevisiae (Baker’s yeast) has a long history as a genetically 
tractable organism, and there is an array of methodologies to manipulate the yeast 
genome. However, until recently it has been necessary to apply selection to isolate clones 
possessing the desired genetic alteration (Kearse et al. 2012; DiCarlo et al. 2013; Lee et 
al. 2015; Kachroo et al. 2017). In cases where arbitrary, scar-less editing of the genome 
is desired, the solution is typically a two-step process: First a selectable cassette 





region of interest, and sometimes containing nuclease targeting sites (i.e., I-SceI sites) to 
aid in the removal of the cassette at the later stage, is knocked in via homologous 
recombination (HR). The small subpopulation of successful integrants are isolated by 
selecting for the cassette. Second, the marker is eliminated through highly efficient 
sequence specific methods such as site-specific recombination or endonuclease cleavage 
(I-SceI) to generate the desired form of the edited genomic locus. Two steps are 
necessary because no method was available which is both scar-less and efficient enough 
such that no selection is required. 
The development of CRISPR/Cas9 technology in yeast has eliminated the need 
for this two-step process. Cas9 efficiently creates double-stranded breaks (DSBs) in yeast 
DNA at virtually any arbitrary locus provided a PAM sequence is proximal to the desired 
cut site. When an appropriate repair template is provided, these DSBs are repaired 
through the endogenous HR system of yeast. Cas9 directed to the desired genomic locus 
via the guide RNA sequence creates double-stranded break (DSB) in the genome. The 
CRISPR target site is retained in cells which fail to repair the target site as expected, 
which allows Cas9 to repeatedly cleave the same region until HR-mediated editing takes 
place. Rarely, non-homologous end-joining (NHEJ) can generate mutations which block 
Cas9 cleavage despite failing to incorporate the expected genomic alterations. More 
commonly, cells simply succumb to the stress of repeated Cas9-induced genomic 
cleavages. In an appropriately conducted experiment, the majority of the surviving 
population tends to be cells which have lost their CRISPR target site by incorporating the 
desired genomic alteration via HR. Cas9 thus acts as a counter-selection acting directly 





Here, we use an approach developed by Dueber and colleagues (Lee et al., 2015) 
to rapidly generate single, self-contained plasmids that express both the Cas9 nuclease 
and guide RNA required for targeting a desired locus. These plasmids, when co-
transformed with an appropriate repair template provided as a linear PCR product, allow 
efficient, precise, single-step replacement of any arbitrary yeast gene with an introduced 
sequence of interest. Only selection for the Cas9 and gRNA-expressing plasmid is 
required, which tends to select for correct genomic modification by proxy due to 
efficiency of targeting and repair. This strategy was used extensively in our ortholog 
complementation research (Kachroo et al., 2017) to rapidly humanize, bacterialize and 
plantize many essential yeast genes. A CRISPR based approach is uniquely suited to this 
case, because it strongly encourages HR with functional alleles. False positives, arising 
from CRISPR sites being mutated by NHEJ without incorporation of a new allele, are 
minimal because they are often not viable. Additionally, disruption of the target gene’s 
function is brief, eliminating the need for constructing and maintaining a complementing 
plasmid to sustain yeast through an otherwise lengthy engineering process. Further, given 
that CRISPR selects against sequence regardless of function, it is still possible and 
practical to alter non-essential genes (or even non-genic regions) with this technique; 
indeed, we have reported successful humanization of the non-essential yeast gene 
HEM14 with this method (Kachroo et al., 2017) and we have used this system to 






A.3. MATERIALS AND METHODS 
1. Reagents 
1. Pipette tips (Mettler-Toledo, catalog number: 17005872, 17005874, 17007089) 
2. 96-well plate (VWR, catalog number: 82006-636) 
3. Yeast (BY4741) 
4. MoClo Yeast Toolkit (YTK, Addgene kit, catalog number: 1000000061). Toolkit 
includes plasmids pYTK050, pYTK003, pYTK072, pYTK083, pYTK036, 
pYTK008, pYTK047, pYTK073, pYTK074, pYTK081 and pYTK084. 
5. NEB 5-alpha Competent E. coli (NEB, catalog number: C2987) 
6. T7 ligase (NEB, catalog number: M0318S) 
7. T4 ligase buffer (NEB, catalog number: B0202S) 
8. Restriction enzymes BsaI (NEB, catalog number: R0535S) and BsmBI (NEB, 
catalog number: R0580S) 
9. PCR template for the sequence which will replace the target gene (e.g., cDNA, 
plasmid-based clone, etc.) 
Note: For demonstration purposes, this protocol will assume replacement of S. 
cerevisiae HEM2 with its human ortholog ALAD. 
10. High-fidelity DNA polymerase for repair template PCR, such as KAPA HiFi 
(Kapa Biosystems, catalog number: KK2601) 
11. Agarose (Thermo Fisher Scientific, catalog number: 16500500) 
12. DNA stain (Thermo Fisher Scientific, catalog number: S33102) 






14. Zymo EZ yeast transformation II kit (Zymo Research, catalog number: T2001) 
15. Optional: 100 mM lithium acetate can be used in place of EZ 1 solution from the 
EZ competent yeast cell kit. Lithium acetate can be obtained from Sigma-Aldrich, 
catalog number: L6883. See Recipes. 
16. Agar (Serva, catalog number: 11396) 
17. LB Broth, Lennox (Fisher Scientific, catalog number: DF0402-07-0) 
18. LB plates with antibiotic selection (see Recipes) 
a. Ampicillin (Sigma-Aldrich, catalog number: 10835242001) 
b. Spectinomycin (Sigma-Aldrich, catalog number: PHR1426) 
19. Chloramphenicol (Sigma-Aldrich, catalog number: C0378)  
20. YPD powder (Fisher Scientific, catalog number: DF0428-17-5) 
21. Yeast nitrogen base without amino acids (Fisher Scientific, catalog number: 
DF0919-15-3) 
22. Ammonium sulfate (Sigma-Aldrich, catalog number: A4418) 
23. Dextrose (Avantor, catalog number: 1919) 
24. SC-Ura dropout powder (Sigma-Aldrich, catalog number: Y1501) 
25. Liquid YPD medium (see Recipes) 
26. YPD and SD-Ura agar plates (see Recipes) 
27. Optional: 5-fluoroorotic acid (Sigma-Aldrich, catalog number: F5013), if counter-
selection will be used (see section titled “Curing of the CRISPR plasmid”). 
28. Zymolyase (MP Biomedicals, catalog number: 320921) 
29. D-Sorbitol (Sigma-Aldrich, catalog number: S3889) 





31. Zymolyase solution (see Recipes) 
2. Equipment 
1. 12-channel pipette (Mettler-Toledo, catalog number: 17013810) 
2. Thermocycler (Bio-Rad, catalog number: 1861096) 
3. Standard gel electrophoresis tank and accessories (Bio-Rad, catalog number: 
1640302) 
3. Software 
1. Geneious v8.0 (Kearse et al. 2012) or higher, to design gRNA and repair template 
(replacement gene). Other gRNA design software can be used as well, such as E-
CRISP (Heigwer et al. 2014). 
2. BLAT (Kent 2002). 
 
A.4. PROCEDURE 
1. Preparation of CRISPR plasmid (for a diagrammatic overview of the cloning 
process, see Figure A.8.2). Design two guide RNA (gRNA) sequences targeting 
the open reading frame (ORF) for the yeast gene to be replaced using Geneious, 
or a similar tool such as E-CRISP (Heigwer et al. 2014). gRNA sequences can 
often have low activity in practice, despite being predicted to be highly 
efficiencient by software tools. In order to minimize setbacks due to a gRNA 
which turns out to function poorly, we advise designing multiple gRNAs from the 





the construction of the CRISPR plasmids. Both plasmids should then be tested for 
their ability to target the yeast genome and kill cells (described in later steps) to 
empirically determine and confirm their activity. We have not noticed a strong 
effect of the location of the gRNA within the ORF. During homologous repair, 
DNA can be resected up to several kilobases from the break site(Mimitou and 
Symington 2009; Chen et al. 2011), so the gRNA need not be very close to either 
terminus of the ORF. It is however important to select a gRNA such that the 
target site is not present in the eliminated by the replacement (i.e., the gRNA 
should target the yeast ORF, but not the replacement gene). Example: For 
targeting HEM2, the sequences GGATTATCGGAGATGAATAG (‘sg1’) and 
CCTGGTACCAAGGATCCAGT (‘sg2’) were predicted to have high activity 
(see Figure A.8.1). Order forward and reverse oligonucleotides with the gRNA 
sequence and Golden Gate compatible overlaps: Forward oligo consists of the 5’ 
insert GACTTT followed by the 20 bp guide sequence specific to the target gene. 
Example forward oligo for HEM2 sg1 (underline indicates 5’ Golden Gate 
overhang): GACTTTGGATTATCGGAGATGAATAG. Reverse oligo consists of 
the 3’ insert AAAC, followed by the reverse complement of the 20 bp guide 
sequence, and a 5’ insert TT. Example reverse oligo for HEM2 sg1 (underline 
indicates 3’ Golden Gate overhang): AAACCTATTCATCTCCGATAATCCAA. 
Mix forward and reverse oligos (50 µM each) for each gRNA in a total volume of 
20 µl and anneal with each other using a thermocycler with the program below. It 
is unnecessary to phosphorylate the insert or vector. 95 °C for 5 min, 55 °C for 15 





2. First Golden Gate cloning reaction to transfer into shuttle vector: Set up cloning 
reaction with annealed oligos and pYTK050 (Table A.9.1). A 2:1 molar ratio of 
insert:plasmid is recommended for optimal Golden Gate cloning of linear DNA. 
3. Transform the reaction into competent bacteria and plate with chloramphenicol 
selection (170 µg/ml). View colonies under UV light and pick the white colonies 
(those not showing GFP fluorescence), then grow in liquid culture and purify 
plasmid. The vectors used in Golden Gate reactions described in this protocol are 
all GFP-dropout vectors: They contain a GFP gene which will be silenced upon 
successful cloning. Therefore, GFP fluorescence indicates an invalid construct, 
while successful constructs will lose the GFP gene and thus resulting colonies will 
be white. Optionally, the plasmid can be sequenced to check for errors or 
mutations in the gRNA sequence, such as may occur during synthesis. 
4. Second Golden Gate cloning reaction to create gRNA cassette plasmid: Set up 
cloning reaction which includes connector plasmids ConL1 and ConRE (Table 
A.9.2). For best efficiency, all plasmids should be present at the same molarity in 
plasmid based Golden Gate assemblies. 
5. Transform the reaction into competent bacteria and plate with ampicillin selection 
(60 µg/ml). View colonies under UV light and pick the white colonies (those not 
showing GFP fluorescence), then grow in liquid culture and purify plasmid. 
6. Third and final Golden Gate cloning reaction to construct the yeast-compatible, 
complete CRISPR plasmid: Set up Golden Gate cloning reaction with connector 






7. Transform the reaction into competent bacteria and plate with kanamycin 
selection (50 µg/ml). View colonies under UV light and pick the white colonies 
(those not showing GFP fluorescence), then grow in liquid culture and purify 
plasmid. 
8. The resulting construct is a self-contained CRISPR plasmid, which when 
transformed into yeast will cause double-stranded breaks (DSBs) at the locus 
determined by the gRNA sequence cloned into it. 500 ng of this will be used for 
each yeast transformation, so if multiple replacements are planned it is helpful to 
dilute the CRISPR plasmid to a standardized concentration for easier 
transformation set up later on. 
9. Preparation of repair template DNA. Design the template DNA using Geneious or 
any other cloning software. Obtain the genomic sequence of the target yeast gene 
(‘old gene’), and the coding sequence (CDS) of the replacing gene (‘new gene’). 
The CDS should not contain introns. Create a gene model for the replaced locus 
by editing the sequence of the old gene so that it contains the new gene in the 
correct position (i.e., the desired outcome of replacement). 
We find that replacement works best if the original yeast stop codon is left intact. 
Otherwise, modifying the new gene, for instance to codon optimize for yeast, has 
proven unnecessary. 
10. Design template PCR primers which anneal to about 25 bp of the 5’ and 3’ ends 
of the new gene’s CDS, and also the 5’ and 3’ UTR immediately adjacent to the 
ORF (the homology arms). Figure A.8.3 shows an example of primer design for 





much easier using the gene model constructed in the previous step: The sequence 
covering the junction points between yeast genome and the new gene CDS can be 
used directly as primer sequence.The length of the region complementary to the 
new gene CDS is determined only by standard PCR efficiency concerns, such as 
melting temperature. This area will serve as a toehold for the first few cycles of 
the PCR. The length of the homology arms is critical for efficient replacement. 
We find that homologies of at least 70 bp are necessary (in which case the entire 
primer oligo will be about 90 bp long), and for some genes, 170 bp homologies 
may be necessary. For even more difficult replacements, longer homology arms 
can be cloned separately, but we have found that homologies longer than 500 bp 
are unlikely to increase efficiency further. 
11. Use template PCR primers to amplify a large amount of repair template DNA 
using a high-fidelity polymerase. We find that it is helpful to first conduct several 
test PCRs with different polymerases. Due to the particular design of the template 
primers, this PCR can sometimes run inefficiently or generate unwanted non-
specific products. Different polymerases have different characteristics, and often a 
reaction which fails with one polymerase will run efficiently with another, 
rendering laborious PCR optimization unnecessary. At least 5 µg of template 
DNA is needed per yeast transformation, which can usually be obtained from a 
single 50 µl PCR. Difficult replacements can often be facilitated by using more 
(10 µg) template DNA, and if multiple transformations are to be performed the 
amount will also need to be scaled up accordingly. Often several PCRs are 





needed, or an efficient PCR is difficult to set up, an alternative method is to clone 
the template sequence onto a plasmid, which can be amplified in bacteria with the 
template DNA excised using restriction enzymes. 
12. Check the template PCR with agarose gel electrophoresis. As long as a sufficient 
amount of the correct template is produced, non-specific products do not 
necessarily constitute a problem for the replacement. Because the non-specific 
products usually lack appropriate homologies, they will not be efficiently 
integrated into the yeast genome. However, if significant amounts of them are 
present, they will cause over-estimation of template DNA during 
spectrophotometry-based quantification; thus the amount of template DNA used 
in the transformation would need to be adjusted accordingly. Alternatively, the 
PCR can be optimized to reduce non-specific products, or only the correct product 
can be quantified from the gel using a DNA ladder calibrated for quantity 
estimation. 
13. Purify template PCR using the Zymo DNA Clean&Concentrator-25 kit. Elute in 
water. Ideally, the volume of DNA included in yeast transformation should be 
small, so as to not interfere with the transformation reagents. The elution volume 
should be adjusted accordingly so that the resulting concentration of DNA is not 
too low. In our experiments, we have found that eluting with 25 µl water will 
usually yield 400-800 ng/µl DNA, which is suitable for transformations. 
14. Yeast transformation: Prepare competent yeast cells using the Zymo EZ 
competent yeast kit according to the kit instructions. The EZ 1 solution in this kit 





transformation efficiency. The amounts given in the kit manual can be slightly 
modified: 2 ml yeast culture can be used to produce 100 µl of competent yeast, 
which is sufficient for two transformations, 50 µl each. 
15. Set up a transformation reaction: Mix 50 µl competent yeast, 500 µl EZ 3 
solution, 500 ng of CRISPR plasmid and 5 µg repair template DNA (up to 50 µl 
total volume). Incubate at 30 °C as directed by kit manual and plate on –Ura 
medium. 
16. When using a new gRNA for the first time, gRNA efficiency can be estimated 
with a control transformation, which is performed as stated but without repair 
DNA. When the CRISPR plasmid is introduced without a repair template, it will 
repeatedly cleave the target locus, causing toxicity. Very few or no colonies are 
the ideal outcome, since this indicates highly efficient CRISPR cleavage and low 
background rate. Cells can survive the CRISPR plasmid uptake without repair 
DNA if the CRISPR activity is stochastically low (such as due to poor gRNA 
efficiency) or mutations at the CRISPR target locus can be tolerated (which 
produces false transformants even in presence of the repair template). 
17. When colonies appear on the –Ura plates, collect up to 12 of them with a pipette 
tip and suspend in 50 µl water. These suspensions will be screened for confirmed 
replacements. Yeast suspensions can be stored at 4 °C and used to start new 
cultures for up to 2 weeks. Typically, colonies will appear on –Ura plates (Figure 
A.8.4) after 1-3 days. In some cases, the replacement will impose a significant 
fitness defect such that up to 6 days may be required for colonies to appear, but 





take longer than 6 days to grow. The uracil dropout medium will select against 
cells which failed to take up the CRISPR plasmid (which confers uracil 
prototrophy), but because the CRISPR plasmid is toxic to cells unless a successful 
replacement occurs (eliminating the CRISPR target locus) only cells which have a 
replaced locus are expected to survive. However, due to spontaneous hypoactivity 
of the CRISPR system, mutations in the CRISPR target locus (DiCarlo et al. 
2013), and cells which manage to survive CRISPR-associated DSBs, there will be 
a background rate in the form of false transformant colonies which do not carry 
the correct genomic replacements. To save time, we recommend collecting 
several transformant colonies and screening them in parallel. To streamline this 
process (especially when several replacements are performed in parallel), pick 
colonies with pipette tips and manually attach them to a multichannel pipette. The 
multichannel pipette can then be used to suspend all 12 samples in one row of 
small PCR tubes or a 96-well plate. 
18. Colony screening via PCR. Design confirmation PCR primers: Primer pairs 
should be selected such that the forward primer anneals to the yeast UTR while 
the reverse primer anneals only to the new gene CDS but not the old gene’s ORF. 
Thus, the product should span the junction point between foreign sequence and 
native yeast genome. The yeast UTR primer should preferably not overlap the 
homology region. Ideally the product size should be small, about 300 bp, for a 
faster and more robust PCR. It is sufficient to check only the 5’ junction point, 
since it is rare for integration to be proceed as expected at one end of the gene but 





be tested by using a reverse primer which anneals to yeast ORF only. However, 
lack of product from such a primer pair is not sufficient to confirm a clone, since 
the reaction is liable to fail for unrelated reasons (such as poor lysis of cells). 
19. Prepare lysates of harvested transformants: Mix 5 µl of each yeast suspension 
with 15 µl zymolyase solution. 
20. Incubate lysates for 30 min at room temperature, then 15 min at 37 °C and 5 min 
at 95 °C. 
21. Set up 20 µl colony PCRs with confirmation primers and using Accuprime Pfx as 
the polymerase. Use 1 µl of the lysate as template DNA. We find that other 
polymerases do not perform well due to impurities from the yeast lysates. Due to 
the impurities introduced by the lysate, the colony PCR may spontaneously fail, 
leading to false negatives. To ameliorate this problem, a positive control PCR can 
be performed for each lysate, which is identical to the confirmation PCR but uses 
primers complementary to an unrelated, unmodified locus in the genome. We use 
two primers targeting a 500 bp segment of the yeast ERG13 promoter for this 
purpose (Forward CGAACTGGATGAGATGGCCG and reverse 
CATGCTGCACCTTTTATAGTAATTTGGC) 
22. Check the colony PCRs for product by agarose electrophoresis. Lysates from 
clones with the correct modifications should generate a product with the 
confirmation primers. Background false transformants (e.g., mutants) will not 
produce a band. A PCR product from the confirmation primers is sufficient 
evidence of successful integration of the repair template. For further verification, 





rarely occur in clones confirmed by PCR, the most common mutations are single-
basepair substitutions or indels, which typically constitute a minority of 
confirmed clones. Lack of product from the confirmation primers is inconclusive 
per se. In such cases, it is worthwhile to consider additional evidence, such as 
whether the positive control PCR worked (if not, the lysis may have failed). 
23. Confirmed clones can be propagated by starting a new culture from the original 
suspensions of yeast in water. 
24. Curing of the CRISPR plasmid. Streak original water suspensions of confirmed 
clones on YPD. The CRISPR plasmid is low copy and can be spontaneously lost 
in absence of selection. Pick 10 colonies from the YPD plate and patch each one 
on YPD and SD-Ura plates. Incubate both plates and collect cells from patches 
which grew only on YPD but not on SD-Ura. Isolates which still carry the 
CRISPR plasmid will grow on uracil dropout medium, but those which have lost 
the plasmid will not. Typically, 3 days is sufficient to confirm lack of Ura 
prototrophy, but if slow growth on uracil dropout is suspected, incubation can be 
extended to up to 6 days to definitively confirm no growth on uracil dropout. The 
plasmid can also be cured by counterselecting on 5-fluoroorotic acid (FOA) plates 
(Boeke et al. 1987). However, there is a possibility that this FOA method will 
generate some colonies that are not cured of the plasmid but rather have acquired 
a mutation in the Ura marker (thus continuing to express the gRNA). Thus, FOA 
counterselection should not be used (as opposed to replicate patches on YPD and 
–Ura) if it is important to ensure curing of the plasmid, rather than simply 





only loss of –Ura heterotrophy is desired, for instance to enable a subsequent 
transformation with a different Ura-selectable plasmid. 
 
A.5. DATA ANALYSIS 
The data analysis needs for this procedure are minimal. Most importantly, when using 
Geneious to design gRNA sequences, it is desirable to select gRNA sequences that 
have high predicted on-target activity (automatically calculated by Geneious). gRNA 
sequences with high predicted activity may have low actual activity, but they will be 
less likely to exhibit low activity than sequences with low predicted activity. The 
distance of the gRNA target site can be up to 1 kb away from either homology region 
without perceptible negative consequence, thus gRNAs should be selected primarily 




1. We have found that even among gRNAs with high predicted activity, some 
will fail to induce double strand breaks with sufficient efficiency for editing. It 
is highly recommended that for each target locus, several gRNA are designed 
and tested in parallel, to ensure that at least one will be a sufficiently good 





2. If a given gRNA exhibits significant off-target activity, the likely outcome is 
that off-target cleavage will kill most of the transformed yeast cells. 
Successful, efficient genome editing relies on lethality associated with DSBs 
at the target locus being rescued by HR (allowing efficient repair of the DSB) 
and abrogation of the gRNA target site (preventing further cleavage). In the 
event off-target activity, HR may likely not take place because no repair 
template with homology to the off-target site has been supplied, moreover the 
gRNA site will not be eliminated for the same reason. Further, the 
confirmation strategy we suggest is such that only repair at the correct locus 
will produce a positive result. However, it is nevertheless worthwhile to 
ensure that selected gRNA target sites do not occur at other locations in the 
genome, where cleavage is not intended. Although it is very unlikely for the 
combined 23 bp target sequence to appear multiple times in the yeast genome, 
we recommend confirming that candidate gRNA sites appear only in the 
target locus using a tool such as BLAT. 
3. gRNA targets consist of a 20 bp sequence (which will also be included in 
sgRNA sequence and become part of the Cas9 complex) followed by a 3 bp 
PAM sequence (which takes the form of NGG for Cas9 described in this 
protocol). The PAM sequence does not become part of the gRNA, but it must 
be present in the target genome for Cas9 cleavage to occur. This can be 
verified by attempting to align the gRNA sequence to the sequence of the 
repair template – typically, CRISPR activity will be very low with more than 





the PAM appear to have more significance (Kuscu et al. 2014). When 
replacing with very similar sequences, such that it is difficult to find good 
gRNA sites unique to the target locus, one strategy that can be adopted is to 
introduce synonymous mutations in the repair template sequence which alter 
the PAM site or PAM-proximal nucleotides. Alternatively, recent research 
suggests that using shorter gRNA may increase specificity, since the 8-17 
PAM-proximal nucleotides contribute disproportionately to CRISPR target 
recognition (Xu et al. 2017). 
4. There is some variability in the yeast transformation step, and depending on 
how the competent cells were prepared, and how the transformation was 
performed. Most commonly, the number of resulting colonies will vary 
somewhat between transformations of identical strains with identical reagents, 
but usually this variation will be less than tenfold. When a transformation 
produces a fair number of colonies (at least 10) yet none of them are found to 
be correct clones upon screening, simply repeating the transformation is 
unlikely to improve results. The most straightforward avenues of increasing 
the number of correct clones are to increase the amount of repair template 
DNA, and to produce repair template DNA with longer homologies. 
5. If no colonies appear after transformation, the reason may be low 
transformation efficiency. In this case, several troubleshooting steps can be 
taken (described in detail in the documentation of the Zymo EZ competent 
yeast kit). We have found the following to be effective: Thoroughly vortexing 





transformation (1.5 hours instead of the 45 minutes). Including more cells in 
the transformation. Competent cells seem to perform slightly better when 
frozen once (slowly in -80 °C) than freshly prepared cells. 
6. When the CRISPR reagents and repair template are transformed into yeast 
cells, the resulting transforming colonies will be of three kinds with respect to 
the targeted locus: Correct transformants which bear the sequence of the 
repair template. False transformants which bear the original, unedited 
sequence. Mutants 
7. In our experiments, we have found that the first two classes predominate 
unless mutants are specifically selected for. Even in the absence of a repair 
template, the majority of false transformants will not be mutants. Due to the 
efficient HR system of S. cerevisiae, if the conditions of the experiment are 
adequate then editing will take place at a very high rate. Thus, typically, the 
proportion between the first two of the three classes listed above will be such 
that the transformants are either mostly correct or all false. The third class, or 
mutants, we have found to be very rare in either case unless specifically 
selected for. As a consequence, it is rarely necessary to screen a very large 
number of colonies to determine whether an editing experiment has 
succeeded. However, it is desirable to collect several confirmed clones to 
minimize issues caused by artifacts, such as for instance mutant edited 
sequence caused by errors during PCR (with the reagents and protocols 
described in this text, we have found clones with mutant edited sequence to 





8. Selecting yeast transformants with a single amino-acid dropout medium is 
normally a straightforward process, and colonies can be seen within 1-2 days 
of plating. However, occasionally the genome editing process itself, or the 
resulting edited sequence, can result in a growth defect in the resulting cells. 
Thus, if no colonies appear, incubating the plate for a longer period can 
produce colonies. In the most extreme case we observed, it took 6 days for 
colonies to appear on a uracil dropout medium, but several clones were later 
confirmed by PCR and sequencing; these clones consistently exhibited slow 
growth in subsequent culture on rich medium (YPD) as well. 
9. Some combinations of target locus and repair template may lead to a mixture 
of large and small yeast colonies after transformation. If this occurs, generally 
it is best to screen an adequate number of colonies for each size class. It may 
be that the correct edits create much slower growing strains, thus the large 
colonies are false while the small ones have the desired edit. Conversely, if 
the desired sequence does not interfere with normal growth, but mutations 
arising from NHEJ do, then larger colonies will tend to be the correct clones. 
We have observed examples of either case when humanizing and 
bacterializing various loci. It is difficult to predict a priori which case will be 
evident for a given transformation, therefore it is often more practical to 
screen colonies and recording their size, and also ensuring that each size is 
adequately represented in the screen. 
10. When picking colonies for the colony PCR screen, only a small quantity of 





PCR product. We have often chosen to collect slightly larger numbers of cells 
to visually confirm their suspension in water by turbidity. However, too many 
cells lead to incomplete lysis and inhibition of the colony PCR. With cell 
clumps larger than 1-2 mm the colony PCR will often fail. So ideally, the cells 
collected from the colony should form only a tiny speck, 0.5 mm or smaller in 
diameter. It is helpful to include the positive control PCR when screening, to 
identify samples which failed to produce a PCR product due to poor lysis. 
Lysis and PCR can be repeated for these samples if needed. 
11. It is possible to adapt the protocol described here for the simultaneous 
replacement of multiple genes. The Mo Clo toolkit allows for cloning up to 4 
different gRNA cassettes on the same CRISPR plasmid; for this, the gRNAs 
would be captured on pYTK050 as described here, but in the second Golden 
Gate reaction, instead of the ConL1 and ConRE plasmids, the first gRNA 
would be cloned with ConL1 and ConR2, the second with ConL2 and ConR3, 
the third with ConL3 and ConR4 and the fourth with ConL4 and ConRE (this 
process is explained in detail in Lee et al. 2015). All of these cassette plasmids 
would then be included in the final Golden Gate reaction to assemble the 
CRISPR plasmid. Then, during transformation of yeast, templates for each of 
the included gRNAs will need to be co-transformed. However, multiple 
replacements are even more dependent on efficient transformation, cleavage 
and repair than single replacements, and some additional work may be 







1. Zymolyase solution (50 ml). Weigh 9.11 g D-sorbitol. Dissolve in 50 ml distilled, 
deionized water to make 1 M sorbitol and autoclave. Weigh 0.25 g zymolyase and 
dissolve in sorbitol solution. Aliquot and store in -20 °C. 
2. Lithium acetate, 100 mM (40 ml). Weigh 0.408 g lithium acetate dehydrate. 
Dissolve in 40 ml distilled, deionized water. Filter sterilize (0.2 µm filter) and 
store at room temperature. 
3. LB medium (1 L). Weigh 25 g LB powder. For solid medium, add 15 g agar. 
Dissolve in distilled, deionized water for 1 L total volume. Autoclave and let it 
cool to 60-70 °C. Pour in petri plates so that the medium covers the visible area of 
the plate. Let plates cool and solidify at room temperature, store in 4 °C. 
4. YPD (1 L). Weigh 50 g LB powder. For solid medium, add 20 g agar. Dissolve in 
distilled, deionized water for 1 L total volume. Autoclave and let it cool to 60-70 
°C. Pour in petri plates so that the medium covers the visible area of the plate. Let 
plates cool and solidify at room temperature, store in 4 °C.  
5. SD-Ura (1 L). Weigh 1.5 g yeast nitrogen base w/o amino acids, 5 g ammonium 
sulfate, 20 g dextrose, 2 g SC-Ura dropout powder. For solid medium, add 20 g 
agar. Dissolve in distilled, deionized water for 1 L total volume. Autoclave and let 
it cool to 60-70 °C. Pour in petri plates so that the medium covers the visible area 








Figure A.8.1. Diagram of the native yeast HEM2 locus, showing positions of the 








Figure A.8.2. Overview of the CRISPR plasmid construction process.  
In the first step Xs and Ys represent the gRNA sequence selected, and BsmBI recognition 







Figure A.8.3. Diagrams of example template primer designs for the replacement of 










Figure A.8.4. Representative assay results.  
Yeast cells are rescued from DSB lethality (Center plate) when an appropriate repair 
template is provided (Right plate). The left plate is a negative control of cells carrying a 
control plasmid with the same selectable marker (URA3) done to estimate the 


















dsOligo 40 fmol 
pYTK050 20 fmol 
NEB T4 buffer 10x 1.0 µl 
NEB T7 ligase 0.5 µl 
NEB BsmBI 0.5 µl 
ddH2O To 10 µl 
 








gRNA on pYTK050 20 fmol 
ConL1 (pYTK003) 20 fmol 
ConRE (pYTK072) 20 fmol 
AmpR-ColE1 (pYTK083) 20 fmol 
NEB T4 buffer 10x 1.0 µl 
NEB T7 ligase 0.5 µl 
NEB BsaI 0.5 µl 
ddH2O To 10 µl 
 







gRNA cassette plasmid with connectors 20 fmol 
Cen6-Ura cassette* 20 fmol 
Cas9 plasmid (pYTK036) 20 fmol 
NEB T4 buffer 10x 1.0 µl 
NEB T7 ligase 0.5 µl 
NEB BsmBI 0.5 µl 
ddH2O To 10 µl 
*Cen6 Ura is constructed by assembling YTK plasmids (008, 047, 073, 074, 081, and 084). 
 






Appendix B: Abundances of transcripts, proteins, and metabolites in 
the cell cycle of budding yeast reveal coordinate control of lipid 
metabolism6 
 
One of the many strengths of the Marcotte lab is being able to use mass-
spectrometry based proteomics to infer protein profiles and the complexes they assemble 
into in cells (Wan et al. 2015). During Michael Polymenis’s sabbatical in the Marcotte 
lab, we extended this approach to infer changes in protein levels across the eukaryotic 
cell cycle. The eukaryotic cell cycle has been studied in detail for many years now but 
understanding the interplay between different biomolecules at the transcript, protein, and 
metabolite levels in the cell has been challenging for a number of reasons. Efforts have 
been predominantly limited by the ability to generate matched datasets to apply such 
multi-omics approaches. The problem is further complicated by the lack of 
synchronization and sampling bias across transcript and protein levels. Here, for the first 
time, we profiled the abundances of transcripts, proteins, and metabolites across the 
budding yeast cell cycle using multi-omics. The most interesting aspect of this project 
was generating experiment-matched datasets using cell size to efficiently sort and 
identify the cell cycle phases in yeast cells.  
 
 
6This chapter was published as Blank, H.M., Papoulas, O., Maitra, N., Garge, R., Kennedy, B.K., Schilling, 
B., Marcotte, E.M., and Polymenis, M. (2020). Abundances of transcripts, proteins, and metabolites in the 
cell cycle of budding yeast reveal coordinate control of lipid metabolism. MBoC 31, 1069–1084. My 







Establishing the pattern of abundance of molecules of interest during cell division 
has been a long-standing goal of cell cycle studies. Here, for the first time in any system, 
we present experiment-matched datasets of the levels of RNAs, proteins, metabolites, and 
lipids from un-arrested, growing, and synchronously dividing yeast cells. Overall, 
transcript and protein levels were correlated, but specific processes that appeared to 
change at the RNA level (e.g., ribosome biogenesis), did not do so at the protein level, 
and vice versa. We also found no significant changes in codon usage or the ribosome 
content during the cell cycle. We describe an unexpected mitotic peak in the abundance 
of ergosterol and thiamine biosynthesis enzymes. Although the levels of several 
metabolites changed in the cell cycle, by far the most significant changes were in the lipid 
repertoire, with phospholipids and triglycerides peaking strongly late in the cell cycle. 
Our findings provide an integrated view of the abundance of biomolecules in the 
eukaryotic cell cycle and point to a coordinate mitotic control of lipid metabolism. 
 
B.2. INTRODUCTION 
Exemplified by the discovery of cyclin proteins (Evans et al. 1983), identifying 
biomolecules whose abundance changes in the cell cycle has been a critical objective of 
cell cycle studies for decades. Recognizing such molecular landmarks in the cell cycle is 






Over the last twenty years, cell cycle-dependent changes in mRNA levels during 
the cell cycle of S. cerevisiae have been comprehensively defined not only from several 
arrest-and-release synchronization approaches (Cho et al. 1998; Spellman et al. 1998; de 
Lichtenberg et al. 2005; Pramila et al. 2006; Granovskaia et al. 2010), but also elutriation 
(Spellman et al. 1998; Blank et al. 2017). Unlike transcript profiling, cell cycle-
dependent proteomic and metabolomic changes have been more limited and challenging 
to interpret due to different or poor synchronization, lack of matched transcriptomic 
datasets, and divergent results among the various studies. For example, there has only 
been one mass spectrometry-based proteomic analysis of the budding yeast cell cycle, 
sampling cultures at four time-points after they were released from arrest (Flory et al. 
2006). Remarkably few proteins had altered levels during the time course of that 
experiment, and there was no correlation with the available transcriptomic datasets (Flory 
et al. 2006). Hence, at least in S. cerevisiae, it is not clear to what extent protein 
abundances are dynamic in the cell cycle, and how tightly they are linked to 
transcriptional changes, if at all. 
The picture is not much clearer in other experimental systems. In fission yeast, 
two recent studies used highly similar arrest-and-release synchronization and protein 
labeling (stable isotope labeling by amino acids in the cell culture (Mann, 2006)) 
methods, followed by mass spectrometry, to probe cell cycle-dependent changes in the 
proteome. In one study only a single protein changed in abundance more than 2-fold 
(Carpy et al. 2014), while in the other report ~150 proteins did (Swaffer et al. 2016). 





transcripts were reported to be periodic in the cell cycle of fission yeast (Rustici et al. 
2004; Oliva et al. 2005).  
In human cells, several reports sampled the proteome in the cell cycle with mass 
spectrometry, but there is little consensus among them (Dephoure et al. 2008; Olsen et al. 
2010; Lane et al. 2013; Ly et al. 2015; Becher et al. 2018; Dai et al. 2018; Schillinger et 
al. 2018). The fraction of proteins identified as periodic ranged from ~5% (Ly et al. 
2015), to >65% (Schillinger et al. 2018). Synchronization was mostly achieved by release 
from chemical arrest, but two studies also used elutriation (Ly et al. 2015; Dai et al. 
2018). In the only report where an experiment-matched transcriptomic dataset was 
generated (Ly et al. 2015), the correlation with transcript abundance was positive 
(ρ=0.63, based on the Spearman rank correlation coefficient). Some of the differences 
among the above studies may arise from the use of different cell lines, such as: HeLa 
(Dephoure et al. 2008; Olsen et al. 2010; Lane et al. 2013; Becher et al. 2018); K562 
(Dai et al. 2018); SW480 (Schillinger et al. 2018); or NB4 (Ly et al. 2015). However, 
even for the same cell line (HeLa), synchronization (release from thymidine block and 
nocodazole arrest), and point in the cell cycle (0.5 h after nocodazole arrest), the relative 
change in abundance of the 3,243 proteins identified in common between the two studies 
(Olsen et al. 2010; Becher et al. 2018) was poorly correlated (ρ=0.245, based on 
Spearman’s rank correlation coefficient; see Materials and Methods). 
In S. cerevisiae, metabolites have been measured in the cell cycle after arrest-and-
release synchronization in minimal medium with ethanol as a carbon source, focusing on 
exogenous control of cell cycle progression and downstream effects on metabolism 





kinase activity triggers lipolysis (Kurat et al. 2009) and mobilizes storage carbohydrates 
(Ewald et al. 2016; Zhao et al. 2016), to provide resources for cell division. In other 
systems, there is evidence of cell cycle-dependent changes on metabolite levels for the 
green alga Chlamydomonas reinhardtii (Jüppner et al. 2017), fly (Sanchez-Alvarez et al. 
2015), and human HeLa cells (Scaglia et al. 2014; Atilla-Gokcumen et al. 2014; Ahn et 
al. 2017). Despite these advances, there has been no experiment-matched sampling of the 
transcriptome or proteome in any of these studies, making it difficult to integrate these 
datasets with gene expression, at the mRNA or protein levels. 
Here, for the first time in any system, we generated comprehensive datasets for 
RNAs, proteins, metabolites, and lipids, from the same samples of S. cerevisiae cells 
progressing synchronously in the cell cycle. Importantly, these samples were from 
elutriated, un-arrested cells, maintaining as much as possible the normal coupling 
between cell growth and division. We found that while there is a broad correlation 
between the relative abundances of mRNAs and their corresponding proteins, cell cycle-
dependent changes in transcriptional patterns are significantly dampened at the proteome 
level. The cellular lipid profile is highly cell cycle-regulated, with triglycerides and 
phospholipids peaking late in the cell cycle, together with protein levels of ergosterol 
biosynthetic enzymes, highlighting the importance of integrating multiple ‘omic’ datasets 






B.3. MATERIALS AND METHODS 
B.3.1. Strains and media 
Unless noted otherwise, the cells were cultivated in the standard, rich, undefined 
medium YPD (1% w/v yeast extract, 2% w/v peptone, 2% w/v dextrose), at 30 °C. 
B.3.2. Elutriation 
To collect enough cells for the downstream measurements of RNA, proteins, and 
metabolites, we followed the same strategy we described previously (Blank et al. 2017). 
Briefly, elutriated wild type, G1 cells (diploid BY4743 background) were allowed to 
progress in the cell cycle until they reached the desired cell size. At that point, they were 
quenched (with 100 µg/ml cycloheximide and 0.1% sodium azide) and frozen away, and 
later pooled with cells of similar size (Fig B.6.1A). Overall, we had to collect 101 
individual samples, to generate the 24 pools shown in Fig B.6.1A. 
For other elutriation experiments (e.g., see Fig.B.6.4 and 5), only an early G1 
elutriated fraction was collected, from which samples were taken at regular intervals as 
the cells progressed in the cell cycle. 
B.3.3. Cell size and DNA content measurements 
The methods to measure DNA content and the cell size (birth or mean size) of 
asynchronous cultures and estimate the critical size of asynchronous cultures, have been 
described in detail previously (Guo et al. 2004; Truong et al. 2013; Soma et al. 2014; 





B.3.4. Proteomic samples 
We used ~1E+09 cells from each of the 24 pools of the cell size series (see Fig 
B.6.1) to prepare extracts for LC-MS/MS. For each sample, the cells were resuspended in 
0.75 ml of lysis solution (10 mM Tris pH 7.8, 10 mM NaCl). Glass beads were added to 
the top of liquid level, the samples were placed in a Mini Beadbeater (Biospec), and the 
cells broken by ‘bead-beating’ twice at the maximum speed for 90 s each time, placed on 
ice for 60 s between. The extract from each sample was collected by punching a hole 
with a 21-gauge syringe needle at the bottom of the tube. Lastly, the soluble material 
from the lysates were clarified by centrifugation at 14,000 g at 4 °C, for 10 m. Insoluble 
pellets were resuspended in 500 μl of lysis buffer and both clarified supernatants and 
pellets were stored at -80 °C until processing for mass spectrometry. 
For mass spectral analysis, clarified extracts were thawed and protease inhibitors 
immediately added. 50 μl of each supernatant sample was mixed with 50 µl 
trifluoroethanol (TFE) and reduced with 5mM tris(2-carboxyethyl)phosphine (TCEP) at 
56 °C for 45 m, cooled for 5 m at room temperature, and alkylated with 25 mM 
iodoacetamide in the dark, at room temperature for 30 m. Samples were diluted 10-fold 
with digestion buffer (50 mM Tris pH 8.0, 2 mM calcium chloride), digested with trypsin 
(added at 1:50 ratio) at 37 °C for 5 h. Digestion was stopped with 100 µl of 10% formic 
acid and sample volumes were reduced to 100-250 μl in a SpeedVac. Following filtration 
with an Amicon® Ultra-15 Centrifugal Filter Unit the peptides were desalted using C18 
Spin Tips, according to the manufacturer’s instructions. The volume of the samples was 





a 95% water, 5% acetonitrile, 0.1% formic acid solution, and subjected to LC-MS/MS 
analysis. 
The insoluble pellets from the same extracts described above were processed 
based on a method reported previously (Lin et al. 2013). The pellets were resuspended in 
50 μl of 2% w/v sodium dodecyl sulfate (SDS), 50 mM ammonium carbonate and heated 
at 95 °C for 10 m. Following clarification each supernatant was transferred to a fresh 
tube, mixed with six volumes of cold acetone (-20 °C), and incubated at 4 °C for 4 h to 
form a precipitate. Precipitate was recovered by centrifugation at 13,000 g for 15 m, the 
supernatant carefully removed by aspiration, and the pellets washed twice with 0.4 ml of 
cold acetone. After each wash the samples were centrifuged at 14,000 g for 1 m and the 
supernatant carefully aspirated. Pellets were solubilized in 500 μl of 1% w/v sodium 
deoxycholate, 50 mM ammonium carbonate with two rounds of sonication (10 m each) in 
a water bath sonicator with 5 m on ice in between. 50 µl of each sample was reduced and 
alkylated with TCEP and iodocateamide as described above. Unreacted iodoacetamide 
was quenched with 12 mM dithiothreitol (DTT). The samples were brought to 80 µl with 
digestion buffer and digested with trypsin (added at 1:50 ratio) at 37 °C for 5 h. Digestion 
was stopped with 1% formic acid and samples were centrifuged at 14,000 g for 10 m to 
pellet the precipitated sodium deoxycholate. Peptides were desalted with C18 Spin Tips, 
and resuspended for LC-MS/MS as described above. 
B.3.5. LC-MS/MS 
Mass spectra were acquired on a Thermo Orbitrap Fusion. 5 µl (supernatant 
samples) or 2 µl (pellet samples) of peptides were separated using reverse phase 





Scientific) with a C18 trap to Acclaim C18 PepMap RSLC column (Dionex; Thermo 
Scientific) configuration. Peptides were eluted using a 3-45% acetonitrile gradient over 
70 min and directly injected into the mass spectrometer using nano-electrospray. Data-
dependent tandem mass spectrometry was performed using a top speed HCD method 
with full precursor ion scans (MS1) collected at 120,000 m/z resolution and a cycle time 
of 3 sec. Monoisotopic precursor selection and charge-state screening were enabled, with 
ions of charge > + 1 selected with dynamic exclusion of 30 s for ions selected once within 
a 30 s window. Selected precursor ions underwent high-energy collision-induced 
dissociation (HCD) at 31% energy stepped +/-4%. All MS2 scans were centroid and done 
in rapid mode. Raw files were processed using Proteome Discoverer 2.2 and the label-
free quantification workflow. 
B.3.6. RNA samples and libraries 
We used the same approach we had described previously (Blank et al. 2017), to 
collect cells from elutriated cultures of wild type (BY4743 strain background). For each 
of the 24 samples, from ~3E+07 cells total RNA was prepared with the hot phenol 
method. Briefly, the frozen pellets were re-suspended in 0.4 ml TES buffer (10 mM Tris 
pH = 7.5, 10mM EDTA, 0.5% SDS), in DEPC-treated water, and ~0.05 ml glass beads 
were added. Then, 0.4 ml of acid phenol:chloroform was added to each pellet, and the 
samples were incubated at 65 °C for 30 m, and vortexed briefly every 5 m during that 
time. The samples were centrifuged at 14,000 g for 5 m, and 0.3 ml of the top, aqueous 
layer were placed in a 2-ml screw-cap tube containing 1 ml cold ethanol with 40 μl of a 
3M sodium acetate solution. The samples were incubated at 4 °C overnight and then 





centrifuged at 14,000 g for 5 m. The pellets were air-dried and resuspended in 25 μl of 
DEPC-treated water. For the RNAseq libraries, we also used the same approach we had 
described (Blank et al. 2017), except that we did not select for polyA-tailed RNAs. 
Instead, from total RNA, we depleted rRNA, using the ‘Ribo-Zero™ Magnetic Gold Kit 
(Yeast)’, according to the manufacturer’s instructions. All libraries were sequenced on an 
Illumina HiSeq4000, with multiplexing, at the Texas A&M AgriLife Genomics and 
Bioinformatics Facility. Raw sequencing data (fastq files) have been deposited (GEO: 
GSE135476). 
The reads were aligned to the S. cerevisiae reference genome (version R64-1-1) 
using the Rsubread R language package (Liao et al. 2019). First, an index was built using 
the command: buildindex(basename = “R64”, reference = 
“Saccharomyces_cerevisiae.R64-1-1.dna.toplevel.fa”, gappedIndex=TRUE). Then, for 
each of the 24 libraries, the paired end reads were aligned with the command: align(index 
= ‘R64’, readfile1 = ‘….fastq.gz’, readfile2 = ‘….fastq.gz’, type = “rna”). For each 
library, we obtained >10 million uniquely mapped reads, and the output BAM files were 
then used in the featureCounts function of the Rsubread package, with the following 
command: featureCounts(files = “…subread.BAM”, ispairedEnd = TRUE, 
requireBothEndsMapped = TRUE, annotext = “Saccharomyces_cerevisiae.R64-1-
1.95.gtf”, countChimericFragments = FALSE, isGTFAnnotationFile = TRUE). 
For differential RNA levels between any two points in the cell cycle using the 
DESeq2 R language package (Love et al. 2014). For this statistical analysis, the 24 cell 





cell size series (see Fig B.6.1A). Additional analyses with ANOVA-based methods were 
performed as for the other biomolecules, and they are described below. 
B.3.7. Metabolite samples and analysis 
The untargeted, primary metabolite, biogenic amine, and complex lipid analyses 
were done at the NIH-funded West Coast Metabolomics Center at the University of 
California at Davis, according to their mass spectrometry protocols. Gas 
Chromatography–Time-of-Flight Mass Spectrometry (GC-TOF MS) was used for 
Primary metabolites. For biogenic amines, separation and detections was achieved by 
Hydrophilic Interaction Chromatography (HILIC), followed by Quadrupole time-of-flight 
(QTOF) MS/MS. Lastly, for complex lipids, Charged Surface Hybrid (CSH™) C18 
separation was followed with QTOF MS/MS for lipids. Extract preparation was also done 
at the same facility, from 1E+07 cells in each sample, from the same ones used for 
proteomic and RNA profiling (Fig B.6.1). The cells were provided to the Metabolomics 
facility as frozen (at -80 °C) pellets. Detected species that could not be assigned to any 
compound were excluded from the analysis. 
B.3.8. ANOVA-based computational approaches to identify differentially expressed 
biomolecules 
For RNA samples, we used the TPM normalized values. For all other 
biomolecules, the input values we used were scaled-normalized for input values per 
sample. All the input and output datasets are shown in . To identify significant 
differences in the levels of biomolecules between any two points in the cell cycle we used 





mcppb20 function, of the WRS2 R language package. For this statistical analysis, the 24 
cell size pools were grouped in 8 groups, for each of the approximately 5 fL increments 
in the cell size series (see Fig B.6.1A). 
B.3.9. SWATH-Mass spectrometry 
The samples used to measure ribosomal protein abundances were from elutriated, 
diploid wild type BY4743 cells. Once the cells reached the desired cell size, they were 
quenched with 100 µg/ml cycloheximide and 0.1% sodium azide. Cells were harvested 
from three independently elutriated cultures (5E+07 cells in each sample). The cells were 
re-suspended in a buffer containing 20 mM Tris·Cl (pH 7.4), 150 mM NaCl, 5 mM 
MgCl2, 1 mM DTT, 100 μg/ml cycloheximide, 1% v/v Triton X-100, and 25 U/ml Turbo 
DNase I, to a volume of 0.35 ml. Then, 0.2 ml of 0.5mm glass beads were added to each 
sample, and vortexed at maximum speed for 15 s, eight times, placing on ice for 15 s in 
between. The lysates were clarified by centrifuging at 5,000 rpm for 5 m, at 4 °C, and 
again for 5 m at 13,000 rpm at 4 °C. The supernatant was transferred to a 13×51 mm 
polycarbonate ultracentrifuge tube, underlaid with 0.90 ml of 1 M sucrose, and the 
ribosomes were pelleted by centrifugation in a TLA100.3 rotor (Beckman) at 100,000 
rpm at 4 °C for 1 h. The protein pellets from three biological replicates for various time 
points during the cell cycle (40, 45, 50, 55, 60, 65, 70 and 75 fL) were then re-suspended 
in PBS, subjected to a Filter-Aided Sample Preparation (FASP) protocol tryptic digestion 
(Wiśniewski et al. 2009), desalted using C-18 Ziptips, and analyzed by data-independent 






Briefly, samples were analyzed by reverse-phase HPLC-ESI-MS/MS using an 
Eksigent Ultra Plus nano-LC 2D HPLC system (Dublin, CA) with a cHiPLC system 
(Eksigent) which was directly connected to a quadrupole time-of-flight (QqTOF) 
TripleTOF 6600 mass spectrometer (SCIEX, Concord, CAN) (Christensen et al. 2018). 
After injection, peptide mixtures were loaded onto a C18 pre-column chip (200 µm x 0.4 
mm ChromXP C18-CL chip, 3 µm, 120 Å, SCIEX) and washed at 2 µl/min for 10 min 
with the loading solvent (H2O/0.1% formic acid) for desalting. Subsequently, peptides 
were transferred to the 75 µm x 15 cm ChromXP C18-CL chip, 3 µm, 120 Å, (SCIEX), 
and eluted at a flow rate of 300 nL/min with a 3 h gradient using aqueous and acetonitrile 
solvent buffers. 
For quantification, all peptide samples were analyzed by data-independent 
acquisition (Gillet et al. 2012), using 64 variable-width isolation windows (Schilling et 
al. 2017; Collins et al. 2017). The variable window width is adjusted according to the 
complexity of the typical MS1 ion current observed within a certain m/z range using a 
DIA ‘variable window method’ algorithm (more narrow windows were chosen in ‘busy’ 
m/z ranges, wide windows in m/z ranges with few eluting precursor ions). DIA 
acquisitions produce complex MS/MS spectra, which are a composite of all the analytes 
within each selected Q1 m/z window. The DIA cycle time of 3.2 s included a 250 ms 
precursor ion scan followed by 45 ms accumulation time for each of the 64 variable 
SWATH segments. 
The DIA/SWATH data was processed with the Spectronaut™ software platform 
(Biognosys) for relative quantification comparing peptide peak areas among different 





based on XICs of 6-10 MS/MS fragment ions, typically y- and b-ions, matching to 
specific peptides present in the spectral libraries. Significantly changed proteins were 
accepted at a 5% FDR (q-value < 0.05). 
B.3.10. Immunoblot analysis 
For protein surveillance, protein extracts were made as described previously 
(Amberg et al. 2006), and run on 4-12% Tris-Glycine SDS-PAGE gels. To detect TAP-
tagged proteins with the PAP reagent, we used immunoblots from extracts of the 
indicated strains as we described previously (Blank et al. 2017). Loading was evaluated 
with an anti-Pgk1p antibody. 
B.3.11. Comparison of the relative protein abundances in (Becher et al. 2018) and 
(Olsen et al. 2010) 
For the datasets generated in human, HeLa cells, 0.5 h after nocodazole arrest, the 
data were from Becher et al. (Becher et al. 2018) and Olsen et al. (Olsen et al. 2010). In 
the former study the authors reported the Log2-transformed ratios of the measured 
abundance over the median abundance of asynchronous cultures. For the (Olsen et al. 
2010) proteins, the data were the isotopic ratios reported. In both cases, these values 
represented the corresponding protein abundances in that sample, among all the proteins 
identified in each sample in each study. To compare the rank order of the 3,243 proteins 








B.4.1. Samples for the multi-omic cell cycle analysis 
To apply genome-wide methods for the identification of cell cycle-dependent 
changes in the abundance of molecules of interest, one must first obtain highly 
synchronous cell cultures. Preferably, synchronization must be achieved in a way that 
minimally perturbs cellular physiology and the coordination between cell growth and 
division (Aramayo and Polymenis 2017). When cells are chemically or genetically 
arrested in the cell cycle to induce synchrony, known arrest-related artifacts can bias the 
results (Ly et al. 2015; Aramayo and Polymenis 2017). An alternative synchronization 
method is elutriation, a physical process that fractionates an asynchronous cell population 
by cell size and sedimentation density properties of the cells, with minimal perturbation 
of cellular functions (Lindahl 1948; Creanor and Mitchison 1979; Banfalvi 2008). Hence, 
we used centrifugal elutriation to obtain our synchronous cell cultures (see Materials and 
Methods, and Fig B.6.1A). Elutriation separates cells primarily based on size, and size is 
used as a normalizing reference across different elutriation experiments. We isolated 101 
different elutriated cultures, which were combined into 24 pools, based on the size at 
which they were harvested. Hence, we generated a cell size-series, spanning a range from 
40 to 75 fL, sampled at approximately every 5 fL intervals. These 24 pools were 
processed as independent samples in all analytical downstream pipelines. For statistical 
analysis (e.g., with the bootstrap ANOVA), the 24 cell size pools were grouped in 8 
groups, for each of the approximately 5 fL increments in the cell size series (see Fig 
B.6.1A). The same 24 distinct pools were aliquoted as needed (see Materials and 





proteins (with LC-MS/MS), and metabolites (GC-TOF MS for primary metabolites; 
HILIC-QTOF MS/MS for biogenic amines; and CSH-QTOF MS/MS for lipids). 
To gauge the synchrony of our samples by microscopy, we used budding as a 
morphological landmark, which roughly coincides with the initiation of DNA replication 
in S. cerevisiae. The percentage of budded cells across the cell size series (Fig B.6.1B) 
rose steadily from ~0% in the smallest cells (at 40 fL), to >80% at the largest cell size (75 
fL). The cell size at which half the cells were budded (a.k.a. ‘critical size’, a proxy for the 
commitment step START) in our cell size series was ~62 fL (Fig B.6.1B). This value is 
the same as the critical size these cells display in typical time-series experiments (Hoose 
et al. 2012). We also measured the DNA content of the cells with flow cytometry (Fig 
B.6.1). These results suggest that the synchrony is excellent for most of the cell cycle, 
except perhaps in the last 1-2 pools, when the cells have grown substantially in size and 
they are more heterogeneous. From the RNAseq data that we will describe later (Fig 
B.6.2), mRNAs that are known to increase in abundance at the G1/S transition (G1 
cyclins; CLN1,2; peaking at 55 fL), or later in G2 phase (cyclin CLB2; peaking at 70 fL), 
peaked as expected in the cell size series (Fig B.6.1C). Hence, based on cytological (Fig. 
B.6.1B and S1) and molecular (cyclin mRNAs, Fig B.6.1C) markers of cell cycle 
progression, the synchrony of our samples was of high quality. 
B.4.2. Overview of the datasets 
One type of extract was analyzed for each class of the following biomolecules: 
RNA, primary metabolites, biogenic amines, and lipids (see Materials and Methods). For 
proteomic analysis, we used soluble protein extracts (designated as ‘sol’ in the datasets 





as ‘pel’ in the datasets. The pellet was subsequently solubilized with detergents (see 
Materials and Methods) and analyzed in parallel to the soluble sample by liquid 
chromatography tandem mass spectrometry (LC-MS/MS). For label-free relative 
quantification of proteins, we used both spectral counts (designated as ‘psm’ in the 
datasets and peak areas (designated as ‘pa’ in the datasets. For RNAs, the signal we used 
for quantification was read counts, either raw or after normalization as Transcripts Per 
kilobase Million (TPM) (see Materials and Methods). For the metabolites, the signal was 
the peak heights from mass spectrometry (designated as ‘ph’ in the datasets). 
For the quantification of proteins and metabolites, each dataset was first 
normalized for input. Hence, for proteins or metabolites, comparisons across the 24 
samples were scaled based on the sum of the signals detected in each of the 24 samples. 
For RNA, we used TPM-normalized values and raw reads. For each dataset, we used a 
bootstrap-based ANOVA (see Materials and Methods; the output files named as ‘anova’ 
in the datasets. Also, for RNA, we used the DESeq2 pipeline ((Love et al. 2014); see 
Materials and Methods; the output file designated as ‘deseq2’. Only biomolecules that 
changed ≥2-fold in our cell size series and had an adjusted p-value or FDR<0.05, were 
considered as significantly changing in the cell cycle. 
For display purposes, in all the heatmaps and most plots, we show Log2-
transformed expressed ratio values. These are the ratios of the levels that we measured 
for each biomolecule in each cell cycle point, reflecting the magnitude of the ratio of 
abundance relative to the average of that biomolecule across all the cell cycle points we 





in yeast (Spellman et al. 1998), and has been the standard in displaying and analyzing 
differential expression in the cell cycle. 
B.4.3. RNAs in the cell cycle 
The RNAseq data were analyzed (see Materials and Methods, Fig B.6.2,), to 
identify RNAs that change in abundance in the cell cycle. The number of identified 
RNAs varied, depending on the computational method. Based on the DESeq2 approach, 
~40% of the transcripts (n=2,456) were significantly different between any two points in 
the cell cycle. The ANOVA-based approach identified 652 RNAs, whose levels changed 
significantly in the cell size series (Fig B.6.2). In addition to the expected clusters of 
RNAs associated with DNA replication (cluster 2) and mitotic cell cycle progression 
(cluster 4), there was a large cluster of transcripts enriched for processes related to 
ribosome biogenesis (cluster 1, Fig B.6.2;), peaking in the G1 phase. These transcripts 
also appeared periodic in past studies that relied on elutriation as a synchronization 
method to identify cell cycle-regulated RNAs (Spellman et al. 1998; Blank et al. 2017), 
but not in studies that used arrest-and-release methods (Spellman et al. 1998). An 
increase in the levels of transcripts involved in ribosome biogenesis before commitment 
to division has also been described in transcriptomic profiles of S. pombe (Oliva et al. 
2005). Despite these changes at the transcript level, whether the ribosome content of the 
cell changes during the cell cycle is not known. We will describe results that do not 
support any cell cycle-dependent changes in assembled ribosomes (Figure 4). 
Early in the cell cycle (cluster 1 & 3, Fig B.6.2), we noticed that there were some 
tRNAs whose levels were higher. Note that tRNAs were not examined in the two prior 





studies focused on polyA-tailed selected transcripts (Spellman et al. 1998; Blank et al. 
2017). It has been argued that polyA selection biases the transcriptome quantification 
(Weinberg et al. 2016). Hence, in this study, we relied only on rRNA subtraction to 
prepare the RNAseq libraries (see Materials and Methods), which does not remove 
tRNAs and other non-coding RNAs. We also note that tRNAs are notoriously difficult to 
measure by RNAseq due to factors such as their high level of modification, sequence 
similarity between different tRNAs, and the difficulty to discriminate between cleaved 
and mature tRNAs. The tRNAs whose levels appeared to change in the cell cycle are 
shown in Fig B.6.2. These results are difficult to reconcile with the extreme stability of 
mature tRNAs (from 9 h to several days -exceeding the duration of multiple cell cycles, 
see (Hopper 2013)), unless these tRNAs are targets of quality control mechanisms 
(Hopper 2013). In any case, as we show later (Fig B.6.8) we found very little evidence to 
support a significant role for altered codon usage in the cell cycle. 
Lastly, we also compared the identified cell cycle genes from the two elutriation 
datasets published previously (Spellman et al., 1998; Blank et al., 2017), and this study 
(Fig B.6.3). The overlap in the identified cell cycle transcripts appears low (e.g., the 
Spellman dataset overlaps ≈20% with either of the other two datasets). However, 
different methods in sample preparation (total RNA in this study vs. polyA-selected 
mRNAs in the other two) and in the computational analyses (ANOVA in this study vs. 
Fourier-transformation in the other two) were used, which could account at least in part 





B.4.4. Cell cycle-dependent changes in the proteome 
From the soluble and insoluble extracts (see Materials and Methods), we 
identified 3,571 S. cerevisiae proteins, at one or more cell cycle points. From the soluble 
extracts 2,236 proteins were identified in all eight cell size groups in the cell cycle, while 
from the insoluble ones that number increased to 2,449 proteins. Although this represents 
a reasonably thorough sampling of the yeast proteome, we did not find some low 
abundance proteins (e.g., cyclins). This was not unexpected, since a recent, aggregate 
analysis of all available datasets of protein abundances in yeast (measured with tandem 
affinity purification (TAP), followed by immunoblot analysis-, mass spectrometry-, and 
GFP tag-based methods), placed proteins of the gene ontology process ‘mitotic cell cycle 
regulation’ as the least abundant group (Ho et al. 2018). The extent to which mRNA 
levels can explain protein levels is debated (Lu et al. 2007; Vogel and Marcotte 2012; 
Csárdi et al. 2015; Lahtvee et al. 2017). For most species, RNA levels explain between 
one to two-thirds of the variation in protein abundances (Vogel and Marcotte 2012). To 
examine the broad correlation between transcript and protein levels, we looked at the 
association of count data from our transcriptomic (reads) and proteomic (spectral counts) 
datasets (Fig B.6.4). Across all the points in our cell size series, the Spearman rank 
coefficients (ρ) for the transcriptome-proteome correlations ranged from 0.52 to 0.63 (Fig 
B.6.4). When we compared the relative abundance of the proteins in our datasets, against 
the consensus abundances calculated by (Ho et al., 2018), the correlation was higher 
(ρ>0.75 in every case, see Fig B.6.5). Hence, both in terms of the number of proteins we 
identified and their relative abundance, the quality of our proteomic datasets was high 





To identify proteins that changed in abundance in the cell cycle, we examined 
separately each of the four proteomic datasets: soluble and insoluble extracts, each 
quantified by spectral counts and by peak areas (see Materials and Methods). The overlap 
between the proteins in each dataset that appeared to change in abundance in the cell 
cycle was minimal (see Fig B.6.6). Based on ANOVA analysis, we identified 333 
proteins whose levels changed significantly in the cell size series, in at least one of the 
four proteomic datasets (shown in the heatmap, in Fig B.6.3B). We will describe 
additional proteins whose levels change significantly in the cell cycle, but due to irregular 
patterns and missing values were not identified as such by the ANOVA-based method we 
used (see Fig B.6.5). 
Our analysis provided numerous examples of physiologically relevant, cell cycle-
dependent changes in protein abundance. Among these, were several whose levels are 
well known to be periodic at both the protein and RNA levels. These include proteins 
involved in DNA replication-related processes, such as both isoforms (Rnr1p and Rnr3p) 
of the large subunit of ribonucleoside-diphosphate reductase, peaking as cells enter S 
phase (Fig B.6.3A, bottom). However, other groups of proteins that we found to change 
in abundance in the cell cycle, were not so at the RNA level. For example, several 
enzymes of ergosterol biosynthesis (Erg1,11,3,5,7p) peaked late in the cell cycle (Fig 
B.6.3A, top). Of those, only the levels of the mRNA for Erg3p (C-5 sterol desaturase) 
changed in the cell cycle. The coordinate upregulation in the levels of enzymes involved 
in ergosterol biosynthesis is consistent with the mitotic increase in lipid levels that we 





Despite the transcriptional upregulation in G1 of transcripts involved in ribosome 
biogenesis (see Fig B.6.2), we did not observe such broad changes at the proteomic level. 
In earlier reports, the synthesis of ribosomal components was not cell cycle-dependent 
(Shulman et al. 1973; Elliott et al. 1979; Warner 1999). To our knowledge, however, it is 
not known if the ribosome content in the cell, or the composition of ribosomal proteins in 
assembled ribosomes, changes in the cell cycle. Hence, we asked if the total amount of 
ribosomal proteins or their proportion in assembled ribosomes varies significantly in the 
cell cycle. To this end, we isolated assembled ribosomes through sucrose ultra-
centrifugation from wild type cells (Fig B.6.4A; see Materials and Methods). Ribosomal 
protein abundance was measured with SWATH-mass spectrometry (see Materials and 
Methods). Note that for this experiment, extracts were not made from pools of different 
elutriated cultures, but from the same early G1 elutriated cells at different points as they 
progressed in the cell cycle (see Materials and Methods). The sum of all ribosomal 
protein abundances in assembled ribosomes did not change significantly in the cell cycle 
(Fig B.6.4B). Since our samples were prepared from the same number of cells, and 
ribosomal proteins accounted for ~60% of the intensities detected, one could reasonably 
assume that ribosome abundance does not change significantly in the cell cycle, but it is 
also possible that our isolation somehow has skewed the results. There were also no 
significant differences in the relative abundance of the individual ribosomal proteins in 
the cell cycle (Fig B.6.4C and S7). We note that the relative levels of each protein in the 
ribosomes of each sample are independent of any putative differences in the amounts of 
assembled ribosomes between samples. Hence, we conclude that gross ribosome 





not unambiguously exclude, the possibility that individual, specialized ribosomes may be 
formed during the cell cycle. However, at least based on these population-averaged 
measurements, the composition of assembled ribosomes seems unaffected in the cell 
cycle.  
Lastly, we interrogated our proteomic data for evidence of differences in codon 
usage during the cell cycle. It has been proposed that optimal codon usage is more 
prevalent in mRNAs expressed in the G1 phase of the cell cycle, contributing to the 
abundance of proteins that peak in G1 (Frenkel-Morgenstern et al. 2012). Altered tRNA 
abundances during stress conditions in S. cerevisiae may also regulate protein synthesis 
(Torrent et al. 2018). To avoid confounding effects from differential transcription of 
RNAs encoding the proteins that we identified to change in abundance in the cell cycle 
(Fig B.6.3B), we focused on the proteins whose corresponding mRNAs were not 
changing in the cell cycle (Fig B.6.2). Moreover, to minimize effects from regulated 
proteolysis, we excluded from the analysis proteins for which there is evidence for 
ubiquitylation and regulated proteolysis (Swaney et al. 2013). For the vast majority of 
codons in the remaining proteins, there were no significant changes between their actual 
and expected frequencies in the cell cycle, based on gene-specific codon usage (Tumu et 
al. 2012). Only four codons (AGC, UAU, AGG, AAC) were used with statistically 
significant differences in the cell cycle, but the magnitude of those differences was 
minimal nonetheless (Fig B.6.8). Overall, despite hints at the transcriptional level (Fig 
B.6.2) for upregulation of processes associated with protein synthesis in the G1 phase, at 
least from these population-based experiments, our data argue against any significant cell 





B.6.4C), or codon usage (Fig B.6.8), suggesting that at the proteome level those changes 
in RNA levels have been dampened extensively. 
B.4.5. Thiamine biosynthesis and TDP-dependent enzymes in the cell cycle 
To identify other proteins whose levels could change in the cell cycle but were not 
identified as such by the computational methods we used, we looked at proteins with the 
largest change in their levels, regardless of missing values or statistical cutoffs. 
Remarkably, a group of enzymes involved in thiamine biosynthesis peaked coordinately 
in abundance late in the cell cycle when the cells reached a cell size of ~65 fL (Fig 
B.6.5A). These enzymes participate in thiamine diphosphate (TDP) synthesis in the 
cytoplasm. Thi7p showed the smallest difference (slightly over 2-fold) in abundance 
during the cell cycle from our mass spectrometry experiments and could provide a good 
measure to validate our results. The THI7 transcript was not identified in the core cell 
cycle regulated transcripts by Spellman et al (Spellman et al. 1998), which did not 
include in their analysis their own elutriation data. However, THI7 was identified as cell 
cycle-regulated in all three elutriation datasets (this study, (Spellman et al. 1998), (Blank 
et al. 2017); and Fig B.6.3), suggesting that THI7 expression is cell cycle-regulated at the 
RNA level, at least in experimental approaches that maintain the coordination of cell 
growth with cell division. To further test this prediction, early G1 cells carrying the 
THI7-TAP allele (the only available THI gene in the TAP-tagged strain collection 
encoding any of the proteins shown in Fig B.6.5A) were obtained by elutriation and the 
levels of the corresponding proteins were evaluated by immunoblotting at regular 
intervals, as the cultures progressed in the cell cycle (Fig B.6.5B). We confirmed by 





B.6.5B; compared to the levels of the control protein Pgk1p). These results are consistent 
with the notion that there might be a coordinate, mitotic upregulation of thiamine 
biosynthesis enzymes. 
Next, we asked if any TDP-dependent enzymes also change in abundance in the 
cell cycle and if strains lacking these proteins have cell cycle-related phenotypes. TDP is 
a cofactor for several enzymes, including transketolase (Tkl1,2p), α-ketoglutarate 
dehydrogenase (Kgd1p), E1 subunit of pyruvate dehydrogenase (Pda1p), pyruvate 
decarboxylase (Pdc1,5,6p), and phenylpyruvate decarboxylase (Aro10p). Only the levels 
of Tkl2p, Pdc5p, and Aro10p appeared to be elevated late in the cell cycle (Fig B.6.5C), 
at the same time as the levels of thiamine biosynthesis enzymes were also raised (Fig 
B.6.5A). 
Cell size phenotypes are often used as a proxy for disrupted cell cycle progression 
with an increased cell size phenotype typically accompanying mitotic defects. Of all 
deletion strains lacking a protein that requires TDP as a cofactor, only the loss of Tkl2p 
increased cell size significantly (Fig B.6.5D). We found that both birth size and the mean 
size of tkl2Δ cells were larger (Fig B.6.5D). Note that the tkl2Δ deletion strain was not in 
the panels that were examined in genome-wide screens of cell size mutants (Jorgensen et 
al., 2002; Zhang et al., 2002). The mitotic upregulation in the levels of thiamine 
biosynthesis enzymes (Fig B.6.5A) and Tkl2p itself (Fig B.6.5C) are suggestive of 
possible mitotic roles for Tkl2p, which might depend on the available TDP pools in the 






B.4.6. Cell cycle-dependent changes in metabolites and lipids 
From the same elutriated pools we used to measure RNAs and proteins (see Fig 
B.6.1), we also measured metabolites and lipids. The assays were performed at the West 
Coast Metabolomics Center at UC Davis, an NIH RCMRC (Regional Comprehensive 
Metabolomics Resource Core). Each class of metabolites was measured with distinct 
mass spectrometry-based assays (see Materials and Methods). From these assays, 
thousands of compounds were detected, but most could not be assigned confidently to 
known metabolites, and they were not considered further. Instead, we focused on the 406 
primary metabolites, biogenic amines, and complex lipids that were identified across the 
cell size series. As with our analysis of RNAs and proteins, we used ANOVA (Fig B.6.6) 
to identify compounds whose levels change in the cell cycle. Previous reports showed 
that storage carbohydrates are mobilized at the G1/S transition (Ewald et al., 2016; Zhao 
et al., 2016). In agreement with these studies, we also found that trehalose levels risein 
G1 to their highest levels when cell size reaches 50 fL but drop significantly at the G1/S 
transition (Fig B.6.6). The levels of other sugars (glucose, fructose, mannose, glucose-6-
phosphate; see Fig B.6.6) were also higher in G1, consistent with an upregulation of 
glycolysis before DNA replication. By far, however, the class of metabolites that changed 
the most in abundance in the cell cycle was complex lipids, which peaked late in the cell 
cycle (Fig B.6.6). These included phospholipids (phosphatidyl-inositol (PI), -
ethanolamine (PE), -serine (PS)) and triglycerides (Fig B.6.6). The higher triglyceride 
levels are also consistent with the elevated levels of neutral lipid droplets late in the 
G2/M phase, as reported previously (Blank et al., 2017). Overall, the coordinate increase 
in the levels of ergosterol biosynthesis enzymes we identified from the proteomic 





metabolism is significantly upregulated late in the cell cycle. In the Discussion, we will 
expand on the significance of these results. 
 
B.5. DISCUSSION 
The sample-matched datasets for RNAs, proteins, metabolites, and lipids we 
generated from budding yeast cells progressing synchronously in the cell cycle provide a 
comprehensive view of these biomolecules in dividing cells. We discuss our approach to 
obtain the analytical samples, and our findings in the context of the relation between the 
transcriptome and the proteome and the integration of metabolite and lipid measurements 
with other ‘omic’ datasets. 
A primary goal and unique aspect of this study are that we took a measure of the 
different biomolecules from the same, experiment-matched samples. Furthermore, to 
maintain the normal coupling between cell growth and cell division as much as possible, 
we used centrifugal elutriation to obtain synchronous cultures, instead of arrest-and-
release methods. However, elutriation merely selects based on cell size a small fraction of 
cells from an asynchronous, larger population. Hence, compared to arrest-and-release 
methods, elutriation suffers from low yields of synchronous cells. To overcome this 
problem, we generated our samples by pooling from different elutriations cells of the 
same size. All the cells we collected from the elutriator were early G1 daughter cells, 
which were then allowed to progress in the cell cycle, before we harvested them once 





pools along a hypothetical cell cycle, generating a size-series (Fig B.6.1). This is different 
from starting with one elutriated sample, typically of small cells in early G1, and then 
taking aliquots at various times as they progress in the cell cycle, generating a time-
series. 
But practical necessities for large quantities of cells aside, how does a size-based 
series compare to a time-based one? We argue that it compares favorably, for the 
following reasons: First, no two, time series-based, elutriations are the same, and cell size 
always has to be used to account for experimental variation properly. A typical metric is 
the critical size for START, defined as the size at which half the cells are budded. We 
note that the critical size of our reconstructed cell cycle profile was ~62 fL (Fig B.6.1B), 
the same as the critical size of the same strain and medium in time-series experiments 
(Hoose et al. 2012). Second, based on DNA content analysis (Fig B.6.1), at least until the 
cells have grown substantially to ~65 fL, the synchrony appears very tight. Only at 70-75 
fL, the samples appear more heterogeneous, with some cells going through the M/G1 
transition, indicated by the rise of cells with G1 DNA content. But this is also a feature of 
time-based elutriations, or even arrest-and-release methods, where there is an inevitable 
loss of synchrony the further one moves along the cell cycle from the starting point. 
Third, every molecular marker we looked at (cyclin mRNAs, see Fig B.6.1C; proteins of 
DNA metabolism, see Fig B.6.3A) peaks as expected in our size-based series. Fourth, 
when comparing the cell cycle abundances of the same protein (Thi7p) from a size-based 
(Fig. C.6.5A) vs. a time-based series (Fig. C.6.5B), the profiles are nearly identical, even 
though the ploidy of the strains was not. For these reasons, our size-based approach 





In yeast, the latest meta-analyses from all available studies estimated that between 
37% and 56% of the variance in protein abundance is explained by mRNA abundance 
(Ho et al., 2018). These estimates are within the range of previous ones from multiple 
species (Vogel and Marcotte 2012). Based on the absolute quantification of protein and 
mRNA abundances (Lahtvee et al. 2017), the overall correlation between mRNA and 
protein abundances was also in that range (R2=0.45, based on Pearson’s correlation 
coefficient). The level of correlation between the transcriptome and the proteome we 
observed appears to be somewhat higher (ρ=0.52-0.63, based on Spearman’s coefficient), 
probably because our experiments were done from synchronous cells, and because cell 
cycle transitions are associated with transcriptional waves (Spellman et al. 1998). A 
critical role for transcription in shaping the proteome takes place as cells transition in 
different environments, and during such transitions changes in protein levels were much 
more highly correlated with the changes in mRNA levels (R2>0.9) (Lahtvee et al. 2017). 
Hence, the relatively high correlation we observed between the transcriptome and the 
proteome in the cell cycle is not surprising, and it is probably an underestimate, since 
some extremely unstable cell cycle regulators whose levels rise as a result of transcription 
(e.g., cyclins, see Fig B.6.1C), were absent from our proteomic datasets because of their 
low abundance. 
Despite the correlation between the transcriptome and the proteome we discussed 
above, there were clear groups of transcripts and proteins whose abundance was 
incongruent. Ribosomal biosynthesis, reflected on the levels of individual ribosomal 
proteins or assembled ribosomes, was not periodic at the proteomic level (Fig. B.6.4 and 





We noted that a similar phenomenon was recently reported for the integrated stress 
response, a well-characterized transcriptional response in yeast involving ~900 transcripts 
(Gasch et al. 2000), which was not seen at all at the protein level (Ho et al. 2018). The 
observation that the ribosome content of the cell is constant in the cell cycle (Fig B.6.4) 
suggests that changes in translational efficiency of some mRNAs described previously 
(Blank et al. 2017) are likely due to transcript-specific mechanisms, rather than global 
changes in the steady-state ribosome content (Lodish 1974). 
The mitotic peak in the levels of TDP biosynthesis enzymes was surprising (Fig 
B.6.5). The physiological significance of such a change in the levels of these enzymes is 
unclear. Through some uncharacterized roles, the TDP-dependent transketolase activity is 
necessary for meiotic progression in mouse oocytes (Kim et al. 2012). In bacteria, 
transketolase participates in chromosomal topology, and E.coli cells lacking transketolase 
are UV-sensitive (Hardy and Cozzarelli 2005). However, we found that yeast tkl2Δ cells 
are not sensitive to UV or other DNA-damaging agents (not shown). Overall, despite the 
intriguing observations that late in the cell cycle, levels of the TDP-dependent Tkl2p 
transketolase were higher (Fig B.6.5C) and loss of Tkl2p increased cell size (Fig B.6.5D), 
the molecular mechanism connecting these observations remains to be determined. 
The coordinate upregulation of ergosterol biosynthetic enzymes late in the yeast 
cell cycle (Fig B.6.3), not evident at the RNA level (Fig B.6.2), was unexpected. To our 
knowledge, there is no prior report of such a response. It should be noted that the lack of 
cell cycle-dependent changes at the levels of mRNAs encoding the enzymes of ergosterol 
biosynthetis was seen not only in our dataset, but also in the other datasets aggregated in 





enzymes we show in Fig B.6.3A, only ERG3 had a rank score of 624, while all others 
were not periodic (scores >800) (Santos et al. 2015). Note that we also found ERG3 
mRNA levels to significantly change in the cell cycle. 
The mitotic rise in the levels of sterol biosynthetic enzymes is significant in the 
context of our metabolite measurements, showing that lipid levels (especially 
phospholipids and triglycerides) increased at the same time (Fig B.6.6). Our observations 
are consistent with several other reports linking lipid metabolism with cell cycle 
progression and mitotic entry in yeast (Sd et al. 2012; McCusker and Kellogg 2012). 
Levels of triglycerides increase in wild‐type cells synchronized in mitosis (Blank et al. 
2017), storage of triglycerides in lipid droplets is thought to fuel mitotic exit (Yang et al. 
2016), and lipid-exchange proteins integrate lipid signaling with cell-cycle progression 
(Huang et al. 2018a). Note that there have not been analytical measurements of distinct 
lipids in the cell cycle in yeast. The data we show here are not only consistent with, but 
also significantly expand the prior studies mentioned above. It is also important to stress 
that an increase in lipids late in the cell cycle cannot simply be due to a need for cell 
surface material. We had shown previously that increased lipogenesis does not increase 
cell size (Blank et al. 2017). Hence, the increase in the abundance of lipids likely reflects 
changes in the composition of membranes or other more specialized, cell cycle-dependent 
process, not necessarily a simplistic need for more cell surface building blocks. 
One also needs to consider the dramatic changes in cellular morphology. 
Especially during mitosis, when the cell adopts the characteristic hourglass structure. The 
lipid content must accommodate dynamic changes in membrane curvature. For example, 





deposited on the outer leaflet of the bilayer (Furse and Shearman 2018). In yeast and 
human cells, inhibition of de novo fatty acid biosynthesis arrests cells in mitosis 
(Hasslacher et al. 1993; Schneiter et al. 1996; Al-Feel et al. 2003; Scaglia et al. 2014). In 
human cells, cholesterol synthesis may affect multiple points in the cell cycle. In an 
earlier report, inhibition of cholesterol synthesis arrested human cells in mitosis (Suárez 
et al. 2002), while in a later report the cells arrested in G1 (Singh et al. 2013). 
Cholesterol’s role in mitosis appears to be complex, not only affecting the distribution of 
phospholipids in the plasma membrane but also governing the formation of a vesicular 
network at the midbody during cytokinesis (Kettle et al. 2015). Interestingly, ergosterol 
may have a cell cycle regulatory role in yeast, distinct from its bulk, structural role in 
membrane integrity (Dahl et al. 1987), but that role remains unclear (Gaber et al. 1989). 
Lastly, our results argue for post-transcriptional mechanisms leading to mitotic 
upregulation of sterol biosynthesis. As to how the differential abundance of the ergosterol 
biosynthetic enzymes might come about, we note that all the enzymes we show in Fig 
B.6.3A, including Erg3p, have been shown to be ubiquitinylated (Peng et al. 2003; 
Swaney et al. 2013), raising the possibility of regulated proteolysis. Another possibility is 
translational control. In our previous analysis of translational control in the cell cycle by 
ribosome profiling, a confounding problem was the poor overlap of the different 
computational pipelines we used to analyze the data (Blank et al. 2017; Aramayo and 
Polymenis 2017). Proteomic data provide an independent metric that allows us to revisit 
the datasets of translationally controlled transcripts in the cell cycle. We found that for 38 
transcripts (from Dataset 5 in (Blank et al. 2017)) identified by the babel pipeline 





by the anota pipeline (Larsson et al. 2011), the corresponding protein levels are indeed 
significantly periodic in the cell cycle. These results validate the translational control of 
transcripts we had not followed up, but were identified by both computational approaches 
(e.g., NQM1, MSC1, with the protein levels peaking as predicted late in the cell cycle), 
and point to new ones, ERG5 among them. Hence, multiple levels of control, such as 
transcription (for ERG3), translation (for ERG5), and protein degradation (possibly for all 
Erg proteins) may contribute to the mitotic upregulation of ergosterol biosynthesis. 
Hence, integrating our proteomic and ribosome profiling datasets increased the 
confidence for 5-fold more transcripts that are likely under translational control in the cell 
cycle, providing an example of the synergy among different studies and datasets. 
Our data also underscore the value of having metabolite measurements along with 
other ‘omic’ datasets, to strengthen the efforts of identifying physiologically relevant 
cellular responses. In future work, employing targeted metabolic profiling and flux 
analysis in the cell cycle will increase our understanding of how the transcriptome and 
proteome shape dynamic changes in metabolism and how resources are allocated during 








Figure B.6.1. Overview of the experimental design to query cell cycle-dependent 
changes in the levels of RNAs, proteins, and metabolites.  
(A) Generation of sample-matched, multiomic datasets from synchronous cultures of 





cycle progression, the percentage of budded cells (y-axis) as a function of cell size (x-
axis) is shown for each cell size pool. Cell size corresponds to the mean cell size of the 
population, and in this case it is the weighted average of all the mean cell sizes of all the 
elutriated samples that constituted each of the 24 pools. (C) The levels of mitotic (CLB2) 
or G1 (CLN1,2) cyclin mRNAs, which are known to be periodic in the cell cycle, are 
shown along with those of a non-periodic transcript (ACT1; encoding actin). Cell size is 
shown on the x-axis (in fL), while the Log2-transformed ‘Transcripts Per Kilobase 
Million’ (TPM) values for each transcript are shown on the y-axis. All 24 values, one for 
each pool, were plotted in these graphs. Loess curves and confidence bands indicating the 
standard errors on the curve at a 0.95 level were drawn using the default settings of the 







Figure B.6.2. Transcripts changing in abundance in the cell cycle.  
Heatmap of the levels of 652 differentially expressed RNAs with significantly different 
levels (p<0.05; Log2(FC)≥1) between any two points in the cell cycle, based on bootstrap 
ANOVA. The levels of each RNA were the average of each triplicate for the cell size 
indicated, which was then divided by the average value of the entire cell size series for 
that RNA. These ‘expressed ratios’ were then Log2-transformed. The Log2(expressed 
ratios) values were hierarchically clustered and displayed with the pheatmap R language 
package, using the default unsupervised algorithms of the package. The different rows of 
the heatmap correspond to the different cell sizes (40-75 fL, top to bottom, in 5fL 
intervals). The cell cycle phases approximately corresponding to these sizes are shown to 
the right of the heatmap. The gene ontology enrichment analysis for each cluster was 







Figure B.6.3. Proteins with cell cycle-dependent abundance.  
(A) Levels of selected proteins whose levels changed significantly (p<0.05; Log2(FC)≥1) 
between any two points in the cell cycle, based on bootstrap ANOVA, in the cell cycle: 
Top, enzymes involved in ergosterol biosynthesis. Bottom, enzymes involved in DNA 
metabolism (Pol32p: DNA polymerase δ; Prs1,2p: PRPP synthase; Rnr1,3p: 
ribonucleoside-diphosphate reductase). The corresponding Log2(expressed ratios) values 
from all 24 data points are on the y-axis, and cell size values are on the x-axis. Loess 
curves and confidence bands indicating the standard errors on the curve at a 0.95 level 
were drawn using the default settings of the panel.smoother function of the latticeExtra R 
language package. (B) Heatmap displaying the relative abundance of the 333 proteins in 
one or more of the four ‘anova’ sets shown in Fig B.6.6. In cases where the same protein 
was in the intersection of more than one datasets, we chose for display the values from 





most significant (i.e., lowest p-value) and greater in magnitude (i.e., highest Log2(FC)). 






Figure B.6.4. Ribosomal protein abundance in ribosomes does not change in the cell 
cycle.  
(A) Elutriated, early G1 cells were cultured, and sampled at regular intervals in the cell 
cycle, in three biological replicates at each 5fL range, from 40 to 75 fL. Protein extracts 
from the same number of cells were then fractionated by sucrose ultra-centrifugation, to 
isolate ribosomes on mRNAs, which were then analyzed by SWATH-mass spectrometry 
(see materials and Methods). (B) The peak areas corresponding to each ribosomal protein 
(RP) detected were summed and averaged across the triplicate for each cell size interval. 
The Log2(expressed ratios) values for the ‘Sum of RP levels’ are shown on the y-axis, 
while cell size is on the x-axis. (C) Correlation matrix of the relative abundance of 
individual ribosomal proteins in assembled ribosomes on mRNAs. The Spearman 
correlation coefficients (ρ) shown in each case were calculated with the rcorr function of 
the Hmisc R language package. The cell cycle profiles for each ribosomal protein are 






Figure B.6.5. Thiamine biosynthesis and TDP-dependent enzymes in the cell cycle. 
(A) Abundances of the indicated proteins of thiamine biosynthesis from LC-MS/MS, 
across the cell size series (x-axis, in fL). The corresponding Log2(expressed ratios) 
values from all 24 data points are on the y-axis. Loess curves and confidence bands 
indicating the standard errors on the curve at a 0.95 level were drawn using the default 
settings of the panel.smoother function of the latticeExtra R language package. (B) The 
abundance of Thi7-TAP by immunoblotting from synchronous, elutriated cells, 
progressing in the cell cycle and sampled at regular intervals, as indicated (%B is the 
percentage of budded cells; fL is the cell size). Pgk1p levels are also shown from the 
same samples, to indicate loading. For the two samples indicated with asterisk (*) in the 
Thi7-TAP series, there were no size data due to instrument malfunction. At the bottom, 





expressed ratios of Thi7-TAP are shown, after they were normalized against Pgk1p. (C) 
Abundances of the indicated TDP-dependent proteins, determined and displayed as in A. 
(D) The birth and mean size of tkl2 cells and experiment-matched wild type (TKL2) 
cultures from exponentially dividing cells in rich, undefined media (YPD). At least 
twelve independent cultures were measured in each case. Significant differences and the 
associated p values were indicated by the non-parametric Wilcoxon rank sum test, 






Figure B.6.6. Lipid levels change significantly in the cell cycle.  
From 406 known metabolites identified from all classes (primary, biogenic amines, 
complex lipids), the levels of 64 with significantly different levels (p<0.05; Log2(FC)≥1) 





heatmap. The levels of each metabolite were the average of each triplicate for the cell 
size indicated, which was then divided by the average value of the entire cell size series 
for that metabolite. These ‘expressed ratios’ were then Log2-transformed. The 
Log2(expressed ratios) values were hierarchically clustered and displayed with the 
pheatmap R language package. The different columns of the heatmap correspond to the 








Figure B.6.S1. DNA content of samples spanning the cell size series from the 
elutriated samples. 
 The DNA was measured with flow cytometry, as described in the Materials and 
Methods. On the y-axis of each histogram is number of cells and on the x-axis the 








Figure B.6.S2. Levels of tRNAs, peaking early in the cell cycle.  
The tRNAs were from clusters 1 and GURE3 in Fig B.6.2, with significantly different 
levels (p<0.05; Log2(FC)≥1) between any two points in the cell cycle, based on bootstrap 
ANOVA. Sequences corresponding to the tRNAs shown peaked in abundance at cell 
sizes from 40 to 50 fL. Cell size is shown on the x-axis (in fL), while the Log2-
transformed ‘Transcripts Per Kilobase Million’ (TPM) values for each tRNA from all 24 
data points are shown on the y-axis. Loess curves and confidence bands indicating the 
standard errors on the curve at a 0.95 level were drawn using the default settings of the 







Fig B.6.S3. Overlap of transcripts whose levels change in the cell cycle, from studies 
that used elutriation to obtain synchronous samples.  
Matrix layout for all intersections of the three sets. The graph was drawn with the UpSet 







Figure B.6.S4. Transcriptome-proteome correlations.  
(A) The spectral counts corresponding to the proteins identified in this study were 
averaged from the three biological replicates for each cell size pool we analyzed from the 
soluble fractions (from the ‘sol_psm’ dataset, and shown on the y-axis. On the x-axis are 
the RNA read counts from the corresponding loci. All values were Log2-transformed for 
display purposes. The Spearman correlation coefficients (ρ) shown in each case were 
calculated with the rcorr function of the Hmisc R language package. (B) Similar analysis 
as in A, except that the input dataset for the spectral counts (y-axis) was from the 







Figure B.6.S5. Relative protein abundances against literature consensus.  
The protein abundances calculated in this study as in Fig B.6.4 for the soluble and 
insoluble fractions were compared to the consensus mean molecules per cell abundances 
from (Ho et al., 2018). The Spearman correlation coefficients (ρ) shown in each case 







Figure B.6.S6. Overlap of protein datasets whose levels change in the cell cycle. 
Matrix layout for all intersections of the four ANOVA-identified sets containing proteins 
with significantly different levels (p<0.05; Log2(FC)≥1) between any two points in the 







Figure B.6.S7. Ribosomal protein abundance in ribosomes is not periodic in the cell 
cycle.  
The levels of each ribosomal protein (see Fig B.6.4) detected were normalized against the 
sum of all ribosomal proteins detected in that sample and displayed as Log2-transformed 
expressed ratios (y-axis), while cell size (in fL) is on the x-axis. In none of the few cases 
(e.g., Rps8,9,26,27,28p; Rpl14,17Ap) where the abundance of the ribosomal protein in 
question appeared to fluctuate somewhat in the cell cycle the changes were periodic 







Figure B.6.S8. Little, if any, evidence for cell cycle-dependent changes in codon 
usage.  
From the 333 cell cycle-regulated proteins shown in Fig B.6.3, we selected the ones who 
were not identified as ubiquitylated by (Swaney et al., 2013), and whose corresponding 
mRNA levels were not changing (from Fig B.6.2). These proteins were further grouped 
according to their cell cycle expression pattern (peaking in G1: in clusters 1&2 (n=29); 
peaking in S: in clusters 3&4 (n=24): peaking in G1/M: in cluster 5 (n=29); peaking in 
G2/M: in clusters 6&7 (n=90)). For each codon in each mRNA encoding each of these 





2012). These values are displayed as violin plots, for the four codons shown that there 
were statistically significant differences between the groups for each codon (based on 
bootstrapped ANOVA: p<0.05). For differences between groups in each codon, the p-
values shown were obtained from posthoc statistical tests, using the mcppb20 function of 
the WRS2 R language package. The red horizontal lines indicate equal actual:expected 





Appendix C: Spatiotemporal transcriptional dynamics of the cycling 
mouse oviduct7 
 
This is chapter contains our investigations studying the cycling transcriptional 
dynamics underlying the mouse oviduct. Understanding temporal dynamics that control 
core processes in development has been of mutual interest both in the Marcotte and 
Wallingford labs well before I joined. This chapter aims to address a central gap in 
reproductive biology and development, particularly understanding the gene expression 
changes regulating the mammalian menstrual/estrous cycle. While this process is one of 
the most commonly occurring across mammals and central to birth, it remains quite 
understudied including in model organisms. This chapter aims to address that gap by 
spatiotemporally profiling gene expression changes occurring across the mouse oviduct. 
The most interesting finding from this work was that the significant remodeling of the 
oviduct was accompanied by lack of large-scale changes temporally across the estrous 
cycle. However, we found strong expression changes spatially across the anteroposterior 
axis particularly towards ciliary genes. 
Led by Elle Roberson, I joined the project with Anna Battenhouse assisting with 
the analysis of the gene expression datasets both across the estrous cycle and between the 
sections of the mice oviduct. 
 
 
7This chapter was published as Roberson, E.C., Battenhouse, A.M., Garge, R.K., Tran, N.K., Marcotte, 
E.M., and Wallingford, J.B. (2021). Spatiotemporal transcriptional dynamics of the cycling mouse oviduct. 
BioRxiv. This work was led by Elle C. Roberson. My contributions were assisting with RNAseq analysis 






Female fertility in mammals requires the iterative remodeling of the entire adult 
female reproductive tract across the menstrual/estrous cycle. However, while 
transcriptome dynamics across the estrous cycle have been reported in human and bovine 
models, no global analysis of gene expression across the estrous cycle has yet been 
reported for the mouse, an important and highly tractable model animal. Here, we 
examined the cellular composition and global transcriptional dynamics of the mouse 
oviduct along the anteroposterior axis and across the estrous cycle. Though we observed 
robust patterns of differential gene expression along the anteroposterior axis of the 
oviduct, we found surprisingly few changes in gene expression across the estrous cycle, 
in marked contrast to other mammals. The absence of significant remodeling observed in 
the oviduct by histology was reflected in turn by relatively limited transcriptional 
dynamics across the estrous cycle. Thus, the mouse oviduct, unlike other mammals, is 
relatively stable in cellular composition and RNA abundances across the estrous cycle. 
We speculate that this is an evolutionarily derived state that may reflect the extremely 
rapid five-day mouse estrous cycle. 
 
C.2. INTRODUCTION 
The adult mammalian female reproductive organs – ovary, oviduct, uterus, cervix, 
and vagina – hold an interesting position in mammalian physiology because they 
constantly and repeatedly engage in a complex remodeling process more commonly 





ovarian steroid hormone secretion drive remodeling of these tissues, characterized by 
changes in epithelial morphology, fluid secretion, proliferation, apoptosis, and/or atrophy 
(Brenner and West 1975). However, while decades of research have revealed how these 
hormones fluctuate across the menstrual/estrous cycle in multiple mammals, we 
understand far less about the mechanisms by which these hormones drive cyclic tissue 
morphogenesis.  
The oviducts are most well-known as the conduit between the ovary and uterus, 
but it is critical to note they also function as the site of fertilization and pre-implantation 
embryonic development (Stewart and Behringer 2012; Coy et al. 2012; Coy and 
Yanagimachi 2015). Interestingly, the oviducts display robust patterning along the 
anteroposterior axis, as the two major epithelial cell types – multiciliated cells (MCCs) 
and secretory cells – are differentially enriched (Agduhr 1927; Stewart and Behringer 
2012; Barton et al. 2020). At the anterior oviduct close to the ovary, MCCs are highly 
enriched and responsible for capturing the ovulated oocyte(s), while at the posterior close 
to the uterus, MCCs are very sparse and act as sperm reservoirs (Talbot et al. 1999; 
Suarez 2016). The reduced proportion of MCCs in the oviduct posterior reflects the 
significant increase in the proportion of secretory cells, which are critical to pre-
implantation development (Coy and Yanagimachi 2015). This anteroposterior pattern of 
the mouse oviduct epithelium is known to be established early in postnatal life and 
requires signaling from the underlying mesenchyme (Yamanouchi et al. 2010). How this 
pattern may change across the estrous cycle is not known. 
In many species, the cellular basis of morphogenesis of oviduct MCCs across the 





(Brenner 1969; Verhage et al. 1973; Shirley and Reeder 1996). In Rhesus monkeys, for 
example, anterior oviduct epithelial cells are cuboidal at the beginning of the cycle, but 
then grow in height and develop cilia at their apical surfaces as estrogen increases 
(Brenner 1969). As estrogen decreases and progesterone increases, the MCCs regress and 
de-ciliate (Brenner 1969). In mice, such cellular changes have not been thoroughly 
investigated, although it was shown that the wet weight of oviducts, as well as RNA and 
protein concentration, increases in the first half of the estrous cycle, and then 
subsequently decreases during the second half (Bronson and Hamilton 1970; 
Yamanouchi et al. 2010). More recently, there is evidence that ciliary beat frequency 
changes in response to estrogen and progesterone (Bylander et al. 2010; Shi et al. 2011). 
Perhaps surprisingly, while steroid hormone signaling in the oviduct is crucial for female 
fertility (Herrera et al. 2020; Winuthayanon et al.), we still lack a comprehensive view of 
how cycling steroids impact cellular morphogenesis in the oviduct, especially in the 
mouse.  
A major hurdle to filling this knowledge gap is our very limited understanding of 
the transcriptional dynamics that underlie cyclical morphogenesis in this tissue. 
Transcriptomic approaches in human, swine, and bovine oviducts have investigated the 
impact of estrogen and progesterone, and some studies have also explored anteroposterior 
patterning in humans and bovine oviducts (Bauersachs et al. 2004; Hess et al. 2013; 
Cerny et al. 2015; Kim et al. 2018; Sowamber et al. 2020). However, the majority of 
these studies have focused on either the transcriptional response to fertilization and early 
embryo development or transcriptional signatures associated with progression of high 





transcriptome across the normal estrous cycle represents a critical gap in our knowledge, 
especially given its potential utility as a model for understanding mammalian fertility. 
Here, we examined both the cellular changes and global transcriptional dynamics 
along the length of the oviduct and across the estrous cycle. First, we provide quantitative 
data on the density of MCCs along the anteroposterior axis of the oviduct and we show 
that MCCs do not remodel across the estrous cycle in mice. In addition, we present 3’ 
RNA-seq (Lohman et al. 2016) data for the anterior (approximate infundibulum) and 
posterior (approximate isthmus) oviduct at each stage of the estrous cycle. While 
transcript abundances vary strongly along the anteroposterior axis, our analyses suggest 
the estrous cycle has a surprisingly limited impact on transcription. Our data complement 
previous studies of transcriptional dynamics in the oviduct of other mammals and provide 
an important new resource for genetic studies of oviduct function in the mouse. 
 
C.3. MATERIALS AND METHODS 
C.3.1. Mice.  
6-8-week-old Swiss Webster female mice were obtained from Charles River and 
allowed to acclimate from travel for 1 week. Mice were housed in individually ventilated 
cages in a pathogen-free facility with continuous food and water, with a controlled light 
cycle (light from 7am-7pm). 7-9-week-old females were estrous cycle staged using 
standard vaginal cytology (Ajayi and Akhigbe 2020). Mice were humanely euthanized 





tracts were dissected. All animal experiments were approved by the University of Texas 
at Austin Institutional Animal Care and Use Committee.   
C.3.2. Tissue processing & immunofluorescence.  
Dissected oviducts were carefully linearized (Fig. C.6.1A) by teasing apart the 
supercoils, gently affixing to a strip of index card to keep the tissue straight, then fixing 
in 4% paraformaldehyde for either 4-6hr at room temperature (RT) or overnight at 4°C. 
Linearized fixed oviducts were washed in PBS, and then incubated in 30% sucrose at 4°C 
overnight. Following a brief incubation in NEG-50 Frozen Section Medium 
(ThermoFisher), oviducts were embedded in NEG-50 using an ethanol/dry ice bath. 
12µm frozen longitudinal sections were cut on a cryostat (Leica) and dried overnight at 
RT. Frozen sections were stored at -20°C.   
Tissue sections were washed in PBS + 0.1% Tween20 (PBST) three times to 
remove NEG-50. Tissues were blocked for at least 30min at RT with 5% normal donkey 
serum + PBS (block buffer). Primary antibodies for cilia (mouse anti-acetylated tubulin, 
1:1000 dilution, Sigma, cat# 6-11B-1) were diluted in block buffer and incubated on 
slides for 2hr at RT or overnight at 4°C. After washing three times with PBST, slides 
were incubated with Alexa-Fluor coupled secondary antibodies (goat anti-mouse 647, 
1:1000 dilution, ThermoFisher) and DAPI (1:1000 dilution, ThermoFisher) for at least 
30min at RT. After washing, slides were mounted with Prolong Gold (ThermoFisher), 
and allowed to cure at RT in the dark overnight. Oviduct sections were imaged on either 






C.3.3. Tissue sectioning and quantitation.  
Two to four sections spaced at least 100µm apart were analyzed for cilia at four 
locations along the anteroposterior axis of the oviduct. Images from the the fimbria, 
anterior third (approximate infundibulum), middle third (approximate ampulla), and 
posterior third (approximate isthmus) were acquired and quantified. We quantified ciliary 
area as previously published (Roberson et al. 2020). Briefly, we used FIJI image 
processing to trace the lumen based on DAPI staining to approximate the luminal length. 
Similarly, the ciliated surface of the lumen was traced and measured based on acetylated 
tubulin staining. From these measurements, the % ciliated surface area was calculated for 
each image, and we plotted using GraphPad Prism 8.   
C.3.4. RNA isolation and cDNA synthesis.  
For 3’ TagSeq (see below), dissected oviduct samples were collected in duplicate 
for each of the four stages across both anterior and posterior regions. For qPCR, samples 
were collected in triplicate for each estrous cycle stage across anterior, middle, and 
posterior thirds of the mouse oviduct. Following storage in RNALater Storage Solution 
(Sigma, cat#: R0901) at -20°C, oviduct tissue was manually disrupted and the lysate was 
spun through a QIAshredder column (Qiagen, cat#: 79656) to fully homogenize. A 
Qiagen RNeasy mini kit (Qiagen, cat#: 74106) was used to harvest RNA for RNAseq, 
and the Qiagen RNeasy micro kit (Qiagen, cat#: 74004) was used to harvest RNA for 
qPCR. Total RNA was then either provided to the Genomic Sequencing and Analysis 
Facility at the University of Texas at Austin for 3’ TagSeq, or cDNA was synthesized 





C.3.5. qPCR.  
Most primers were designed from a database for mouse and human qPCR primers 
incorporated into the UCSC genome browser (Zeisel et al. 2013). Primers for Foxj1 and 
Msx2 were designed using Primer3Plus software. We confirmed specificity of primers by 
ensuring that they BLAST to no more than 1 site in the genome. There were four outliers 
to this BLAST assessment: all four ribosome primer sets blasted to more than 1 site in the 
genome, likely because there are numerous ribosomal pseudogenes scattered throughout 
the genome (Sisu et al. 2020). In addition, we only used primers whose melting curve 
displayed a single peak.  
Primer sets were diluted from a stock (100µm in TE buffer) to 1µM in distilled 
deionized H2O. 2µL of each primer set (in technical duplicates) was allowed to dry in the 
bottom of a well in a MicroAmp Fast Optical 96 Well Reaction Plate (Thermofisher, 
cat#: 43-469-06). 10µL of a master mix of cDNA (250pg/well), Applied 
Biosystems SYBR Select Master Mix (Thermofisher, cat#: 44-729-18), and distilled 
deionized water was added to each well, the plates were sealed with MicroAmp Optical 
Adhesive Film (Thermofisher, cat#: 43-119-71) and allowed to incubate at RT in the dark 
for at least 15min to rehydrate primer. Plates were run on a ViiA-7 Real-Time PCR 
system (ThermoFisher), and CT values were auto-determined by the ViiA-7 software. 
The standard 2-DDCt method was then used to determine fold change based on the 






C.3.6. TagSeq.  
Tissue samples were collected in duplicate for each of the four estrous stages 
across both anterior and posterior regions of the mice oviduct, accounting for 16 samples 
in total. Library preparation and sequencing for TagSeq (Meyer et al. 2011; Lohman et 
al. 2016), a form of 3’ RNA sequencing, were performed by the Genomic Sequencing 
and Analysis Facility (GSAF) at The University of Texas at Austin. Total RNA was 
isolated from each sample by addition of Trizol (Thermo Fisher) and the sample was 
transferred to a Phasemaker tube (Thermo Fisher). Total RNA was extracted following 
the protocol supplied by the manufacturer and further cleaned up using a RNeasy 
MinElute Cleanup Kit (Qiagen). RNA integrity number (RIN) was measured using an 
Agilent Bioanalyzer and 100 ng of RNA was used for the TagSeq protocol. The 
fragmentation/RT mix was prepared and added to each RNA sample, then heated to 95°C 
for 2.5 minutes on a Thermocycler and immediately put on ice for 2 minutes. After 
cooling and addition of the template switching oligo and SmartScribe RT, the fragmented 
RNA reaction was incubated at 42°C for 1hr, 65°C for 15 min. Next an AmPure bead 
clean-up was completed for the cDNA before it was amplified to incorporate the Illumina 
sequencing primer site, followed by another cleanup. The remaining portions of the 
Illumina adapter (the i5 and i7 indices) were then added through an additional 4 cycles of 
PCR. Final libraries were quantified with PicoGreen then pooled equally for size 
selection using the Blue Pippin from 355-550 bp. Resulting libraries were sequenced 





C.3.7. Sequence data pre-processing.  
Fastq datasets were initially processed to collapse duplicates based on TagSeq 
molecular barcodes (Matz). Sequencing data quality, both before and after TagSeq pre-
processing, was evaluated using the FastQC tool (v0.11.9) (Andrews) and reports were 
aggregated with the MultiQC program (v1.0) (Ewels et al. 2016). 
C.3.8. TagSeq data analysis.  
Single-end pseudo-alignment was performed against the mouse transcriptome 
(GENCODE M23 transcript sequences (Frankish et al. 2019)) using kallisto (v0.45.0) 
(Bray et al. 2016) with options -l 200 -s 50 --single-overhang –bias. Downstream analysis 
of transcript abundance data was performed in R (v3.4.4) following protocols outlined in 
Bioconductor (Gentleman et al. 2004). The tximport package (v1.6.0) (Soneson et al. 
2015) was first used to roll up transcript-level counts into gene-level counts provided to 
the DESeq2 package (v1.18.1) (Love et al. 2014). Before further analysis, count data 
matrices were filtered to remove genes with fewer than 1 read across all included 
samples. A number of models were analyzed to explore the oviduct location/estrous stage 
relationship: Posterior versus Anterior locations, first providing Early and Late data 
separately (n=8 each), then again providing all datasets (n=16); and Late versus Early, 
first providing Anterior and Posterior location data separately (n=8 each), then again 
providing all datasets (n=16). Differentially expressed gene results reported are those 
with maximum adjusted p-value 0.05 and log2 fold change greater than 1.0 or less than -
1.0.  
Gene ontology (GO) analysis was performed using topGO R package (v2.34.0) 





and Fisher’s exact test were used in count data mode. Input genes had maximum adjusted 
p-values of 0.10. Separate analyses were performed for up-regulated (log2 fold change 
0.5 or higher) and down-regulated (log2 fold change -0.5 or lower) genes. The 
background gene universe consisted of observed genes used in the DESeq2 analysis. 
Full DESeq2 and topGO results are provided in the supplementary zip file for 
GEO accession GSE164718. 
 
C.4. RESULTS AND DISCUSSION 
C.4.1. Quantification of multiciliated cell density in the cycling mouse oviduct.  
Oviducts in most mammals consist of two key epithelial cell types – secretory and 
multiciliated cells (MCCs) – and these are unevenly distributed across the anteroposterior 
axis.   MCCs are enriched anteriorly and secretory cells, posteriorly (Agduhr 1927; 
Yamanouchi et al. 2010). While dynamic morphology changes across the estrous cycle 
have been described in the oviducts of many mammals (Novak and Everett 1928; 
Brenner 1969; Ferenczy et al. 1972; Verhage et al. 1973; Shirley and Reeder 1996), the 
issue has not been investigated thoroughly in the mouse. To stringently assess cellular 
remodeling of the anteroposterior axis of the mouse oviduct across the estrous cycle, we 
linearized the normally supercoiled oviduct by carefully teasing apart each coil along the 
length of the organ (Fig. C.6.1A), and generated longitudinal sections of linearized tissue. 
We then performed immunostaining for acetylated tubulin (TubAc) to label MCC cilia, 





By examining fimbria, anterior (approximate infundibulum), middle (approximate 
ampulla), and posterior (approximate isthmus) regions of the oviduct, we clearly 
observed the anterior bias in MCC density (Fig. C.6.1B-E). We quantified this pattern by 
calculating the percentage of cilia that line the oviduct lumen, based on TubAc staining as 
described previously (Roberson et al. 2020) (Fig. C.6.1F).  
By performing parallel analyses on linearized oviducts from each stage of the 
estrous cycle, we found that this pattern displayed no temporal changes, with the anterior 
oviduct being significantly enriched for MCCs at all stages (Fig. C.6.1F). The absence of 
significant remodeling of MCCs across the estrous cycle in the mouse oviduct presents a 
marked contrast to other mammals (Brenner 1969; Verhage et al. 1973; Shirley and 
Reeder 1996). We hypothesize that this discrepancy may relate to the very short (4 to 5 
day) mouse estrous cycle (Ajayi and Akhigbe 2020) and time required to eliminate and 
re-establish ciliated cells.  
C.4.2. Determining spatiotemporal transcriptome dynamics in the mouse oviduct. 
In addition to the cellular morphology changes, patterns of secretion, and bulk 
RNA and protein concentrations are known to change during the mouse estrous cycle 
(Bronson and Hamilton 1970). To ask if such changes have a transcriptional basis, we 
performed 3’ TagSeq, a high-throughput RNAseq profiling method that captures and 
sequences the 3’ ends of mRNA transcripts, enabling efficient estimation of relative gene 
expression (Meyer et al. 2011; Lohman et al. 2016). We performed two biological 
replicates of 3’ TagSeq on isolated anterior (highly ciliated) and posterior (minimally 
ciliated) oviducts at each stage of the estrous cycle (Fig. C.6.2A). Principal component 





axis (72% of variance), while the estrous cycle accounts for much less variance (13%) 
(Fig. C.6.2B).  
The lack of strong variation across the estrous cycle was striking, so we 
considered that our data might be underpowered to detect statistically significant trends 
across time (n=2 per estrous cycle stage). We therefore repeated our analyses, collapsing 
the estrous cycle stages into ‘Early’ (proestrus and estrus) and ‘Late’ (metestrus and 
diestrus). This approach improved differentiation between the major cycle phases; the 
majority of differentially expressed genes (DEGs) were still found along the A/P axis, not 
across the estrous cycle. For example, of the 1,758 DEGs enriched in the anterior oviduct, 
over 65% of them (1,158) were shared between Early and Late phases (Fig. C.6.2C). 
Similarly, of the 1,203 DEGs enriched in the posterior, 45% (542) were shared between 
Early and Late (Fig 2D).  
A more granular view of these data using volcano plots illustrates this finding. In 
the anterior oviduct, we identified only 27 early and 14 late DEGs (Fig. C.6.2E). 
Similarly, modest enrichments were identified in the posterior, with 54 early and 40 late 
DEGs (Fig. C.6.2F). The magnitude of the expression changes was also modest, with the 
majority of DEG effect sizes (absolute value of the log2 fold change) of two or less (59% 
of estrous cycle DEGs, vs. 44% of A/P DEGs). This result contrasts starkly to the 
transcriptional dynamics in the oviducts of other organisms, including human, bovine, 
and swine, across the menstrual/estrous cycle (Bauersachs et al. 2004; Hess et al. 2013; 
Cerny et al. 2015; Kim et al. 2018). For example, in bovine anterior oviducts, 972 genes 





human anterior oviducts, 650 genes have been reported as enriched early and 683 
enriched late (Hess et al. 2013). 
In contrast to the muted transcriptional dynamics across the estrous cycle, we 
observed highly robust and spatially-restricted patterns of gene expression along the A/P 
axis of the mouse oviduct. We identified 1337 genes enriched in the anterior, and 770 in 
the posterior early in the estrous cycle (Fig. C.6.2G). Similarly, late in the estrous cycle, 
1579 genes were enriched in the anterior and 975 in the posterior (Fig. C.6.2H). Thus, our 
data suggest that the mouse oviduct experiences relatively modest transcriptional changes 
as it progresses through the estrous cycle, but displays robust transcriptional differences 
along the A/P axis. 
C.4.3. The mouse oviduct transcriptome is relatively stable across the estrous cycle.  
While our finding of modest transcriptional variation across the estrous cycle in 
the mouse oviduct was consistent with the general lack of robust tissue remodeling, it 
was still surprising given the impact of cycling steroid hormones on oviduct function 
(Barton et al. 2020). To ask if the small number of DEGs we observed across time were 
enriched in particular classes, we performed Gene Ontology (GO) analysis (Alexa and 
Rahnenfuhrer 2020) on the early versus late DEGs. In the late stages, DEGs were subtly 
enriched for xenobiotic metabolism: xenobiotic metabolic process, cellular response to 
xenobiotic stimulus, and xenobiotic catabolic process (Supp. Fig. C.6.1B).  
More interestingly, DEGs in the early stages were enriched for translation-related 
terms: peptide metabolic process, peptide biosynthetic process, translation, gene 
expression, and cellular amide metabolic process (Supp. Fig. C.6.1A). This enrichment 





concomitant increase in protein concentration (Bronson and Hamilton, 1971). In 
agreement with the GO analysis, manual annotation revealed an enrichment of large and 
small ribosome subunit genes expressed in the early estrous cycle compared to late (Fig. 
C.6.3A), with these genes displaying a 2 to 4-fold change in abundance (Fig. C.6.3B).  
Further curation identified potentially interesting candidates based on their known 
or hypothesized function in female fertility. For example, Mki67, Ddit4, Atp1a1, 
Slc7a11, Mmp11, Mmp7, Spock1, and Wsb1 were each enriched at early stages, while 
Mamdc4, Gstp2, Gsta3, Susd2, and Ap1g2 were enriched late, either in the anterior, 
posterior, or both (Fig. C.6.3C). Among these, Mmp7 and Slc7a11 were especially 
interesting, because both were upregulated early and down regulated late, a pattern that is 
consistent with that observed in the cycling human oviduct (Hess et al. 2013). Mmp7 is 
part of the matrix-degrading enzyme family, and its down-regulation late in the human 
menstrual cycle is hypothesized to help maintain oviduct matrix integrity as the pre-
implantation embryo travels through the organ (Hess et al. 2013). Slc7a11 is a 
glutamate/cysteine antiporter that is similarly regulated in the bovine oviduct (Cerny et 
al. 2015). The majority of these DEGs also displayed modest effect sizes, similar to the 
ribosomal genes (Fig. C.6.3D).  
To independently verify the observed stability of the oviduct transcriptome across 
the estrous cycle, we performed qPCR for several of the DEGs. Consistent with the 
transcriptome-wide data, we did not observe statistically significant changes across the 
estrous cycle for most genes assayed (Fig. C.6.3E-K), but the trends in expression 
consistently reflected trends in our TagSeq data. The robust differential expression 





negative findings across the cycle do not reflect a lack of sensitivity in our assays. Rather, 
we conclude that the relatively modest remodeling observed in the oviduct by histology 
(Fig. C.6.1) is reflected by relatively muted transcriptional dynamics across the estrous 
cycle. While future work will be required, it seems reasonable to suggest that the stability 
of the mouse oviduct across the estrous cycle represents an evolutionarily derived state 
associated with the extremely rapid mouse estrous cycle, which at four to five days, is 
much faster than in other organisms (Brenner and West 1975). 
C.4.4. The mouse oviduct displays robust transcriptional patterning along the 
anteroposterior axis.  
To better understand the systems and processes differentially varying along the 
A/P axis, we again turned to GO Term analysis (Alexa and Rahnenfuhrer 2020). 
Consistent with the strong anterior enrichment of MCCs observed by histology (Fig. 
C.6.1), anterior-enriched DEGs were highly enriched for cilia-related processes (Supp. 
Fig. C.6.1C). In the anterior, complexes that function in MCCs, including intraflagellar 
transport, transition zone, CPLANE, and BBSome proteins (Garcia et al. 2018), as well 
as ciliary motility (Legendre et al. 2020) and MCC transcription factors (Lewis and 
Stracker 2020) were enriched (Fig. C.6.4A). To provide additional resolution to these 
patterns of expression for MCC-specific genes, we performed qPCR for several at each 
estrous cycle stage, using not just anterior and posterior regions but also the intervening 
middle region of the oviduct. We observed robust, statistically significant enrichment in 
the anterior region for a ciliary transcription factor (Foxj1), a transition zone complex 
gene (Tmem231), two ciliogenesis genes (Ift140 and Ift57), and one gene encoding a 





To investigate whether mouse anterior oviduct DEGs are similar to human 
multiciliated tissues, we compared our MCC-enriched dataset to the recently published 
human multiciliated tissue transcriptional signature (Patir et al. 2020). The analysis of 
four human multiciliated tissues, including ependymal, oviduct, trachea, and sperm, 
identified 248 genes expressed by all four tissues. Of those, we find 166 of them to be 
differentially expressed in the anterior of the mouse oviduct, suggesting that, 
transcriptionally, multiciliated genes of the mouse oviduct are highly similar to those of 
human multiciliated tissues.  
Non-ciliated epithelial cells in the posterior oviduct consist predominantly of 
secretory cells (Agduhr 1927; Ghosh et al. 2017). Accordingly, our posterior-enriched 
gene set was strongly enriched for transport and secretion GO Terms (Supp. Fig. C.6.4), 
including solute carriers, transport ATPases, Ca2+ and K+ channels (Fig. C.6.4A). These 
GO terms are similar to previously published datasets from other mammals, including 
cows and humans, where vesicle-mediated transport, endocytosis, and exocytosis were 
among the main processes enriched in the posterior (Maillo et al. 2016; Gonella-Diaza et 
al. 2017; Rose et al. 2020). We confirmed this trend using qPCR for a transport ATPase 
(Atp1b1) and a solute carrier (Slc39a8); both were significantly enriched in the posterior 
(Fig. C.6.4K, L). 
Interestingly, certain genes enriched in the mouse oviduct posterior are 
differentially expressed across the human menstrual cycle (Hess et al. 2013). For 
example, of the 33 solute carrier (Slc) genes that are enriched in the posterior of the 
mouse oviduct, eight of them are also differentially expressed across the human 





Slc4A7, Slc8a1 (Hess et al., 2013). These Slc genes are hypothesized to be important for 
secreting amino acids and other nutrients into the oviductal lumen to aid in 
preimplantation embryonic development. Further studies investigating SLC expression 
dynamics across both humans and mice may offer insights into the evolution of 
mammalian reproduction and divergence underlying these secretory cell types.  
C.4.5. Patterned expression of known developmental signaling systems along the 
anteroposterior axis of the adult oviduct. 
Our analysis of anteroposterior gene expression patterns also revealed several 
previously unreported trends. First, the genes up-regulated specifically in the posterior 
oviduct were strongly enriched for GO Terms related to embryonic development (Supp. 
Fig. C.6.1D). For example, all three non-canonical Wnt ligands, Wnt5a, Wnt7a, and 
Wnt11 were enriched in the posterior region of the oviduct (Fig. C.6.4B, N, O). 
Moreover, two antagonists of canonical Wnt signaling were also differentially expressed, 
but in a curious fashion: Dkk2 was enriched in the posterior, while Dkk3 was enriched in 
the anterior (Fig. C.6.4B). Components of the FGF signaling pathway were also 
differentially expressed: Fgf1, Fgf16, and Fgf2 were enriched in the posterior, while only 
the FGF receptor, Fgfr3, was enriched in the anterior (Fig. C.6.4C). Finally, multiple 
transcription factors were differentially expressed, including Msx2 (Fig. C.6.4M) and 
several Hox genes, including Hoxa9 and Hoxa10 (Fig. C.6.4D), both of which are 
involved in female reproductive tract development (Du and Taylor 2016). Other 
differentially expressed Hox genes include Hoxb2, Hoxb7, Hoxb8, and Hoxc10 (Fig. 
C.6.4D). We confirmed the differential expression of many of the developmental 





Not all signaling pathways displayed patterned expression, and an excellent 
example is the Planar Cell Polarity (PCP) pathway (Fig. C.6.4E). The PCP system is 
essential for normal polarized ciliary beating in the oviduct, so most PCP genes are 
expressed in the oviduct (Shi et al. 2014; Koyama et al. 2019). Strikingly however, none 
displayed enrichment along the A/P axis (Fig. C.6.4E).  
The posterior-enrichment of non-canonical Wnt ligands was especially 
interesting, and for multiple reasons. First, Wnt signaling is necessary to maintain 
stemness in human oviduct organoid cultures (Kessler et al. 2015), and secretory cells are 
thought to be the progenitors of MCCs in the mouse oviduct. Thus, it may be that 
posteriorly enriched Wnt signaling maintains the progenitor capabilities of posteriorly 
enriched secretory cells (Ghosh et al. 2017). Second, Wnt5a/7a/11 are known to orient 
PCP signaling, providing directional cues for the apical surface of cells and driving 
coordinated ciliary beating in multiciliated tissues (Gao et al. 2011; Ossipova et al. 2015; 
Butler and Wallingford 2017; Koyama et al. 2019). While the oviduct is planar polarized 
– i.e. Vangl2 localizes anteriorly in oviduct epithelial cells – it is unknown where the 
directional cue originates (Shi et al. 2016). Our data raise the possibility that posteriorly 
enriched Wnt5a/7a/11 orients Vangl2 localization to the anterior side of the oviduct 
epithelium, thereby regulating ciliary flow towards the posterior oviduct. Our 
experiments also indicate that PCP signaling components are evenly expressed across the 
A/P axis of the oviduct, which is consistent with the entire length of an epithelium being 
planar polarized. While the impact of planar polarization on MCCs is fairly well studied, 







In summary, our transcriptome profiling data fills a major gap in mouse oviduct 
investigations. While confirming reports made using other methods, our detailed 
anteroposterior axis and estrous stage analyses reveal novel gene expression patterns as 
well as providing a foundation for further studies. Hypotheses generated from these data 
can inform additional explorations using orthogonal methods such as single-cell 
sequencing and proteomics. Such studies have the potential to identify specific cell types 
associated with expression trends observed here, as well as quantifying actual cellular 









Figure C.6.1. The mouse oviduct displays anteroposterior patterning that does not 
change across the estrous cycle.  
A) A linearized mouse oviduct, where the anterior is close to the ovary and the posterior 





(insert, arrow). Oviducts were collected at B) proestrus, C) estrus, D) metestrus, and E) 
diestrus, linearized, and imaged for nuclei (DAPI, magenta) and cilia (TubAc, green) 
along the A/P axis (fimbria, anterior, middle, and posterior). Scale bar = 100µm. F) 
Quantitation of the percent ciliated surface area along the oviduct lumen in each of the 
four estrous stages (in temporal order: Proestrus, Estrus, Metestrus, Diestrus). Some error 







Figure C.6.2. RNAseq of the oviduct shows major differences along the 
anteroposterior axis and minor change across the estrous cycle. 
A) Oviducts were dissected and linearized from each stage of the estrous cycle (n=2 each 
stage). RNA from the anterior and posterior thirds of each oviduct was collected and 
submitted for 3’ TagSeq. B) Principal Component Analysis (PCA) of the sixteen 
3’TagSeq datasets. A/P location (displayed as symbols) accounts for most of the variance 
while estrous cycle stage (displayed as colors) accounts for a lesser part with good 
separation between early (Proestrus, Estrus) and late (Metestrus, Diestrus) phases. C) 





between the posterior DEGs at early and late phases of the estrous cycle. Volcano plots of 
oviduct E) anterior and F) posterior compare early and late DEGs. Volcano plots of 
estrous cycle G) early and H) late phases cycle show anterior and posterior DEGs. Red 
points are genes significant at both adjusted P-value (<= 0.05) and effect size (log2 fold 







Figure C.6.3. The mouse oviduct transcriptome is remarkably stable across the 
estrous cycle.  
A) Heatmap depicting expression of ribosomal genes across the estrous cycle where rows 
indicate genes and columns indicate the estrous cycle stage (P- proestrus, E- estrus, M- 
metestrus, D- diestrus). B) The effect size (absolute value of the log2 fold change) of the 
ribosomal genes was generally modest (under 2). C) Heatmap of other DEGs. D) These 





select genes from B and D along the anteroposterior axis at each estrous cycle stage. All 






Figure C.6.4. The mouse oviduct displays robust transcriptional patterning along 
the anteroposterior axis.  
A) Heatmap showing expression dynamics of DEGs across the anterior and posterior, 





calcium and potassium channels. Additional heatmaps of genes in developmental 
signaling pathways, including B) Wnt signaling, C) FGF signaling, D) Hox genes, and E) 
PCP signaling. F-R) qPCR histograms of select genes from A-E along the anteroposterior 
axis at each estrous cycle stage: anterior-enriched genes Foxj1, Tmem231, Ift140, Ift57, 
Dnah9; posterior-enriched genes Atp1b1, Slc29a8, Msx2, Wnt7a, Wnt5a; and other qPCR 







Figure C.6.S1. Significant GO terms associated with oviduct transcriptome analysis. 
Histograms depicting significant GO terms for A) early, B) late, C) anterior, and D) 
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